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Abstract 
This thesis describes a series of observational studies that examine the relationship between 
the systemic inflammatory response, glucose, micronutrients concentrations and outcomes in 
patients with critical illness with reference to a large nutrition screen cohort. Data and stored 
samples were available from cohorts which had been defined previously.  The critical illness 
cohort comprised of medical or surgical patients ≥ 18 years admitted to the Intensive Care 
Unit (ICU) of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008.  The nutrition screen cohort comprised samples and associated information which had 
been processed by the Pathological Biochemistry Department of the GRI.  The samples had 
been received for vitamin and / or trace element assessment of patients from both GRI and 
other Scottish hospitals between January 2006 and March 2013.  Samples had been referred to 
the lab for analysis of a number of variables related to nutrition, including glucose, albumin, 
C-reactive protein (CRP), lutein, lycopene, vitamins A, B1, B2, B6, C, D and E, and zinc, 
selenium, copper, and manganese.  Data was not available for all variables for all samples, 
hence studies varied in the number of observations.  plasma glucose was measured in sodium 
floride blood sample whole-blood samples underwent for routine analysis of concentrations of 
lutein, lycopene, α-carotene and β-carotene, 25-hydroxyvitamin D (25 (OH) D), ascorbic 
acid (vitamin C), α-tocopherol (vitamin E) in plasma, zinc, selenium, copper, B1, B2, B6 in 
plasma and red cells. 
In Chapter 2 the relationship between glucose and markers of the systemic inflammatory 
response was examined in detail in patients from the critical illness cohort (n=100).  The 
results of this study showed that plasma glucose concentration - even within the context of 
tight insulin protocol - was influenced by many factors.  Surgical and medical patients differed 
in their requirements for insulin; medical patients have higher plasma glucose and insulin 
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administration accordingly compared with surgical patients.  However, catecholamine and 
steroid administration were also associated with higher insulin requirements. 
In Chapter 3 the relationship between plasma asymmetric dimethylarginine (ADMA) and 
related arginine metabolism (homoarginine, arginine, symmetric dimethylarginine (SDMA)) 
and outcome was examined in patients from critical illness cohort (n=104).  Patients with 
critical illness experience metabolic disorders including catabolism and hyperglycaemia and 
these were associated with poor outcome.  Plasma ADMA and SDMA concentrations were 
higher in patients with critical illness and were also associated with disease severity and 
mortality.  In contrast, plasma homoarginine concentrations were lower in patients with 
critical illness and were also associated with disease severity and mortality.  These results 
suggest that ADMA metabolism is perturbed with likely knock on effects on nitric oxide 
synthase (NOS) and endothelial function.  There is a need for further work on in vivo 
dimethylaminohydrolase (DDAH) activity in critical illness and the effect of critical illness on 
the cationic amino acid transporters (CAT)-mediated exchange of ADMA between intra and 
extra-cellular compartments.  It was proposed that ADMA and SDMA may not only be 
indicators of the severity of illness and may even contribute to adverse events in patients with 
critical illness. 
In Chapter 4 the relationship between markers of the systemic inflammatory response, as 
evidenced by CRP and albumin, and mortality, in patients from critical illness cohort (n=261) 
was examined.  In this cohort, the combination of CRP and albumin predicted ICU and 
hospital mortality as effectively as APACHE II. 
In Chapter 5 the relationship between markers of the systemic inflammatory response and 
plasma glucose was examined in a nutrition screen cohort (n=5248).  The results of this study 
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showed that plasma concentrations of glucose were independently positive and negative 
associated with both CRP and albumin respectively, and were consistent with the systemic 
inflammatory response as having an impact on glucose concentrations.  However, such 
relationships were not apparent in patients with critical illness (n=116).  It was concluded that 
plasma concentrations of glucose were independently associated with both CRP and albumin, 
and were consistent with the systemic inflammatory response as a determinant of its 
concentrations. 
In Chapter 6 the relationship between markers of the systemic inflammatory response and 
plasma concentrations of carotenoids was examined in a nutrition screen cohort (n=1074).  
The results of this study showed that the clinical interpretation of plasma carotenoids requires 
knowledge of the magnitude of the systemic inflammatory response, even after adjustment for 
cholesterol.  It was concluded that a reliable clinical interpretation can be made only for 
plasma lutein, lycopene and β-carotene if the CRP is less than 20 mg/L. 
In Chapter 7 the relationship between markers of the systemic inflammatory response and 
plasma 25-hydroxyvitamin D (25(OH) D) was examined in a nutrition screen cohort (n=5327, 
and in patients from critical illness cohort n=117).  The results of this study showed that 
plasma concentrations of 25(OH) D were independently associated with both CRP and 
albumin.  It was concluded that the systemic inflammatory response was a major confounding 
factor in determining vitamin D status. 
In Chapter 8 the relationship between markers of the systemic inflammatory response and 
plasma vitamin E (α-tocopherol) and vitamin C (ascorbic acid) was examined in a nutrition 
screen cohort (n=359, n=494 respectively and in patients from critical illness cohort n= 82).  
The results of this study showed that α-tocopherol/ cholesterol ratio and ascorbic acid were 
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independently associated with both CRP and albumin.  It was concluded that the systemic 
inflammatory response was a major confounding factor in determining vitamin E and C status. 
In Chapter 9 the relationship between markers of the systemic inflammatory response and 
plasma zinc, selenium was examined in a nutrition screen cohort (n=743, n=833, respectively 
and in patients from the critical illness cohort n= 114).  The results of this study showed that 
plasma concentrations of zinc were associated with both CRP and albumin.  However, the 
impact of the systemic inflammatory response (as evidenced by elevation of CRP 
concentrations) on plasma zinc concentrations could be largely adjusted by albumin 
concentrations.  Plasma concentrations of selenium were associated with both CRP and 
albumin.  However, the impact of the systemic inflammatory response on plasma selenium 
concentrations could not be reasonably adjusted by albumin concentrations.  It was concluded 
that plasma zinc and selenium concentrations were independently associations with CRP and 
albumin as markers of systemic inflammatory response. 
In Chapter 10 the relationship between markers of the systemic inflammatory response and red 
cell zinc, selenium and copper was examined in patients from critical illness cohort (n= 125).  
The results of this study showed that altered red cell concentrations of zinc, selenium and 
copper were likely to be more reliable measures of status in the presence of a systemic 
inflammatory response. 
In Chapter 11 the relationship between markers of the systemic inflammatory response and red 
cell vitamins B1, B2 and B6 was examined in nutrition screen cohort (n= 553, n=251, n= 313, 
respectively and in patients from critical illness cohort n=94).  The results of this study 
showed that in contrast to plasma concentrations of B1, B2 and B6, red cell concentrations do 
not fall as a part of the systemic inflammatory response.  It was concluded that red cell 
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concentrations of B1, B2 and B6 were likely to be more reliable measures of status in the 
presence of a systemic inflammatory response. 
In summary, studies in the present thesis showed that, during the systemic inflammatory 
response, plasma concentration of glucose had multiple determinants other than insulin.  
Furthermore, in the presence of systemic inflammatory response, plasma lutein, lycopene, α-
carotene and β-carotene, 25 (OH) D, C, E, zinc, selenium, and copper were unreliable, and 
that intracellular micronutrients concentrations such as red cell zinc, selenium, copper, B1, B2 
and B6, were more reliable as indicators of vitamin and trace element status in patients subject 
to nutrition screen and in patients with critical illness.  These results have implications for the 
assessment of glucose and micronutrient status in the general population and for treatment in 
patients with critical illness. 
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1. Introduction 
Hyperglycaemia, glucose intolerance and insulin resistance have significant effects on 
outcomes in patients with critical illness.  A reduction of body antioxidant concentrations has 
been reported to have a similar effect.  There is evidence that these metabolic derangements 
are associated with the systemic inflammatory response as evidenced by systemic 
inflammatory response syndrome (SIRS) criteria, the elevation of CRP and hypoalbuminemia.  
Hyperglycaemia and micronutrient deficiencies are also been associated with increased 
morbidity and mortality in this group.  Researchers have therefore focused on the treatment of 
hyperglycaemia and on the provision of optimal nutrition and micronutrient supplements, in 
order to reduce organ dysfunction and mortality.  The assessment of micronutrient status has 
been monitored either by measuring micronutrient concentrations in plasma or by using 
functional tests (enzymatic activity).  However, since most micronutrients behave as acute 
phase reactants, the value of such plasma measurements has been questioned (Galloway et al. 
2000).  Recent advances in methods of micronutrient assessment allow the direct measurement 
of their concentrations within plasma and red cells (Talwar et al. 2003a).  For example, based 
on these direct methods it has been shown that redistribution of B-vitamins between plasma 
and blood cells takes place during elective surgery (Gray et al. 2004) and critical illness 
(Talwar et al. 2003b; Quasim et al. 2005).  This questions the resultant frequency and severity 
of micronutrient deficiency in these patients. 
1.1. Defining critical illness 
An intensive care unit describes the specialised area in a hospital for patients with potential or 
established organ failure, which offer comprehensive care and support in relation to the 
diagnosis, treatment and prevention of multi-organ failure (Department of health 1999; 
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Capuzzo et al. 2010).  Critically ill patients have been defined as those “with potential 
recoverable diseases who can benefit from more detailed observation and treatment than is 
generally available in the standard ward and departments” (Department of health 1996). 
1.2. Epidemiology.  
In 2008 Wunsch and colleagues demonstrated that there was international variation in critical 
care services.  They presented data from eight countries across North America and Western 
Europe (Table 1-1).  The data shows that Germany had the highest number of acute care 
hospital beds, while the US had the fewest.  Germany and Belgium had the highest number of 
ICU beds per 100,000 of population, with seven times as many beds compared with the UK, 
which had the lowest proportion (Wunsch et al. 2008). 
There was a wide variation in the ICU admission rates, e.g. Germany had ten times as many 
admissions to ICU compared with the UK, and six times as many compared with Canada 
(Wunsch et al. 2008).  Although the US had the largest number of acute care hospitals and 
beds, it has the smallest portion of acute care hospital beds per 100,000 of population. 
According to the Scottish Intensive Care Audit Group (SICSAG, 2008) data, since 1995 there 
has been a gradual and significant elevation in the number of patients admitted to ICU in 
Scotland.  For example, in 2007 there were 18,157 patients admitted to high dependency units, 
while 10,453 were admitted to ICU, with an occupancy rate of 75% for each (SICSAG 2008; 
SICSAG 2014). 
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Table 1-1:  Acute care hospital services population, and numbers of ICU and ICU beds, per head of the population in 2005 in eight 
different countries across North America and Western Europe (Adapted from Wunsch et al, 2008). 
Countries Acute 
care 
hospitals 
Acute 
care 
hospitals 
beds 
Acute care 
hospitals beds 
(per 100.000 
population) 
Total 
adult 
ICU 
Total 
adult ICU 
Beds 
% of total 
adult ICU 
Beds 
adult ICU Beds 
(per 100,000 
population) 
Annual ICU 
admissions  
Annual ICU 
admissions (per 
100,000 
population) 
Germany 1,695 489,433 593 NA 20,259 4.1 24.6 1,941,347 2,353 
Belgium 121 52,548 500 135 2,304 4.4 21.9 110,475 1,051 
France 2,134 231,900 380 550 5,707 2.5 9.3 260,000 426 
Spain 669 146,598 332 258 3,628 2.5 8.2 NA NA 
Netherlands 97 49,304 302 115 1,367 2.8 8.4 76,000 466 
Canada 622 98,262 300 319 3,388 3.4 13.5 97,813 389 
UK 1,815 179,512 298 268 2,131 1.2 3.5 130,000 216 
US 7,914 655,664 221 5,980 59,162 9.0 20.0 5,700,000 1,923 
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1.3. The cost of ICU care. 
It has been reported that the US is by far the highest spender on healthcare (currently 15% 
of gross domestic product), followed by Canada, Germany and France ranged between 9-
11% , and the UK and Spain spending the least at 7- 8 % (Wunsch et al. 2008). 
It has been estimated that annual spending in the UK intensive care was approximately 
£675 million, which was estimated to be 2% of the UK’s hospital budget (Cronin et al. 
2007).  It has been estimated that the daily cost per intensive care bed was £1,000-£1,800 
(The intensive care society 2006). 
1.4. ICU admission criteria. 
The Society of Critical Care Medicine (SCCM, 1999) provided criteria for patients with 
critical illness who are entitled to receive treatment in ICU according to their disease.  
There are three different models, which are: the diagnosis model, the objective variables 
model and the prioritisation model (SCCM 1999). 
The diagnosis model specified medical conditions or diseases that were severe enough for 
treatment in the ICU, and classified these medical disorders under the following categories; 
cardiovascular diseases, pulmonary or respiratory system diseases, gastrointestinal 
disorders, neurological disorders, endocrine disorders, drug overdose and surgical causes.  
In contrast, the objective variables model specified the medical examination and 
investigation findings such as vital signs, laboratory values, radiographic findings, 
electrocardiographic findings and physical findings at the acute onset (SCCM 1999). 
Other criteria, Other criteria, known as levels of care, that specified the patient’s medical 
condition and their need to admission to the ICU accordingly; this criteria is used 
principally in the UK, which includes levels 0 to 3, in Table 1-2: 
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Table 1-2:  Levels of Care (Department of Health. Comprehensive critical care—a 
review of adult critical care services. London: Department of Health, 2000 cited in 
Hudson & Boyd, 2007, p 117). 
Level 0 Patients whose needs can be met through normal ward care in an acute 
hospital. 
Level 1 Patients at risk of their condition deteriorating, or those recently relocated 
from higher levels of care, whose needs can be met on an acute ward with 
additional advice and support from the critical care team.  
Level 2 Patients requiring more detailed observation or intervention, including 
support for a single failing organ system or postoperative care and those 
‘stepping down’ from higher levels of care. 
Level 3 Patients requiring advanced respiratory support alone or basic respiratory 
support together with support of at least two organ systems. This level 
includes complex patients requiring support for multiorgan failure’. 
1.5. ICU length of stay and patient outcomes. 
Although the median length of stay in ICU as well as in high dependency units in the UK 
is around two days, the mean length of stay is 4.3 and 2.7 days in ICU and high 
dependency units respectively.  This was dependent on the cause of admission.  For 
example, patients with primary respiratory diagnosis or in septic shock stay much longer 
than other groups of patients (SICSAG 2014).  It has been reported that following 
admission to ICU in Scotland in 2014 the hospital mortality rate was 19% and reflects the 
severity of illness and co-morbidity among these patients (SICSAG 2014). 
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1.6. Scoring systems for illness severity. 
APACHE score 
Some specific scoring systems such as the Acute Physiology and Chronic Health 
Evaluation (APACHE) scoring system were adapted specifically to assess patients with 
critical illness.  In 1985 APACHE II was introduced, it is a simpler form of the APACHE 
and contains 12 physiological variables that include age and chronic health (Figure 1-1) 
(Knaus et al. 1985; Knaus et al. 1991). 
APACHE III was launched in 1991 and is similar to APACHE II, apart from containing 
more information about the patient’s previous location and the medical issue necessitating 
their ICU admission.  Although APACHE III is the newest form of this scoring system, 
APACHE II is the most commonly used form in the UK (Knaus et al. 1991).  
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The APACHE II severity of disease classification system 
 
Figure 1-1: The Acute Physiology and Chronic Health Evaluation (APACHE) II score 
system. 
(Knaus et al. 1985) 
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SOFA score 
The Sequential Organ Failure Assessment (SOFA) is a combined score that grades from 
one to four and includes six organ systems: cardiovascular, respiratory, renal, neurological, 
hepatic and coagulation (Figure 1-2).  This is carried out on a daily basis while the patient 
is in ICU; it is a dynamic score that estimates the severity of the illness and the progression 
of organ dysfunction over time.  It has been proposed that using this scoring system in a 
repetitive manner is a useful predictor of ICU mortality rates (Vincent et al. 1996; Capuzzo 
et al. 2010). 
The use of scoring systems remains controversial.  Their main use is in comparative audit, 
such as comparing patient outcomes with other hospital unit.  Scoring systems that include 
mortality rates are used to assess ICU unit performance and is known as Standardised 
Mortality Ratio.  This ratio is calculated by dividing the actual mortality rate by the 
predicted rates, if the score < 1, this means that the ICU performance was better than 
predicted (Hudson and Boyd 2007). 
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SOFA score 1 2 3 4 
Respiration 
PaO2/FiO2 mmHg  
<400 <300 <200 
With respiratory support 
<100 
With respiratory 
support 
Coagulation 
Platelets x 10
3
/mm
3
 
<150 <100 <50 <20 
Liver 
Bilirubin. mg/dl (μmol/L) 
1.2-1.9 
(20-32) 
2.0-5.9 
(33-101) 
6.0-11.9 
(102-204) 
>12.0 
(>204) 
Cardiovascular 
Hypotension
 a
 
MAP <70 
mmHg 
Dopamine ≤ 5 or 
Dobutamine (any 
dose) 
Dopamine < 5 or epinephrine 
≤ 0.1 or norepinephrine ≤ 0.1 
Dopamine > 1.5 or 
epinephrine > 0.1 or 
norepinephrine > 0.1 
Central Nervous System 
Glasgow coma score 
13-14 10-12 6-9 < 6 
Renal 
Creatinine. mg/dL (μmol/L) or urine 
output 
1.2-1.9 
(110-170) 
2.0-3.4 
(171-299) 
3.5-4.9 
(300-440) or <500 mL/day 
>5.0 
(>440) or <200 mL/day 
a
 adrenergic agents administered for at least one hour (doses given are in μg/Kg. min) 
Table 1-3: Sequential Organ Failure Assessment (SOFA) score system. 
(Vincent et al. 1996)  
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1.7. Specific causes of ICU admissions. 
It has been reported that in the UK the most common source of ICU admission was from 
operating theatres (60-70%), and those from emergency departments (Hudson and Boyd 
2007).  The ICU post-operative admissions were mainly from emergency surgery.  In 
contrast, the high dependency unit’s admissions were mainly from elective planned surgery 
(SICSAG 2011) 
The most common medical issues or causes of ICU admissions are: 
 ‘Previous severe cardio-respiratory illness such as acute myocardial infarction, 
chronic obstructive pulmonary disease, and stroke. 
 Late-stage vascular disease involving the aorta. 
 Age  more than 70 with limited physiological reserve in one or more vital organs 
 Extensive surgery for carcinoma such as oesophagectomy, gastrectomy, and 
cystectomy. 
 Acute abdominal catastrophe with haemodynamic instability such as peritonitis, 
perforated viscus, pancreatitis. 
 Acute massive blood loss more than 8 units. 
 Septicaemia. 
 Positive blood culture or septic focus. 
 Respiratory failure: PaO2 <8.0 kPa on FiO2 >0.4 or mechanical ventilation >48 
hours. 
 Acute renal failure: urea >20 mmol/l or creatinine >260 μmol/l’ (Hudson and 
Boyd 2007). 
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1.8. The systemic inflammatory response 
The systemic inflammatory response is a complex response to acute and chronic injury and 
is associated with a number of clinical conditions, such as tissue injury, infection, sepsis, 
ischemia, burns, multiple trauma, haemorrhagic shock, and immunologically mediated 
organ injury (Bone et al. 1992; Levy et al. 2003).  Systemic inflammation may generally be 
beneficial to the host until its clinical manifestations become unmanageable by the body 
(Bone 1996). 
Almost all patients with critical illness display systemic inflammatory response syndrome 
(SIRS) (Pittet et al. 1995).  This generalised inflammatory response may lead to 
progressive organ failure, which has a high mortality rate (Lobo et al. 2003).  The systemic 
inflammatory response includes an elevation of CRP and a reduction in plasma albumin 
concentrations.  In contrast, urine and tissue albumin concentration increase (Gabay and 
Kushner 1999) (Figure 1-3). 
The SIRS is manifested by two or more of the following clinical conditions: 
Temperature > 38º C or < 36º C; 
heart rate > 90 beats per minute 
respiratory rate > 20 breaths per minute or PaCO2 <32 mm Hg 
white blood cell count >12,000/ cu mm, <4,000/ cu mm, or >10% immature (band) 
forms 
Table 1-4: The systemic inflammatory response syndrome (Bone et al. 1992; Levy et 
al. 2003) 
1.8.1. Local reaction at the site of injury or infection. 
At this stage the source of infection such as traumatic injury, infection or burn injury may 
enhance the release of a wide range of mediators.  These include cytokines such as 
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interleukin-1, interleukin-6 and Tumour Necrosis Factor (TNF-α).  These induce a 
proinflammatory state and there may be a release of mediators that have multiple 
overlapping effects and which are designed to limit any new damage, as well as to 
ameliorate any damage that has already occurred. 
These mediators may destroy the damaged tissue and pathogenic organisms, neoplastic 
cells and any foreign antigens stimulate the growth of new tissue.  This response is 
followed directly by a compensatory anti-inflammatory response through the release of 
interleukins such as interleukin -4, 10, 11 and 13, soluble Tumour Necrosis Factor (TNF-α) 
receptors and transforming growth factor-β to ensure that the proinflammatory mediator 
effects do not become destructive and which in turn may restore homeostasis. 
At this stage if the original site of injury or infection is severe, proinflammatory and anti-
inflammatory mediators will appear in the systemic circulation in large amounts.  
Proinflammatory mediators usually present in the systemic circulation and work as a part 
of the normal response to infection, and as a warning signal that the local 
microenvironment is not able to control the initiating insult. 
The proinflammatory mediators enhance the migration of neutrophils, T cells, B cells, 
platelets, and coagulation factors to the site of injury or infections; this process enhances 
the compensatory systemic anti-inflammatory response, which in turn may quickly down-
regulate the initial proinflammatory response.  At this stage a few signs and symptoms may 
appear, however marked organ dysfunction is quite rare. 
1.8.2. Excessive systemic inflammation. 
At this stage there may be a loss of regulation of the proinflammatory response, which may 
lead to a massive systemic reaction that manifests itself as the systemic inflammatory 
response syndrome.  The pathological changes include: a) endothelial dysfunction and 
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increased microvascular permeability, b) sludging of platelets, c) stimulation of the 
coagulation system, and d) vasodilatation, redistribution of blood flow, and fluid 
transudation all of which may lead to profound shock.  Ultimately organ dysfunction and 
failure may occur unless homeostasis is restored. 
Where there is multiple organ dysfunction this can result in immunologic dissonance and 
characterised by inappropriate excessive responses of the immunomodulatory system.  In 
this stage there is an overwhelming systemic inflammation that may sustain and multiple 
organ dysfunction increasing risk of death.  
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Figure 1-2: Acute phase proteins and the systemic inflammatory response. 
(From Gitlin & Cotlen 1987 as modified in Gabay & Kushner 1999) 
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1.9. Management of the critically-ill patients. 
Sepsis. 
“Sepsis encompasses a spectrum of illness that ranges from minor signs and symptoms 
through to organ dysfunction. Sepsis ranks in the top 10 causes of death and it is a life-
threatening condition, especially amongst patients with a chronic disease” (Bone et al. 
1997; Russell 2007; Lever 2007).  The most common source of the bacteria infection 
includes: 
 The lining of the brain (meningitis). 
 The lungs (bacterial pneumonia). 
 The bowel (usually seen with peritonitis). 
 The kidneys (upper urinary tract infection or pyelonephritis). 
 The liver or the gall bladder. 
 The skin (cellulitis). 
 In hospitalized patients, common sites of infection include intravenous lines, 
surgical wounds, surgical drains, and sites of skin breakdown such as bedsores 
(Russell 2007). 
The symptoms of sepsis include a fall in blood pressure, which may lead to shock, and may 
be associated with multi organ dysfunction.  A change in mental status and an increase in 
the respiratory rate, could indicate early signs, as well as other symptoms such as: chills, 
shaking, confusion or delirium, decreased urine output, fever or hypothermia, warm skin, 
hyperventilation, headache, tachycardia, and skin rash (Russell 2007). 
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Pathophysiology of sepsis. 
It has been reported that sepsis may have five stages in the development of multiple organ 
dysfunction, which are: (1) local reaction at the site of injury or infection; (2) initial 
systemic response; (3) massive systemic inflammation; (4) excessive immunosuppression; 
and (5) immunologic dissonance (Bone et al. 1997). 
Patients with sepsis on admission to ICU often receive intravenous antibiotics, oxygen, 
parenteral fluids.  Also vasopressor and inotropic may be required, as well as dialysis in 
case of renal failure and mechanical ventilation in case of respiratory failure.  Treatment 
with powerful anti-inflammatory drugs, such as corticosteroids or recombinant human 
activated protein C is no longer routinely used (Dellinger et al. 2008). 
Initial resuscitation. 
Resuscitation should be started immediately in patients with severe sepsis or sepsis 
induced hypoperfusion shock which is characterised as severe hypotension or elevation in 
serum lactate > 4 mmol/l.  During the first six hours the following resuscitation goals are 
have been recommended. 
 ‘Central venous pressure (CVP) 8–12 mm Hg.  
 Mean arterial pressure ≥65 mm Hg. 
 Urine output ≥0.5 mL.kg-1.hr-1. 
 Central venous (superior vena cava) oxygen saturation ≥70%, or mixed venous 
≥65%’ (Dellinger et al. 2008). 
 If venous oxygen saturation target is not achieved the following steps of treatment 
may be considered  
 Consider further fluid. 
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 Transfuse packed red blood cells if required to hematocrit of ≥30% and/or 
 Dobutamine infusion max 20 μg.kg−1.min−1’ (Dellinger et al. 2008). 
Diagnosis of sepsis. 
Diagnosis of sepsis needs to be confirmed by body fluid cultures, such as blood, urine, 
cerebrospinal fluid, wound swab, and respiratory secretions.  These should be collected 
before antibiotic treatment begins in order to identify the causative organisms (Dellinger et 
al. 2008).  Other tests could be carried out, such as blood gases, renal function tests, blood 
differential red cell and white blood cell counts (Dellinger et al. 2008).  Furthermore, 
imaging studies such as an ultrasound scan must be considered to identify the source of 
infection to remove a foreign body or drain an abscess (Dellinger et al. 2008). 
Antibiotic therapy. 
Administration of antibiotics is recommended to start as early as possible and at the initial 
recognition of septic shock; a broad spectrum antibiotic is highly recommended in order to 
cover different suspected organisms. 
Antibiotic therapy regimen may take seven-to-ten days and should be reassessed daily to 
‘optimise efficacy, prevent resistance, avoid toxicity & minimise costs’ (Dellinger et al. 
2008).  The treatment may take longer than ten days if patients have a slow response, 
undrainable foci of infection, or in patients with immunologic deficiencies.  Finally, 
antibiotic therapy may be stopped if the cause of inflammation is found to be non-
infectious (Dellinger et al. 2008). 
Fluid therapy. 
Crystalloids and colloids fluids are commonly used during resuscitation to maintain central 
venous pressure ≥ 8 mmHg and ≥ 12 mmHg if the patient is on mechanical ventilation.  
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Fluid challenge with either 1000 ml of crystalloid or 300 to 500 ml of colloids that are 
given over 30 minutes may be considered with simultaneously assessment of the 
improvement of haemodynamic status.  In cases with sepsis-induced tissue hypoperfusion, 
large fluid volumes with rapid administration may be required.  Recently it has been 
established that colloids are not associated with better outcomes compared to crystalloids 
(Dellinger et al. 2008). 
Drugs. 
 Vasopressor agents such as nor-epinephrine or dopamine may by required to 
maintain the main arterial blood pressure ≥ 65 mmHg. 
 Inotropic therapy such as dobutamine or epinephrine may be required in patients 
with myocardial dysfunction. 
 Steroids such as dexamethasone may be required if a patient with septic shock has 
hypotension that poorly responds to fluid resuscitation measures and vasopressor 
agents (Dellinger et al. 2008). 
Sepsis complications may include disseminated intravascular coagulation, problems with 
blood flow to vital organs such as brain, heart and kidneys, septic shock and death (Russell 
2007). 
1.10. Hyperglycaemia in patients with critical illness (pathophysiology). 
Patients with critical illness may suffer from hyperglycaemia, glucose intolerance and 
insulin resistance even without pre-existing diabetes (Falciglia et al. 2009).  This elevation 
of plasma glucose concentrations due to the presence of acute illness is known as stress 
diabetes or diabetes of injury. 
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Patients with or without diabetes who suffer from hyperglycaemia during critical illness 
may have increased morbidity and mortality rates (Van den Berghe et al. 2006; Treggiari et 
al. 2008).  Hyperglycaemia may influence the outcome of patients with critical illness 
through the suppression of immune function; inducing oxidative stress and endothelial 
damage, hepatocyte mitochondrial damage, and may potentiate tissue ischemia due to 
inflammation and acidosis (Treggiari et al. 2008). 
1.11. Diabetes of injury. 
Schricker (2001) has demonstrated that there may be a marked insulin resistance post-
operatively that may lead to hyperglycaemia, even without complications or sepsis, and 
this may persist up to 20 days following surgery; this situation has been called ‘ diabetes of 
injury’(Schricker 2001). 
Acute illness may enhance the catabolic response by the release of inflammatory cytokines 
and counter regulatory hormones such as catecholamines, cortisol, glucagon, and growth 
hormone, as well as stimulating the sympathetic nervous system that may lead to elevation 
in cortisol, noradrenaline and adrenaline concentrations (Vanhorebeek and Van den Berghe 
2006).  Drugs, such as exogenous catecholamines and glucocorticoids, may suppress the 
secretion and the action of insulin, may inhibit glycogen synthesis, stimulate 
gluconeogenesis and alter insulin-mediated glucose uptake by tissues.  This may result in 
insulin resistance, nitrogen loss and hyperglycaemia.  Intravenous fluid such as dextrose 
and parenteral nutrition, may also contribute to hyperglycaemia (Saberi et al. 2008; Ead 
2009; Kavanagh and McCowen 2010).  Figure 1-4 below shows the pathophysiology of 
hyperglycaemia in critical illness. 
It has been reported that hyperglycaemia may extend to the post-operative care period 
depending on the magnitude of surgery.  For example, with major surgical operations, such 
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as cardiovascular surgery, plasma glucose levels increase up to 10- 12 mmol/l and stay at 
this level for more than 24 hours following surgery in non-diabetic patients, even in minor 
operations the hyperglycaemia may persist more than five days after surgery (Marks 2003; 
Rahman and Beattie 2004; Ead 2009). 
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Figure 1-4: The pathophysiology of hyperglycaemia in critical illness Adapted from (Anger and Szumita 2006)   
Endogenous accrues: 
Count-regulatory 
hormones 
-Epinephrine 
-Norepinephrine 
-Growth hormone 
Inflammatory mediator 
 -Tumor necrosis 
factor-α 
-Interleukin-2 
Increase lipolysis 
Insulin resistance 
Exogenous accrues: 
Glucose administration 
-intravenous fluid 
resuscitation 
-Enteral nutrition 
-Parenteral nutrition 
-Drugs administration 
Drugs  
-Corticosteroids 
-Catecholamine 
-Tacrolimus 
-Cyclosporine 
-Propofol. 
  Plasma glucose 
Pancreas: 
β islet cell secretion of 
insulin 
 Plasma insulin  
Insulin-mediated 
stimulation of 
glycogenesis and 
suppression of 
gluconeogenesis 
Liver: 
Glycogenesis 
 Glycogen synthesis 
Gluconeogenesis 
 Hepatic glucose production 
Glycogenolysis (inhibited by insulin) 
 Glycogen breakdown 
Fatty acid synthesis 
 Gluconeogenesis 
Corticosteroids 
-Epinephrine 
-Norepinephrine 
Insulin-mediated uptake 
into peripheral tissue 
Lipolysis (fat 
breakdown) 
-Corticosteroids 
-Growth hormone 
-Epinephrine 
-Norepinephrine 
Adipose tissue: 
triglyceride storage 
Skeletal muscle insulin 
resistance 
-Corticosteroids 
-Epinephrine 
-Tumor necrosis factor-α 
-Growth hormone 
Skeletal muscle: 
Glycogenesis 
-Glycogen 
synthesis 
Glycolysis 
-Krebs cycle 
-ATP synthesis 
46 
 
1.12. Hyperglycaemia and cell damage 
Oxidative stress. 
Oxidative stress is an imbalance between reactive oxygen species (ROS) production and 
antioxidants.  Free oxygen radicals are missing an electron which may make them highly 
active and unstable and they cause to oxidative damage to cell membranes, proteins and 
genes by reducing the bioavailability of endothelium-derived nitric oxide, which in turn 
may lead to vasoconstriction, smooth muscle cell proliferation and platelet activation 
(Papaharalambus and Griendling 2007; Hatzitolios et al. 2009).  In addition, free radicals 
may enhance the deposition of low-density lipoproteins (LDLs) in the walls of blood 
vessels and, as a result, atherosclerotic changes may take place (Papaharalambus and 
Griendling 2007; Hatzitolios et al. 2009). 
Advanced Glycosylated end- products (AGEs). 
AGEs are complex compounds formed as a result of non-enzymatic glycosylation 
reactions of proteins and lipoproteins (Goh and Cooper 2008).  AGEs are normally formed 
at a constant and slow rate throughout life.  Chronic hyperglycaemia may accelerate 
glycosylation of proteins and lipoproteins, which may lead to production of AGEs in the 
walls of the blood vessels (Goh and Cooper 2008; Hatzitolios et al. 2009). 
AGEs may form irreversible bonds with and between proteins to alter their structures and 
activity.  AGEs may interact with cell surface AGE-binding receptors (known as RAGE).  
When AGEs bind to their corresponding receptors this can lead to LDL lipoprotein 
deposition, enhancement of the oxidative reaction, enhancement of the formation of foam 
cells and the atheromatous plaque, and alteration of the gene transcription.  In addition, 
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AGEs may lead to endothelial dysfunction, macrophage activation and impaired vascular 
smooth muscle-cell function (Goh and Cooper 2008; Hatzitolios et al. 2009). 
Specific protein kinase C isoforms activity and Aldose reductase activity (the polyol 
pathway). 
Hyperglycaemia may activate protein kinase C (PKC).  The activation of PKC has a 
significant influence in blood vessels and endothelial function.  Normally, glucose uptake 
by cells is dependent on insulin.  However, in some cells, such as nerves, it enters without 
insulin.  The glucose is metabolized principally by the glycolytic pathway, with less than 
5% of the glucose being metabolised by the polyol pathway (Hatzitolios et al. 2009). 
The intracellular polyol pathway is the intracellular converts of glucose to sorbitol by the 
effect of aldose reductase.  This polyol pathway may promote formation of diacylglycerol, 
which in turn may stimulate PKC.  Protein kinases (PKS) are a group consisting of 12 
isoforms; stimulation of specific PKC isoforms, such as PKC-β and PKC-δ, may lead to 
the proliferation of blood vessel cells, impairment in glucose and lipid metabolism, 
reduction of vasodilatation, expression of atherosclerosis-promoting genes, and enhanced 
vascular permeability (Hatzitolios et al. 2009). 
When the polyol is trapped inside the cells, it can create an osmotic gradient and make 
sodium and water flow into the cell.  Sorbitol is converted to fructose by the effect of 
sorbitol dehydrogenase.  High fructose may lead to AGEs and more damage may occur 
(Hatzitolios et al. 2009). 
1.13. Glycaemic control in patients with critical illness. 
Rigorous hyperglycaemia management protocols using insulin therapy have been reported 
(Van den Berghe et al. 2001).  Intensive insulin therapy reduced the morbidity and 
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mortality rate regardless of those patients who had a previous history of diabetes or not 
(Krinsley 2006).  These studies are summarised in Table 1-5.  However, some studies, such 
as the original Van den Berghe et al (2001) paper and Preiser et al (2009) have been 
criticised because the population were predominately post cardiac surgery.  It was already 
well known that following myocardial injury hyperglycaemia had significant harmful 
effects and associated with poor outcomes (Malmberg 1997; Malmberg et al. 2005).  
These, studies may not be representative of all critically ill patients and in particular those 
with sepsis.  Other studies have major limitations, Krinsley et al (2004) demonstrated a 
substantial mortality reduction (an absolute reduction of over 6% and a relative reduction 
of 29%), and this was based on historical controls which severely reduce the validity of 
any conclusions.  The Specialised Relative Insulin Nutrition Tables (SPRINT) study also 
demonstrated significant improvements in outcome but was also based on historical 
controls (Chase et al. 2008). 
More recent studies such as the Normoglycaemia in Intensive Care Evaluation-Survival 
Using Glucose Algorithm Regulation (NICE-SUGAR Study 2009) have reported that 
patients who had intensive glucose control with plasma glucose target between 4.4-6.0 
mmol/l had a higher mortality rate than conventional glucose control patients with plasma 
glucose target <10 mmol/l within 90 days of ICU admission.  Also, severe hypoglycaemic 
episodes, where plasma glucose < 2.2 mmol/l, were more common in the intensive glucose 
control group (Van den Berghe et al. 2003; Cheung et al. 2006).  However, the mortality 
rate among intensive glucose control group of patients was not clear, whether due to the 
reduction of plasma glucose concentration, the increase of insulin administration, the 
occurrence of hypoglycaemia or due to the study methodology (The NICE-SUGAR Study 
Investigators 2009).  Further analysis of the data from the NICE Sugar trial confirmed the 
association between the hypoglycaemia and outcome but could not establish as causal link 
(The NICE-SUGAR Study Investigators 2009; Finfer et al. 2012).  Several recent studies, 
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have also studied factors influencing glycaemic control.  These studies have significant 
limitations, for example Dossett et al (2008) did not report on the intake of calories from 
nutrition support and Egi et al (2009) did not include any analysis of the drugs likely to 
influence insulin sensitivity (Dossett et al. 2008; Egi et al. 2009).  Therefore, the treatment 
of hyperglycaemia in critically ill patients remains a controversial issue (Mehta et al. 
2005).  Moreover, the frequency of hyperglycaemia and/or hypoglycaemia and the 
association with the other medical conditions that occur in patients with critical illness 
requiring insulin therapy is not clear. 
In a much larger study Flaciglia reported that hyperglycaemia was associated with severity 
of illness and outcome.  This study looked at over 250,000 patients in 153 critical care 
units.  Their definition of hyperglycaemia was based upon the averages of all of the 
laboratory glucose measurements made for each patient.  Their findings indicated that in 
some patients hyperglycaemia was more difficult to treat and that hyperglycaemia was 
more strongly associated with a poor outcome in some medical diagnoses compared with 
surgical patients.  It was not established whether the resistance to insulin per se or 
administering high dose of insulin was the cause of poor outcomes.  Indeed, in the NICE 
sugar study a unique concern was that excessive insulin administration in the context of a 
tight glucose control protocol was the cause of the excess mortality. 
Indeed, counter-regulatory hormone administration and fluid balance are the essential 
aspect of the treatment of hypovolaemic shock in patients with critical illness in order to 
increase cardiac output and systemic vascular resistance.  Khoury and McGill (2011) 
reported that norepinephrine led to a reduction in insulin sensitivity in non-critically ill 
patients and suggested that during the haemodynamic support in the treatment of acute 
illness the insulin administration rate will need to be increased or decreased according to 
the administration or discontinuation of catecholamines (Khoury and McGill 2011).  
Therefore, insulin protocols do not take into account the physiological changes that may 
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occur due to the drugs administration in the intensive care setting such as catecholamines, 
which in turn, may increase the risk of both hypoglycaemia and hyperglycaemia.  This may 
be avoided with better understanding of the metabolic effect of these drugs (Khoury and 
McGill 2011).  However, this had a small study sample (n=11) and therefore it is difficult 
to generalize their findings to all critically ill patients.  Most of these studies were in 
surgical patients, it may be inappropriate to generalise their findings to critical illness due 
to medical conditions.  This may be because the cause of illness, or its management.  
Surgical and medical patients should possibly be considered separately both in terms of the 
clinical protocol and research investigations of hyperglycaemia control in patients with 
critical illness. 
In the SPRINT study that also studied tight glycaemic control in a general ICU there was a 
similar frequency of severe hypoglycaemia.  However, the incidence of moderate 
hypoglycaemia between 2.2 mmol/l and 4.4 mmol/l was 12.8%.  They could not identify 
an association between glycaemia and mortality when the tight glycaemic protocol was 
used.  In the SPRINT study the analysis of glycaemic control was over the entire ICU stay 
rather than on a daily basis and the use of drugs that influence glycaemia apart from insulin 
was not examined. 
It has been established that hyperglycaemia in patients with critical illness may directly or 
indirectly have harmful effects independent of diabetes.  However, it is not clear or 
established the frequency of this medical issue and the association with other different 
medical conditions that may critically ill patients suffer from (Van den Berghe et al. 2001).  
Several observational studies have shown that patients with critical illness may suffer from 
hyperglycaemia; this elevation of plasma glucose level may increase the morbidity and 
mortality rates thereafter independent of pre-existing diabetes.  Hyperglycaemia has been 
reported in many studies to be more common in patients with critical illness, who suffer 
from acute myocardial infarction, acute stroke, sepsis, and postoperative cardiac surgery, 
51 
 
whether those patients had previous history of diabetes or not.  However, it is not clear or 
established the frequency of this medical issue and the association with other different 
medical conditions that may critically ill patients suffer from.  Some studies have shown 
that management of the hyperglycaemia has been considered to have beneficial effects but 
the ideal target for plasma glucose, as well as the critical ill population that would benefit 
most from this treatment remains controversial (Krinsley 2006). 
In contrast, other studies have presented that treatment of hyperglycaemia did not reduce 
morbidity and mortality rates among those patients (Malmberg et al. 2005; Chuang et al. 
2006; Treggiari et al. 2008; The NICE-SUGAR Study Investigators 2009). 
There are a few important questions from this work; 
- Why hyperglycaemia occurs in ICU patients without a previous history of diabetes (Is 
hyperglycaemia a marker or a cause of adverse outcomes)? 
- Why hyperglycaemia appears to be so deleterious? 
- What is the mechanism underlying the development of hyperglycaemia in critically ill 
patients? 
- Are there are variable effects of hyperglycaemia in different diseases? 
- What are the most appropriate glycaemic targets for different populations of ICU 
patients? 
- Which population of ICU patients would benefit most from glycaemic control 
intervention?  
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1.14. The inflammatory response and outcome in critical illness 
1.14.1. The prognostic role of C-reactive protein in critical illness 
C-reactive protein (CRP) is an acute-phase protein that has been evaluated extensively in 
the clinical setting (Gabay and Kushner 1999; Ho et al. 2008).  Although CRP is not 
diagnostic of sepsis and in particular reflects a systemic inflammatory state, in the clinical 
context it is routinely used to raise suspicions of infection and further investigations such 
as imaging and blood cultures.  Moreover, a change in CRP concentrations can however 
suggest a response to treatment (Povoa et al. 2006) and may a reliable marker of outcomes 
during the post-ICU period (Ho et al. 2008; Grander et al. 2010; Ranzani et al. 2013).  Ho 
and co-workers (2008) who studied the association between discharge CRP concentration 
and prediction of in-hospital mortality in 603 unselected patients with critical illness and 
showed that a high CRP concentration at ICU discharge was an independent predictor of 
in-hospital mortality after ICU discharge (Ho et al. 2008).  A subsequent prospective study 
by Grander and co-workers (2010) who studied the maximum and discharge CRP 
concentrations in 765 nonsurgical patients with critical illness, reported that CRP levels 
during critical illness independently associated with post-ICU survival (Grander et al. 
2010).  In contrast, an observational study by Al-Subaie and co-workers (2010) who 
studied the CRP and albumin concentration on the day of ICU discharge in 1487 medical 
and surgical patients with critical illness, reported that plasma CRP was not associated with 
ICU readmissions and in-hospital mortality (Al Subaie et al. 2010).  However, it might be 
expected that patients will only leave ICU when they are fit enough and therefore exit CRP 
concentration may not be useful. 
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1.14.2. The prognostic role of albumin in critical illness 
Serum albumin is a negative acute-phase protein; thus, the degree of hypoalbuminemia in 
critically ill patients correlates with the intensity of the inflammatory response triggered by 
infection (Ho et al. 2008; Al Subaie et al. 2010; Ranzani et al. 2013).  Hypoalbuminaemia 
at admission may be associated with ICU and hospital mortality and poor outcomes in 
patients with critical illness (Al Subaie et al. 2010).  Hypoalbuminaemia in critically ill 
patients is mainly related to the underlying systemic inflammatory processes, including 
increased breakdown secondary to inflammatory mediators, loss through capillary leak, 
and renal injury (Ballmer 2001).  The association between low albumin concentrations and 
poor outcome may be directly related to loss of colloid osmotic pressure and reduction in 
antioxidant effects, or may be secondary to an ongoing inflammatory process (Vincent et 
al. 2003).  However, Cochrane review reported that “no evidence that albumin reduced 
mortality and a strong suggestion that it might increase the risk of death in patients with 
hypovolaemia, burns, or hypoproteinaemia” (Cochrane Injuries Group Albumin Reviewers 
1998)   
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1.15. Micronutrients  
Micronutrients are substances that are needed in small amounts and have significant 
physiological functions such as antioxidant effects.  Antioxidants either inhibit or delay the 
oxidation of substrates (Berger and Shenkin 2006).  There are a number of antioxidants 
such as uric acid, glutathione, albumin, bilirubin, vitamins and phenols, and enzymatic 
antioxidants such as superoxide dismutases, catalase, and the glutathione peroxidase 
(Berger and Shenkin 2006). 
Endogenous antioxidant activity balances the reactive oxygen species production but the 
normal person loses 1% of antioxidants daily.  The most important source of antioxidants 
is from nutrition.  Trace elements, including selenium and zinc, are also essential elements 
of the defence mechanism.  Nutrition antioxidants have several mechanisms; the most 
important one is as free radical scavengers, which include the following; neutralisation of 
free radicals such as reactive oxygen species production by quenching iron and reduction 
of the peroxide concentrations and repair of oxidised membranes (Heyland et al. 2005). 
1.15.1. Carotenoids  
Carotenoids enhance immune function (Hughes 1999) and appear to have a protective 
effect against ageing and several common diseases such as cancer, cardiovascular disease 
and stroke in epidemiological, however, trials of supplement have shown no benefit 
(Mayne 1996; Krinsky and Johnson 2005).  The most common carotenoids that were found 
in measurable concentration in human plasma and intracellular are lycopene, lutein, α-
carotene and β-carotene (Voutilainen et al. 2006).  The properties of carotenoids appear to 
be mediated by a reduction of oxygen derived radicals (Bast et al. 1998). 
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1.15.2. Vitamin D 
Although the principle metabolic effect of vitamin D is on maintaining bone health it may 
also effect the glycaemic control both directly and indirectly (Pittas et al. 2007).  Directly, 
through enhancing the expression of insulin receptor, which in turn enhances insulin 
function for glucose transport (Maestro et al. 2000).  ).  Indeed, a review by Badawi and 
co-workers (2010) reported that the active biological metabolite of vitamin D, 1, 25-
dihydroxy vitamin D (1, 25(OH)2D), stimulates insulin synthesis and secretion through 
vitamin D receptors (VDR).  Several studies have discussed the relationship between 
single nucleotide polymorphisms (SNPs) in the genes regulating vitamin D receptor (VDR) 
and vitamin D-binding protein (DBP) with glucose intolerance and insulin secretion (Fu et 
al. 2009; Badawi et al. 2010). 
This relationship explains the reported link between Vitamin D and diabetes type 2, 
whereby the overall risk rate of type 2 diabetes was reduced in individuals who consume at 
least 800 IU/d of vitamin D daily. 
There is an immunomodulatory function of vitamin D, as VDRs are found in many types 
of immune cells.  In addition, (1, 25(OH)2D), has a significant influence in the modulation 
and production of immunostimulatory and immunosuppressive cytokines, for example 
interleukin 12 and interleukin 10 respectively (Badawi et al. 2010). 
Vitamin D and calcium homeostasis may reduce the risk of type 1 and 2 diabetes (Pittas et 
al. 2007).  Calcium may have a role in insulin secretion and function, but it works together 
with vitamin D (Pittas et al. 2007).  The indirect method by which vitamin D regulates 
glucose concentration in blood is mainly by regulating the extracellular calcium levels and 
the influx of the calcium via cellular membrane.  Insulin release depends mainly on this 
indirect method (Pittas et al. 2007).  As a result, insulin secretion is a calcium dependant 
process, any inadequate vitamin D or calcium intake may disturb the balance in the influx 
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of the β-cells extracellular and intracellular calcium pools, which in turn may alter the 
normal insulin secretion.  This may explain that the deficiency in these micronutrients may 
adversely affect the glycaemic control (Pittas et al. 2007).  Overall, the supplement 
combination of both vitamin D and calcium may improve and optimize the glucose 
metabolism and control (Pittas et al. 2007).  However, this has not been examined with 
critical illness. 
1.15.3. Vitamin E and C 
Vitamin E is a fat-soluble vitamin, which has potent anti-inflammatory and anti-oxidant 
functions.  Vitamin E consumption may inhibit the peroxidation of low density lipoprotein 
(LDL), neutralize free radical produced from normal cellular metabolism.  This in turn 
prevents the oxidative stress that hyperglycaemia may cause, reduce the expression of 
cytokine gene.  Vitamin E may have a role in treatment and prevention of long-term 
hyperglycaemia complications by reducing protein glycation, lipid oxidation, and by 
suppressing platelet aggregation and adhesion (O'Connell 2001).  Vitamin E deficiency 
may be associated with increasing the incident rate of diabetes, and having it as a 
supplement improved the glycaemic control and reduced oxidative stress markers. 
Recently, the relationship between vitamin E and vitamin C in improving insulin 
sensitivity has been discussed.  Taking a 1000mg/day vitamin C combined with 400 
IU/day vitamin E may reduce the development of insulin sensitivity resistance (Ristow et 
al. 2009). 
1.15.4. Zinc and selenium 
Zinc is importance in human health, as a cofactor in many catalytic processes and zinc also 
has a structural role.  Selenium is essential for the catalytic activity of glutathione 
peroxidase (GSH-Px) protecting against membrane lipid peroxidation (Thomas et al. 
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1990).  Zinc also combats oxidative stress as a cofactor in zinc superoxide dismutase.  Zinc 
and selenium both play important functions in immune regulation (Fraker et al. 2000).  
Adequate trace element status is considered to be of particular importance in critically ill 
patients who have significantly reduced circulating and body stores of antioxidants, such as 
zinc superoxide dismutase and GSH-Px, therefore increasing reactive oxygen species 
(Heyland et al. 2005). 
Concentrations of zinc and selenium decrease significantly following severe trauma, 
surgery, sepsis and severe systemic inflammatory response and remain low for several 
days and weeks (Berger et al. 1998; Heyland et al. 2006).  It has been proposed that this 
reduction in trace element concentrations may deplete circulating antioxidants leading to 
an elevation of reactive oxygen species and so exacerbating the severity of illness (Berger 
and Chiolero 2007).  Other groups have also suggested that decreased plasma trace 
elements concentrations are associated with increased severity of critical illness (Goode et 
al. 1995; Metnitz et al. 1999; Rinaldi et al. 2009). 
It has been reported that the changing of the concentration of insulin and zinc in human 
pancreas has a similar effect.  Zinc is required in insulin synthesis, secretion and storage; it 
also has shown to improve glucose levels in patients with type 2 diabetes and may delay 
the effect of oxidative stress and the development of diabetes chronic microvascular and 
macrovascular complications (Akhuemokhan et al. 2013). 
1.15.5. B vitamins 
Vitamins B1, B2 and B6 serve as cofactors for several enzymes important in energy 
metabolism.  They are important for the production of reducing substances used in oxidant 
stress defences.  There is evidence that plasma concentrations of B-vitamins, fall as part of 
the systemic inflammatory response and therefore this may be a confounding factor in their 
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interpretation.  In order to address this issue the use of red cell measurements of B1 
(Thiamine diphosphate), B2 (Flavin adenine dinucleotide) and B6 (pyridoxal phosphate) 
has been proposed. 
Vitamin B1 is an important cofactor for enzymes involved on carbohydrate metabolism, 
also it is a cofactor for several enzymes, such as pyruvate dehydrogenase, oxoglutarate 
dehydrogenase and transketolase (Gray et al. 2004; Fattal-Valevski A 2011).  Vitamin B2 
and its two cofactors flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).  
FAD was mainly found in red blood cells, FMN and FAD act as cofactors in oxidation-
reduction reaction and in the respiratory chain and are thus involved in energy production 
(e.g. cytochrome, glutathione reductase, glutathione peroxidase, xanthine oxidase and 
methylene tetrahydrofolate reductase) (Talwar et al. 2003b; Talwar et al. 2005).  Vitamin 
B2 is required for normal immune function, by maintenance of glutathione status (Grimble 
1997).  It also has  a suppressive effect on the production of tissue inflammatory mediators 
and decreases plasma elevated nitric oxide levels (Kodama K et al. 2005).  Vitamin B6, 
also known as  pyridoxal phosphate, acts as cofactor for a wide variety of enzymes of 
intermediary metabolism, particularly proteins, carbohydrates, fats and homocysteine and 
synthesis of several neurotransmitters and heam (Leklem 1991; Quasim et al. 2005).  
These vitamins act as cofactors for many enzymes that regulate glucose, lipid and amino 
acid metabolism and neurotransmitter synthesis (O'Connell 2001). 
1.16. Assessment of vitamin and trace elements status in hospitalised patients 
Vitamin and trace element status can be defined as the extent to which an individual’s 
physiological need for vitamins and trace elements is being met.  Optimal vitamin and 
trace element status is a balance between intake and requirements.  Vitamin and trace 
element intakes depend on actual food consumption which can be influenced by various 
factors such as economic status, eating behaviour, emotional status, cultural influences, 
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disease, and the ability to absorb the vitamins and trace elements consumed.  Vitamin and 
trace elements requirements are also influenced by many factors, including infection, 
disease, fever or trauma, growth and pregnancy.  Adequate intake is necessary, but 
provision of excess supplements to patients who do not need them may be harmful.  Single 
micronutrient deficiency states are comparatively easily recognised and treated.  
Subclinical deficiency, often of multiple micronutrients, is more difficult to recognise, and 
laboratory assessment is often complicated by the present of systemic inflammatory 
response.  Shenkin concluded that “clinical benefit was most likely in those patients who 
are severely depleted and at risk of complications”(Shenkin 2006).  
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1.17. Aim of the thesis 
The aim of the thesis is to examine the relationship between the systemic inflammatory 
response, as evidenced by both CRP and albumin, on plasma glucose, plasma and red cell 
concentrations of vitamins and trace elements in a nutrition screen cohort and a critical 
illness cohort.  
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Table 1-5: Summary of the hyperglycaemia studies. 
Author (S)/ year Subject Population Findings  Comments 
Malmberg, 1997 
DIGAMI 1 study. 
Stockholm/Sweden. 
 
Hyperglycemia and 
patients with 
critical illness. 
620 patients with 
diabetes and acute 
myocardial 
infarction. Medical 
ICU. 
A significant reduction in haemoglobin 
A1c in both groups. Significantly more 
in infusion group. 
30% reduction of one year mortality 
rate in intervention.  
97% of all deaths in both groups 
occurred due to cardiovascular causes. 
There was a significant reduction in 
these events in the intervention group 
-The subjects were patients with diabetes. 
-Cardiac patients (MI). 
-The findings may suggest that long term 
glycaemic control may be important in 
the prevention cardiovascular causes of 
death in patients with diabetes. 
-After DIGAMI study the intervention to 
control plasma glucose levels in patients 
with myocardial infarction become a 
standard practice. 
-Glycaemia focussed study. 
Scott et al, 1999. 
England, the UK. 
 
Hyperglycemia and 
patients with 
critical illness. 
50 patients with 
stroke.  Medical 
ICU. 
-Glucose potassium insulin (GKI) 
infusion treatment to control mild to 
moderate  hyperglycemia in patients 
with stoke is reported to be safe, 
practical, and has a significant 
improvement of lowering the high 
plasma glucose without any significant 
episodes of hypoglycaemia , 
cardiovascular events and excess 
mortality rate at first four week post 
stroke. 
-Pilot study. 
-Non- diabetic patients. 
-Patients with acute stroke. 
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Van Den Berghe et 
al, 2001. 
Belgium 
Hyperglycemia and 
patients with 
critical illness. 
1,548 critically ill 
patients/ surgical 
ICU. 
Significant reduction mortality rate. 
Decrease in overall hospital mortality 
rate, bloodstream infection, acute renal 
failure that required dialysis or 
heamofltration, red cell transfusion, 
clinical illness polyneuropathy, the need 
for mechanical ventilation. 
- Prospective randomized controlled 
study. 
- Heterogeneous surgical ICU population, 
lead to difficulties to extrapolate the 
result to medical ICU patients. 
-63% cardiac patients. 
-Male: Female ratio 71:29. 
-Single-centre study. 
Van Den Berghe et 
al, 2003 
Belgium 
Hyperglycemia and 
patients with 
critical illness. 
Extension study to 
Van Den Berghe et 
al, 2001 study. 
Same number of 
patients. 
Normoglycaemia was achieved safely 
within 24 hours of the ICU admission. 
- Heterogeneous medical and surgical. 
ICU patients. 
Krinsley, 2004 
Stamford, Conn, the 
USA. 
Hyperglycemia and 
patients with 
critical illness. 
1,600 medical-
surgical ICU 
critically ill patients.  
-No significant changes in ICU 
infection acquired rate. 
-Significant improvement of patient’s 
glucose levels. 
- Significant improvement in renal 
function. 
-Significant reduction in mortality rate 
between control and treatment group by 
21% to 15% respectively (29% 
reduction in overall mortality rate of 
ICU patients after applying the 
protocol). 
- ICU length of stay was decreased from 
- Heterogeneous medical and surgical 
ICU patients. 
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3.6 days in control group to 3 days in 
treatment group. 
Malmberg, 2005 
DIGAMI 2 study. 
Stockholm/Sweden 
Hyperglycemia and 
patients with 
critical illness. 
1253 patients with 
diabetes and acute 
myocardial 
infarction. 
-There was no significant improvement 
in the morbidity and mortality rates in 
patients who have diabetes and 
presented with acute myocardial 
infarction after acutely induction of 
long term insulin treatment compared 
with conventional treatment. 
- The study epidemiological analysis 
demonstrates that the plasma glucose 
level is a strong, independent prognostic 
factor for long term mortality among 
those patients, which in turn glucose 
control is an essential part of their 
management. 
-Multicentre prospective randomized 
blinded controlled study. 
-44 centres were in Sweden, 
Finland, Norway, Denmark, The 
Netherlands, and the UK. 
-Glycaemia focussed study. 
The CREATE-
ECLA Trial Group 
Investigation, 2005 
The USA 
Hyperglycemia and 
patients with 
critical illness. 
20,210 patients with 
ST-segment 
elevation myocardial 
infarction (STEMI). 
- No marked difference in the mortality 
rate within 7 and 30 days. 
-No significant differences between the 
both groups in the occurrence of 
ventricular fibrillation, tachycardia, 
advanced second or third degree heart 
block, electromechanical dissociation, 
and fluid volume overload. 
-A new episode of heart failure in both 
groups after 7 and 30 days of ICU 
- Randomized controlled study 
- Cardiac patients. 
- High dose of GIK infusion has neutral 
effect on mortality. 
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admission. 
-Hypoglycaemia episodes were more 
common in intervention group as well 
as hyperkalemia. 
- High dose of GIK infusion has no 
significant effect on the mortality rate 
on patients with ST- segment elevation 
myocardial Infarction. 
Van Den Berghe et 
al, 2006 
Belgium 
Hyperglycemia and 
patients with 
critical illness. 
1,200 medical ICU 
patients. 
- hypoglycemia 73% and 62% in 
conventional and intensive treatment 
group respectively. 
- A reduction of the ICU mortality rate 
by 10% among intensive insulin therapy 
group who stayed more than five days.  
- A significant improvement in the time 
of mechanical ventilation weaning, 
discharge from medical ICU and 
hospital among intensive insulin 
treatment group of patients. 
- Prospective randomized controlled 
study. 
- Heterogeneous medical ICU patients. 
- Single-centre study. 
Krinsley,2006 
Stamford, Conn, the 
USA. 
Hyperglycemia and 
patients with 
critical illness. 
5,365 non-cardiac 
surgical  ICU 
patients. 
- Hospital mortality rate was low among 
patients who plasma glucose level was 
between 4.0 -5.5 mmol/l, and increased 
progressively with the increasing in the 
level of plasma glucose. 
- The mortality rate was 40% higher 
among patients with diabetes. 
-Prospective cohort study. 
- Heterogeneous medical, surgical and 
trauma ICU patients. 
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- Hypoglycemic episodes were 1% in 
control group and 2% in intervention 
group. 
Cheung and 
colleagues (2006) 
New South Wales, 
Australia. 
Hyperglycemia and 
patients with 
critical illness. 
240 patients with 
acute myocardial 
infarction. 
- There was no significant difference in 
mortality rate between two groups. 
-There were low rate of cardiac failure 
and of reinfarction rate in the insulin 
infusion therapy group. 
-There was 13 hypoglycaemia events in 
insulin infusion therapy group compare 
with only 2 events in the conventional 
therapy group. 
-Multicentre open-label randomized 
controlled clinical study. 
- 6 hospitals in the state of New South 
Wales, Australia. 
Treggiari et al, 2008 
Washington/ the 
USA 
Hyperglycemia and 
patients with 
critical illness. 
10,456 medical, 
surgical, trauma and 
neurosurgical ICU 
patients. 
-Plasma glucose at ICU admission was 
lower after applying of intensive insulin 
treatment protocol. 
-The proportions of patients receiving 
insulin infusion increased dramatically 
over the study periods. 
-The average SAPS II and APS III 
scores were lower in period III than in 
periods I and II. 
-Reduction in the requirement of 
mechanical ventilation. 
-An increase in hypoglycaemia 
episodes three to four times from 
period I to III. 
- Cohort study. 
- Heterogeneous ICU patients. 
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-Hypoglycemic was the main cause of 
death.  
-The overall ICU mortality rate was 
significantly different between periods 
II and III compared with period I. 
-There was an increase in the mortality 
rate in patients that stayed ≤ 3 days in 
ICU. 
-A policy of intensive insulin therapy in 
a group of ICUs from a single 
institution was not associated with a 
decrease in hospital mortality. 
Egi et al, 2008 
Australia and New 
Zealand. 
Hyperglycemia and 
patients with 
critical illness. 
4,946 ICU patients. -There was a strong association 
between plasma glucose level and the 
mortality rate in non-diabetic critically 
ill patients compared with those with 
diabetes. 
-The mortality rate was four times 
greater in patients without diabetes. 
-This may support the hyperglycaemia 
may have poor outcome in critically ill 
patients who do not have pervious 
history of diabetes.  
- Retrospective observational cohort study. 
- Heterogeneous ICU patients. 
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The NICE-SUGAR 
2009 
Australia and New 
Zealand. 
Hyperglycemia and 
patients with 
critical illness. 
6,104 medical and 
surgical ICU patients 
from 42 hospitals. 
-Patients treated with intensive glucose 
control had a higher mortality rate than 
conventional glucose control patients in 
90 days of ICU admission. 
- Randomized controlled study. 
- Evaluation of the ICU mortality rate at 
90 days of ICU admission. 
- Heterogeneous ICU patients. 
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2. The relationship between glucose concentrations and 
clinicopathological factors within the context of an insulin protocol 
in patients with critical illness.  
2.1. Introduction 
Acute illness leads to a significant metabolic response.  An important mechanism is 
through the enhancement of the catabolic response by the release of pro-inflammatory 
cytokines such as interleukin-1 (IL-1), interleukin-6 (IL6), interleukin-8 (IL8) and tumour 
necrosis factor (TNF) (Hill 1999) and counter regulatory hormones such as: 
catecholamines, cortisol, glucagon, and growth hormone (Desborough 2000).  This may in 
turn lead to hyperglycaemia, glucose intolerance and insulin resistance which are 
associated with multiple organ dysfunction and increased morbidity and mortality 
(Vanhorebeek and Van den Berghe 2006; Egi et al. 2008).  The overall metabolic effect of 
the hormonal changes is increased catabolism which mobilises substrates to provide energy 
sources, and a mechanism to retain salt and water and maintain fluid volume and 
cardiovascular homeostasis (Desborough 2000). 
The elevation in plasma glucose concentrations may occur due to the increase of glucose 
production in liver and increase insulin resistance in skeletal muscle (Cuthbertson 1979).  
Moreover, secretion of pituitary hormones and stimulation of sympathetic nervous system 
appear to have a secondary effect on both the release and action of cortisol, 
norepinephrine, and epinephrine (Van den Berghe et al. 2001; Vanhorebeek and Van den 
Berghe 2006), resulting in increase in plasma glucose concentration by increasing 
glucagon secretion and reducing the insulin secretion. 
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Finally, the use of some drugs in ICU such as exogenous catecholamines and 
glucocorticoids may suppress the secretion and the action of insulin, and in turn may 
inhibit glycogen synthesis, stimulate gluconeogenesis and alter insulin-mediated glucose 
uptake by tissues.  Clearly these exogenous hormones may exacerbate insulin resistance, 
nitrogen loss and hyperglycaemia (Saberi et al. 2008; Ead 2009; Kavanagh and McCowen 
2010; Thomas et al. 2010).  The degree of insulin resistance induced by exogenous 
hormones such as glucocorticoids is greater in the critically ill compared to healthy 
individuals receiving these drugs (Pretty et al. 2011).  Therefore, the clinical situation is 
complex and involves combinations of endogenous and exogenous hormones leading to 
alterations of glucose homeostasis and therefore a tendency to produce hyperglycaemia  
(Khoury and McGill 2011).  It is now recognised that hyperglycaemia may directly or 
indirectly have harmful effects on organs (Van den Berghe et al. 2001).  Several 
observational and interventional studies have shown that most patients with critical illness 
may suffer from hyperglycaemia and this has a significant effect on outcome (Krinsley 
2006).  However, it was not clear whether all patients with critical illness are equally 
susceptible to the adverse effects of hyperglycaemia and whether all would have similar 
benefit from treatment (Falciglia et al. 2009). 
Therefore, the aim of the present study was to evaluate in detail glucose concentrations in 
patients with critical illness during their ICU admission and to examine the multiple 
determinants of hyperglycaemia and outcome, including severity of illness, administration 
and use of drugs that can influence glycaemic control. 
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2.2. Patients and methods 
2.2.1. Patients and study design 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008.  At this time the ICU in Glasgow Royal Infirmary had nine beds with an annual 
admission with approximately 340 patients per year.  The median length of stay was 6.9 
days and the median predicted mortality rate was 37%.  Only patients with an ICU stay of 
seven days were included in this retrospective observational study. 
APACHE II score (Knaus et al. 1985) ( predicted hospital mortality and ICU length of stay 
were recorded.  Medical variables included prick (Point of Care (POC) capillary blood 
glucose concentration, laboratory plasma glucose concentration (Lab-Glucose), CRP, and 
white cell count, albumin and fluid balance were measured in daily basis in all patients.  
Drugs that may have influenced plasma glucose were also recorded such as insulin, 
epinephrine, norepinephrine, dobutamine and hydrocortisone, and the drug doses were 
recorded on a daily basis.  The data were collected manually from the Royal Infirmary ICU 
computer using Carevue programme, such data was collected as part of routine clinical 
care. 
Albumin was measured by a BCP dye-binding method and C-reactive protein was measured 
using an automated analyser (Architect, Abbott Diagnostics, USA).  For C-reactive protein the 
limit of detection was 5 mg/l.  The inter-assay coefficient of variation was less than 3% and 
5% over the sample concentration range for albumin and C-reactive protein respectively.  The 
limit of detection for albumin was 10 g/L. 
There were several enteral feeding preparations used in the ICU such as Jevity (1 cal/ml), 
Jevity Plus (1.2 cal/ml), Jevity 1.5 (1.5 cal/ml) and Osmolite (1 cal/ml), Osmolite Plus (1.2 
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cal/ml), Peptisorb (1 cal/ml), Perative (1.31 cal/ml) and Nepro (2 cal/ml). Patients routinely 
received 2L of one of these preparations per day, amounting to an intake of 2000-2500 
calories per day.  The caloric intake was measured in each patient and presented on a daily 
basis. 
The study was previously approved by the ethics committees of the North Glasgow NHS 
Trust and Multicentre Research Ethics Committee (MREC) Scotland.  Where patients were 
unable to give signed informed consent, consent was obtained from the patients’ next of 
kin or welfare guardian in accordance with the requirements of the Adults with Incapacity 
Scotland (2000) Act (Appendix 1, 2). 
2.2.2. ICU insulin protocol 
In the ICU, Glasgow Royal Infirmary, hyperglycaemia was treated according to Insulin 
Protocol Ward 25 GRI as of July the 5th 2006.  This continued to be used over the period 
of the study.  The target of plasma glucose concentration for critically ill patient in ICU 
was 4.4- 6.9 mmol/l.  In order to maintain this concentration, patients who required insulin 
infusion were infused with a standard concentration of 50 units of insulin in 50 ml 0.9% 
saline (Blood glucose control protocol Figure 2-1 p. 91). 
2.2.3. Statistical analysis 
Data from patients with critical illness was presented as median and range.  Comparisons 
between the medical and surgical critically groups were performed with the use of the 
Mann-Whitney U test.  Correlations between variables were performed with the use of the 
Spearman’s rank correlation.  Data from different time points in the patient groups were 
tested for statistical significance with the use of the Wilcoxon signed rank test.  All 
statistical tests were 2-tailed, and because of the number of statistical comparisons a P 
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value of <0.01 was considered to be significant.  Analysis was performed with the use of 
SPSS software (version 19; SPSS Inc, Chicago, IL). 
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2.3. Results 
2.3.1. Study population and baseline characteristics 
In total, one hundred adult patients with critical illness (medical n=56, surgical n=44) were 
studied.  With reference to glucose, there was a collection of the finger stick plasma 
glucose concentrations on each patient.  The frequency of these measurements was 
dependent upon the stability of the patient’s plasma glucose, clinical condition and 
nutrition intake in ICU. 
Due to the number of observations only the first 50 patients were examined.  In the first 50 
patients over the first seven days of ICU stay, there was a total of 3,674 Point of Care 
(POC) capillary blood glucose measurements.  In these patients, there was a median of 11 
Point of Care (POC) capillary blood glucose measurements in a 24 hour period.  On 
analysis of these 3,674 Point of Care (POC) capillary blood glucose measurements there 
were 5 (0.1%) were <2.2mmol/l, 242 (6.6 %) were between 2.2- 4.4 mmol/l, 1747 (47.6%) 
were between 4.4-6.9 mmol/l, 1,067 (29%) were between 6.9-9.0 mmol/l, and 613 (16.7%) 
were >9.0 mmol/l.  The daily average of these individual POC capillary glucose 
measurements were consequently correlated with the daily Lab-Glucose measurements.  
These were significantly associated with each other over days 1-7 (rs=0.802, P<0.001), (rs 
= 0.564, P<0.001), (rs = 0.428, P<0.01), (rs = 0.606, P<0.001), (rs = 0.519, P<0.001), (rs = 
0.441, P<0.01) respectively.  Therefore, the daily Lab-Glucose measurements were 
subsequently correlated with other 24 hour measurements in all 100 patients. 
The characteristics of the patients with critical illness on admission are shown in Table 2-1.  
The majority of patients were male (59%) and over the age of eighteen.  The median ICU 
stay was 11.7 days; the median APACHE II score was greater than 22, and a predicted 
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hospital mortality rate of ≥ 40%.  Sixty five patients survived and thirty five patients died 
in the ICU. 
The admission clinicopathological characteristics of the patients with critical illness are 
shown in Table 2-1.  The median of finger stick glucose measurements was similar to that 
of the Lab-Glucose measurements (6.4 mmol/l and 6.6 mmol/l respectively), which was 
above the normal values and close to the upper limit of the target glucose concentration in 
the insulin protocol that applied in the study period (Figure 2-1 p. 91).  The median daily 
caloric intake was 30.8 Kcalories.  The median CRP concentration was elevated at 134 
mg/l, median white cell count was close to the upper normal level 11.7 x 10
9
, and the 
median albumin concentration was low with median concentration of 16 g/l.  The mean 
administration of insulin, norepinephrine, epinephrine, hydrocortisone and dobutamine 
were 0.8 U hour 
-1
, 0.5 mg hour
-1
, 0.1 mg hour
-1
, 1.5 mg hour
-1
, 3.4  mg hour
-1
 respectively.  
The administration of insulin ranged from zero to 9.3 units per hour, norepinephrine from 
zero to 4.1 mg per hour, epinephrine from zero to 2.7 mg per hour, hydrocortisone from 
zero to 16 mg per hour and dobutamine from zero to 76.4 mg per hour. 
The admission clinicopathological characteristics of surgical and medical patients with 
critical illness medical are shown in Table 2-2.  Compared with medical patients, surgical 
patients more likely to be male (P <0.05) and had lower insulin administration on 
admission day (P <0.05).  This was also the case in the subsequent six days of ICU stay, 
which was the mean of insulin administration in medical patients at the second day 2.6 
u/hour and in surgical patients 1.2 u/hour (P <0.01), on the third day 2.8 u/hour for medical 
patients and 1.3 u/hour for surgical patients (P <0.01), 2.8 u/hour versus 1.2 u/hour in the 
fourth day (P <0.001), 3.0 u/hour versus 1.3 u/hour on the fifth day (P <0.001), 2.7 u/hour 
versus 1.6 u/hour on the sixth day (P <0.01), and 2.6 versus 1.3 u/hour in the seventh day 
(P <0.01). 
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The relationship between plasma glucose and other variables and ICU death is shown in 
Tables 2-3.  Compared with survivors, on the admission day non-survivors were older (P 
<0.01), had higher albumin concentration (P < 0.01).  On multivariate logistic regression 
analysis of the significant variable identified (Table 2-4), only albumin (OR 0.895, 95%CI 
0.825-0.971, P =0.007) was independently associated with death in ICU. 
2.3.2. Relationship between plasma glucose and other variables  
The inter-relationships between plasma glucose , CRP, white cell count, albumin, fluid 
balance, insulin, norepinephrine, epinephrine, dobutamine and hydrocortisone were 
examined and presented in series of supplemental Tables (2-5, 2-6 and 2-7) for the first, 
fourth and seventh days after admission to ICU. 
On the first, forth and seven days after admission to ICU the inter-relationships between 
plasma glucose , CRP, white cell count, albumin, fluid balance, insulin, norepinephrine, 
epinephrine, dobutamine and hydrocortisone were examined and presented in series of 
supplemental Tables (2-5, 2-6 and 2-7). 
Plasma glucose was directly associated with insulin on admission day (rs=0.321, P <0.01, 
Table 2-5).  It was also had a direct associated with epinephrine on admission day 
(rs=0.307, P <0.01; Table 2-5), with albumin on the fourth day (rs =298, P <0.01; Table 2-
6), and with fluid balance on the seventh day (rs =285, P <0.01; Table 2-7).  Caloric intake 
was inversely associated with norepinephrine on admission (rs = -0.323, P =0.001; Table 
2.5). 
White cell count was directly associated with norepinephrine on admission day (rs =0.262, 
P <0.01; Table 2-5).  It was also associated with hydrocortisone on fourth day (rs= 0.316, P 
<0.01; Table 2-6), and with fluid balance on the seventh day (rs= 0.283, P <0.01; Table 2-
7).  Albumin was inversely associated with body fluid balance on admission day (rs= -
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0.538, P <0.001; Table 2-5) and fourth day (rs = -0.424, P <0.001; Table 2-6).  It was also 
inversely associated with norepinephrine on fourth (rs = -0.450, P <0.001; Table 2-6) and 
seventh day (rs = - 290, P < 0.01; Table 2-7).  Fluid balance was directly associated with 
epinephrine on the fourth day (rs = 0.285, P <0.01; Table 2-6).  It was also associated with 
norepinephrine on fourth (rs = 0.595, P <0.001; Table 2-8), and with hydrocortisone on the 
fourth (rs =258, P <0.01; Table 2-6) and seventh day (rs = 0.285, P <0.01; Table 2-7). 
Insulin administration was directly associated with hydrocortisone on the seventh day (rs= 
262, P < 0.01; Table 2-7).  Norepinephrine was directly associated with dobutamine on 
admission day (rs=259, P <0.01; Table 2-5), fourth (rs= 0.304, P <0.01; Table 2-6) and 
seventh day (rs= 0.277, P <0.01; Table 2-7), and with hydrocortisone on admission day 
(rs= 0.499, P <0.001; Table 2-5), fourth (rs= 0.359, P <0.001; Table 2-6) and seventh day 
(rs= 308, P <0.01; Table 2-7).  Epinephrine was directly associated hydrocortisone on 
admission day (rs=391, P <0.01; Table 2-5) and seventh day (rs= 0.272, P <0.01; Table 2-
7). 
Of the 100 patients who were admitted in the ICU, they were had two further follow up 
samples during their ICU stay first was on forth day and last was on seventh day (Tables 2-
8 and 2-9 respectively).  On the first follow up there was a significant increase in caloric 
intake (P <0.001), low albumin (P = 0.005), positive fluid balance (P =0.007) and high 
insulin administration (P < 0.001).  On the last follow up there was a significant increase in 
caloric intake (P <0.001), low albumin (P = 0.011), high insulin administration (P < 0.001) 
and low norepinephrine and epinephrine administration (P <0.001, P = 0.003 respectively). 
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2.4. Discussion 
The results of the present study show that, using a standard insulin protocol in patients with 
critical illness, few patients had glucose concentrations outwith the target results and in 
particular hypoglycaemia was a rare event.  This was consisted with the target glucose 
concentration being in the range defined as tight control.  Despite this tight insulin control, 
plasma glucose in patients with critical illness was also dependent on several variables 
including caloric intake and administration of corticosteroids. 
These results are consistent with the work of Duska and Andel (2008) also reported that in 
a small study of 20 patients, that plasma insulin concentrations were determined more by 
endogenous secretion than insulin infusion, even during the systemic inflammatory 
response when exogenous insulin requirements are high (Duska and Andel 2008).  For 
example, insulin administration may be interrupted and other drugs such as epinephrine 
and norepinephrine given that may destabilize the plasma glucose concentration 
(Braithwaite et al. 2006). 
In the last two decades several studies have reported a relationship between the elevation 
of plasma glucose concentrations in patients with critical illness and their poor outcomes 
regarding a variety of settings and disorders including post-operative ICU surgical cardiac 
patients (Van den Berghe et al. 2001) post-operative ICU non cardiac patients (Krinsley 
2006), mixed population from surgical and medical ICU (Scott et al. 1999; Krinsley 2004), 
myocardial infarction (Malmberg 1997; Cheung et al. 2006) , stroke (Malmberg 1997; 
Cheung et al. 2006) trauma (Scott et al. 1999), and neurosurgical ICU patients (Scott et al. 
1999). 
In view of this information more rigorous hyperglycaemia management protocols using 
insulin therapy have been undertaken in patients with critical illness (Van den Berghe et al. 
2001).  These studies reported that intensive insulin therapy reduced the morbidity and 
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mortality rate regardless of those patients had a previous history of diabetes or not (Van 
den Berghe et al. 2001; Krinsley 2004; Krinsley 2006; Van den Berghe et al. 2006; 
Treggiari et al. 2008).  However, some of these studies, such as the original Van den 
Berghe et al (2001) paper and Preiser et al (2009) have been criticised because the 
population were predominately post cardiac surgery.  Indeed, it was already well known 
that following myocardial injury hyperglycaemia had significant harmful effects and 
associated with poor outcomes (Diabetes Mellitus Insulin-Glucose Infusion in Acute 
Myocardial Infarction Study, (Malmberg 1997; Malmberg et al. 2005).  Therefore, studies 
which have a population of patients with cardiac injury may not be representative of all 
critically ill patients and in particular those with sepsis.  Other studies have major 
limitations, Krinsley et al (2004) demonstrated a substantial mortality reduction (an 
absolute reduction of over 6% and a relative reduction of 29.3%), and this was however 
based on historical controls which severely reduce the validity of any conclusions 
regarding cause and effect.  The SPRINT study also demonstrated significant 
improvements in outcome but was also based on historical controls (Chase et al. 2008). 
More recent studies such as NICE-SUGAR Study (2009) have reported that patients who 
had intensive glucose control with plasma glucose target between 4.4-6.0 mmol/l had a 
higher mortality rate than conventional glucose control patients with plasma glucose target 
<10 mmol/l within 90 days of ICU admission.  Also, severe hypoglycaemic episodes, 
where plasma glucose < 2.2 mmol/l, were more common in the intensive glucose control 
group (Van den Berghe et al. 2003; Cheung et al. 2006).  However, the cause behind the 
increasing of mortality rate among intensive glucose control group of patients was not 
clear, whether due to the reduction of plasma glucose concentration, the increase of insulin 
administration, the occurrence of hypoglycaemia or due to the study methodology (The 
NICE-SUGAR Study Investigators 2009).  Further analysis of the data from the NICE 
Sugar trial confirmed the association between the hypoglycaemia and outcome but could 
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not establish as causal link (The NICE-SUGAR Study Investigators 2009; Finfer et al. 
2012).  Several recent studies, have also studied factors influencing glycaemic control.  
These studies have significant limitations, for example Dossett et al (2008) did not report 
on the intake of calories from nutrition support and Egi et al (2009) did not include any 
analysis of the drugs likely to influence insulin sensitivity (Dossett et al. 2008; Egi et al. 
2009).  Therefore, the treatment of hyperglycaemia in critically ill patients remains a 
controversial issue (Mehta et al. 2005).  Moreover, the frequency of hyperglycaemia and/or 
hypoglycaemia and the association with the other medical conditions that occur in patients 
with critical illness requiring insulin therapy is not clear. 
In a much larger study Flaciglia reported that hyperglycaemia was associated with severity 
of illness and outcome.  This study looked at over 250,000 patients in 153 critical care 
units.  Their definition of hyperglycaemia was based upon the averages of all of the 
laboratory glucose measurements made for each patient.  Their findings indicated that in 
some patient’s hyperglycaemia was more difficult to treat and that hyperglycaemia was 
more strongly associated with a poor outcome in some medical diagnoses compared with 
surgical patients.  Neither this nor the present study established whether the resistance to 
insulin per se or administering high dose of insulin is a cause of poor outcomes.  Indeed, in 
the NICE sugar study a unique concern was that excessive insulin administration in the 
context of a tight glucose control protocol was the cause of the excess mortality. 
In the present study it was of interest that, on admission, surgical patients had less 
requirement for insulin to control glucose concentration on admission and over the 
subsequent 6 days, they also had less catecholamine administration.  It was of also of 
interest that, at the daily level, when a counter-regulatory hormone such as norepinephrine 
was given there was a tendency for other counter-regulatory hormones to be given.  
Indeed, counter-regulatory hormone administration and fluid balance are the essential 
aspect of the treatment of critically ill patient with hypovolaemic shock in order to increase 
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cardiac output and systemic vascular resistance.  Khoury and McGill (2011) reported that 
norepinephrine led to a reduction in insulin sensitivity in non-critically ill patients and 
suggested that during the haemodynamic support in the treatment of acute illness the 
insulin administration rate will need to be increased or decreased according to the 
administration or discontinuation of catecholamines (Khoury and McGill 2011).  
Therefore, insulin protocols may not take into account the physiological changes that may 
occur due to the drugs administration in the intensive care setting such as catecholamines, 
which in turn, it may increase the risk of  both hypoglycaemia and hyperglycaemia.  This 
may be avoided with better understanding of the metabolic effect of these drugs (Khoury 
and McGill 2011).  However, this had a small study sample (n=11) and therefore it is 
difficult to generalize their findings to all critically ill patients.  Nevertheless, as 
norepinephrine was used more frequently in medical patients there may be a relationship 
between this and hyperglycaemia treatment.  Furthermore, as most of the studies that have 
investigated the benefits of glucose control using insulin in patients with critical illness 
have been in surgical patients this may suggest that medical patients behave differently.  
This may be related to the cause of illness, or its management.  Taken together these 
findings would suggest that surgical and medical patients should be considered separately 
both in terms of the clinical protocol and research investigations of hyperglycaemia control 
in patients with critical illness. 
In the present study, using detailed glucose analysis over 7 days, approximately 48% of 
plasma glucose concentrations were within the target range of 4.4-6.9 mmol/l, 7% were 
below and 45% were above the target range.  More recent insulin protocols have widened 
the target range with the intention of reducing the frequency of hypoglycaemia.  Of note in 
the present study was that the occurrence of clinical hyperglycaemia was very low.  In the 
SPRINT study that also studied tight glycaemic control in a general ICU there was a 
similar frequency of severe hypoglycaemia.  However, the incidence of moderate 
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hypoglycaemia between 2.2 mmol/l and 4.4 mmol/l was much higher in the SPRINT study 
12.8% v 6.6%.  Similar to the present study they could not identify an association between 
glycaemia and mortality when the tight glycaemic protocol was used.  In the SPRINT 
study the analysis of glycaemic control was over the entire ICU stay rather than on a daily 
basis and the use of drugs that influence glycaemia apart from insulin was not examined. 
It was also of interest that there was a significant relationship between albumin, fluid 
balance and catecholamines in the present study.  This may have been expected to occur 
due to the development of systemic inflammatory response syndrome, capillary leak and 
vasodilatation, which was treated with fluids and counter-regulatory hormones 
administration. 
Limitations of the present study were principally that it was a single centre study and a 
relatively small sample size.  Furthermore, the cohort was mixed in term of surgical and 
medical patients and there was considerable variation in the severity of illness. 
In summary, the present study differs from previous studies of glycaemic control in 
patients with critical illness in its detailed daily examination of glycaemic control.  It has 
been shown that, despite concern over the accuracy of near patient testing of glycaemia, 
there was a direct relationship between the results of fingertip testing and laboratory 
measured glucose as measures of glycaemic control.  Also, that insulin and counter 
regulatory hormone administration and caloric intake accounted for only a small part of the 
daily fluctuation of glucose concentrations in these patients with critical illness.  Therefore, 
it would appear that a plasma glucose concentration, even within the context of an insulin 
protocol, is complex and multifactorial in patients with critical illness. 
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Table 2-1:  Patient clinical characteristics on admission to ICU. 
 Reference Intervals Patients with critical 
illness (n=100) 
Age (Year) N/A 60 (18-86) 
Gender (Male/Female) N/A 59/41 
ICU stay (Days) N/A 11.7 (4.2-76.4) 
Predicted mortality rate (%) N/A 39.9 (2.0-95.2) 
APACHE II N/A 22 (6-40) 
Admission cause (Surgical/Medical) N/A 44/56 
Alive/Dead  N/A 65/35  
   
Finger stick glucose (mmol/l) 3.5-5.5 6.4 (2.9-16.7) 
Lab-Glucose (mmol/l) 3.5-5.5 6.6 (2.8-30.6) 
Intake (Kcalories/ml) N/A 30.8 (10-83) 
C-reactive protein (mg/l)  <10 134 (2-565) 
White cell count (10
9
/L) 4-11 x10
9
 11.7 (0.5-45.4) 
Albumin (g/l) 35-55 16 (10-39) 
Fluid balance (ml) N/A 856 (-176-5182) 
   
Insulin (U hour 
-1
) 
a
 N/A 0.8 (0.0-9.3) 
Norepinephrine (mg hour
-1
)
 a
 N/A 0.5 (0.0-4.1) 
Epinephrine (mg hour
-1
)
 a
 N/A 0.1 (0.0-2.7) 
Hydrocortisone (mg hour
-1
)
 a
 N/A 1.5 (0.0-16.0) 
Dobutamine (mg hour
-1
)
 a
 N/A 3.4 (0.0-76.4) 
Median (range), 
a
 Mean (range). 
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Table 2-2:  Patients clinical characteristics on admission to ICU according to 
specialities. 
Median (range), 
a
 Mean (range). 
  
 Reference 
Intervals 
Medical (n=56) Surgical (n=44) P-value 
Age (Year) N/A 57 (18-81) 62 (20-86) 0.249 
Sex (Male/Female) N/A 28/28 31/13 0.040 
ICU stay (Days) N/A 12 (4.6-65.1) 11.1 (4.2-76.4) 0.715 
APACHE II N/A 22 (9-38) 21 (6-40) 0.087 
Predicted mortality rate (%) N/A 41.9 (4.9-92.6) 37.8 (2.0-95.2) 0.181 
Alive/Dead (%) N/A 36/20 (36%) 29/15 (34%) 0.867 
     
     
Finger stick glucose 
(mmol/l) 
3.5-5.5 6.8 (3.4-16.7) 6.1 (2.9-9.9) 0.189 
Lab-Glucose (mmol/l) 3.5-5.5 6.7 (2.8-30.6) 6.5 (3.1-13.2) 0.513 
Intake (Kcalories/ml) N/A 30.8 (10-80) 30.6 (10-83) 0.953 
C-reactive protein (mg/l) <10 134 (2-565) 132 (2-447) 0.865 
White cell count  (10
9
/l) 4-11 x109 11.5 (0.5-45.5) 11.7 (2.4-31.3) 0.576 
Albumin (g/l) 35-55 18 (10-39) 15 (10-32) 0.062 
Fluid balance (ml)  781 (-176-4946) 941 (-25-5182) 0.650 
     
Insulin (u/hour)
 a
 N/A 1.2 (0.0-9.3) 0.4 (0.0-6.0) 0.036 
Norepinephrine (mg hour
-1
)
 a
 N/A 0.5 (0.0-4.1) 0.6 (0.0-4.0) 0.967 
Epinephrine (mg hour
-1
)
 a
 N/A 0.2 (0.0-2.7) 0.1 (0.0-1.6) 0.056 
Hydrocortisone (mg hour
-1
)
 a
 N/A 2.0 (0.0-16.0) 0.9 (0.0-8.0) 0.122 
Dobutamine (mg hour
-1
)
 a
 N/A 3.7 (0.0-76.4) 0.1 (0.0-50.0) 0.627 
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Table 2-3:  Patient characteristics and measurements between survivors and non-
survivors on admission to ICU. 
 Admission Survivors 
(n=65) 
Admission Non-survivors 
(n=35) 
P-value 
Age (year) 57 (18-86) 67 (20-81) 0.008 
Sex (Male/Female) 40/25 19/16 0.484 
Patients (Medical/Surgical) 36/29 20/15 0.867 
APACHE II 21 (6-40) 23 (10-34) 0.098 
Predicted mortality rate (%) 34.8 (2.0-95.2) 42.5 (11.7-87.5) 0.113 
ICU stay (Days) 11.0 (4.2-76.4) 12.8 (4.6-59.5) 0.515 
    
Finger stick glucose (mmol/l) 6.6 (2.9-16.7) 6.1 (3.8-13.9) 0.285 
Lab-Glucose (mmol/l) 6.6 (3.1-30.6) 6.6 (2.8-26.4) 0.591 
Intake (Kcalories/ml) 30.0 (10-63) 33.7 (10-83) 0.211 
C-reactive protein (mg/l) 122 (2-447) 141 (2-565) 0.908 
White cell count (10
9
/l) 10.8 (0.5-45.4) 12.2 (3.3-33.1) 0.435 
Albumin (g/l) 19 (10-39) 14 (10-28) 0.005 
Fluid balance (ml) 586 (-176-4663) 861 (-160-5182) 0.665 
    
Insulin (U hour 
-1
)
 a
 0.7 (0.0-9.3) 1.0 (0.0-8.0) 0.159 
Norepinephrine (mg hour
-1
)
 a
 0.6 (0.0-4.1) 0.4 (0.0-4.0) 0.543 
Epinephrine (mg hour
-1
)
 a
 0.1 (0.0-2.7) 0.1 (0.0-1.0) 0.701 
Hydrocortisone (mg hour
-1
)
 a
 2.0 (0.0-16.0) 0.7 (0.0-8.0) 0.071 
Dobutamine (mg hour
-1
)
 a
 4.2 (0.0-76.4) 2.0 (0.0-50.0) 0.532 
Median (range), 
a
 Mean (range). 
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Table 2-4:  The relationship between admission characteristics, the parameter, drugs 
and hospital mortality in patients with critical illness.  Univariate and multivariate 
binary logistic regression analysis. 
 
 Univariate analysis  Multivariate 
analysis 
 
 OR (95%CI) P-value OR (95%CI) P-value 
Age (years) 1.03 (1.004-1.06) 0.026   
Sex (male/female) 1.35 (0.586-3.09) 0.482   
Patients (medical/surgical) 1.07 (0.469-2.461) 0.866   
APACHE II score 1.05 (0.990-1.112) 0.103   
Predicted mortality rate (%) 1.013 (0.996-1.03) 0.135   
ICU length of stay (days) 1.008 (0.978-1.04) 0.596   
Lab-Glucose (mmol/L) 1.026 (0.927-1.136) 0.616   
Intake (K calories/ml) 1.023 (0.991-1.056) 0.154   
C-reactive protein (mg/l) 1.001 (0.997-1.004) 0.782   
White cell count (10
9
/l) 1.012 (0.996-1.062) 0.608   
Albumin (g/l) 0.895 (0.830- 0.970) 0.007 0.895 (0.825-0.971) 0.007 
Fluid balance (ml) 1.000 (1.000-1.001) 0.256   
Insulin (u/hour) 1.102 (0.877-1.384) 0.405   
Norepinephrine (mg hour
-1
) 0.834 (0.505-1.376) 0.477   
Epinephrine (mg hour
-1)
 0.905 (0.317-2.582) 0.851   
Hydrocortisone (mg hour
-1 
) 0.866 (0.738-1.017) 0.080   
Dobutamine (mg hour
-1  
) 0.982 (0.940-1.025) 0.400   
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Table 2-5:  The relationship between the parameter and drugs. Lab-Glucose, CRP, white cell count, Albumin, fluid balance, insulin, 
norepinephrine, epinephrine, hydrocortisone, and dobutamine in critically ill patients on admission day (n=100). 
 Lab-
Glucose 
Caloric 
intake 
CRP White cell count Albumin Fluid balance Insulin Norepinephrine Epinephrine Hydrocortisone Dobutamine 
Lab-Glucose  0.101 -0.155 0.0101 -0.062 -0.109 0.321** -0.023 0.307** 0.206* 0.176 
Caloric intake   -0.093 -0.067 -0.019 0.160 0.136 -0.323** -0.041 -0112 0.133 
CRP    0.13 -0.17 0.112 -0.106 0.051 0.172 0.168 -0.115 
White cell 
count 
    0.057 0.062 0.174 0.262** -0.015 0.177* 0.093 
Albumin      -0.538** 0.062 -0.250* -0.025 -0.245* 0.128 
Fluid balance       -0.116 0.119 0.035 0.067 -0.384* 
Insulin        -0.002 0.249* 0.08 0.098 
Norepinephrine         0.189 0.499*** 0.259** 
Epinephrine          0.391** 0.226* 
Hydrocortisone           0.17 
Dobutamine            
*p<0.05, **p<0.01, ***p<0.001, correlations between variables in the critically ill patients were carried out using the Spearman rank correlations (rs).  
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Table 2-6:  The relationship between the parameter and drugs Lab-Glucose, CRP, white cell count, albumin, fluid balance, insulin, 
norepinephrine, epinephrine, hydrocortisone, and dobutamine in critically ill patients on day 4 (n=100). 
 Lab-
Glucose 
Caloric 
intake 
CRP White cell 
count 
Albumin Fluid balance Insulin Norepinephrine Epinephrine Hydrocortisone Dobutamine 
Lab-Glucose  0.014 0.004 0.027 0.298** -0.162 0.033 -0.104 -0.022 0.101 0.109 
Caloric intake   -0.079 -0.071 0.111 -0.031 0.184 -0.128 -0.066 -0.131 -0.058 
CRP    0.038 -0.141 0.019 -0.013 0.07 0.072 -0.159 0.041 
White cell count     -0.193 0.072 0.111 0.215* -0.135 0.316** 0.061 
Albumin      -0.424*** 0.141 -0.382*** -0.036 -0.076 -0.088 
Fluid balance       0.075 0.595*** 0.285** 0.258* 0.185 
Insulin        0.151 -0.169 0.039 0.037 
Norepinephrine         0.246* 0.359*** 0.304** 
Epinephrine          0.026 0.087 
Hydrocortisone           0.02 
Dobutamine            
*p<0.05, **p<0.01, ***p<0.001, correlations between variables in the critically ill patients were carried out using the Spearman rank correlations (rs) 
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Table 2-7:  The relationship between the parameter and drugs Lab-Glucose, CRP, white cell count, albumin, fluid balance, insulin, 
norepinephrine, epinephrine, hydrocortisone, and dobutamine in critically ill patients on day 7 (n=100). 
 Lab-
Glucose 
Caloric 
intake 
CRP White cell count Albumin Fluid balance Insulin Norepinephrine Epinephrine Hydrocortisone Dobutamine 
Lab-Glucose  0.125 0.081 0.137 0.069 0.285 0.148 0.09 -0.006 0.167 -0.034 
Caloric intake   -0.127 -0.114 -0.029 -0.101 0.226 0.048 -0.006 -0.207 0.127 
CRP    0.169 -0.174 -0.009 0.044 0.067 0.165 -0.023 0.141 
White cell count     -0.194 0.283** -0.038 0.116 -0.06 0.158 0.05 
Albumin      -0.275* 0.034 -0.290** -0.164 -0.041 0.013 
Fluid balance       0.154 0.258* 0.087 0.285** -0.02 
Insulin        0.114 0.041 0.262** 0.014 
Norepinephrine         -0.04 0.308** 0.277** 
Epinephrine          0.272** -0.01 
Hydrocortisone           -0.037 
Dobutamine            
*p<0.05, **p<0.01, ***p<0.001, correlations between variables in the critically ill patients were carried out using the Spearman rank correlations (rs). 
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Table 2-8:  The relationship between patient characteristics and plasma glucose 
concentrations in patients with critical illness on admission and day 4 after admission. 
 Admission (n=100) Follow up  (n=100) P-value
b 
Age (Year) 60 (18-86)   
Gender (Male/Female) 59/41   
ICU stay (Days) 11.7 (4.2-76.4)   
Predicted mortality rate (%) 39.9 (2.0-95.2)   
APACHE II 22 (6-40)   
Admission cause (Surgical/Medical) 44/56   
    
Finger stick glucose (mmol/l) 6.4 (2.9-16.7) 6.4 (3.9-20.0) 0.290 
Lab-Glucose (mmol/l) 6.6 (2.8-30.6) 6.5 (3.7-19.5) 0.046 
Intake (K calories/ml) 30.8 (10-83) 67.7 (20-104) <0.001 
C-reactive protein (mg/l) 134 (2-565) 116 (18-430) 0.440 
White cell count (10
9
/l) 11.7 (0.5-45.4) 11.7 (2.3-64.3) 0.363 
Albumin (g/l) 16 (10-39) 14 (10-38) 0.005 
Fluid balance (ml) 856 (-176-5182) 1881 (-10268-9629) 0.007 
    
Insulin (U hour 
-1
) 
a 0.8 (0.0-9.3) 2.1 (0.0-17.0) <0.001 
Norepinephrine (mg hour
-1
)
 a 0.5 (0.0-4.1) 0.4 (0.0-4.9) 0.032 
Epinephrine (mg hour
-1
)
 a 0.1 (0.0-2.7) 0.04 (0.0-1.0) 0.014 
Hydrocortisone (mg hour
-1
)
 a 1.5 (0.0-16.0) 2.3 (0.0-16.0) 0.071 
Dobutamine (mg hour
-1
)
 a 3.4 (0.0-76.4) 3.0 (0.0-117.0) 0.683 
Median (range), a Mean (range), 
b
 Wilcoxon rank test. 
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Table 2-9:  The relationship between patient characteristics and plasma glucose 
concentrations in patients with critical illness on admission and day 7 after admission. 
 Admission (n=100) Follow up  (n=100) P-value
 b
 
Age (Year) 60 (18-86)   
Gender (Male/Female) 59/41   
ICU stay (Days) 11.7 (4.2-76.4)   
Predicted mortality rate (%) 39.9 (2.0-95.2)   
APACHE II 22 (6-40)   
Admission cause (Surgical/Medical) 44/56   
    
Finger stick glucose (mmol/l) 6.4 (2.9-16.7) 6.5 (3.1-12.1) 0.109 
Lab-Glucose (mmol/l) 6.6 (2.8-30.6) 6.2 (3.8-10.3) 0.024 
Intake (K calories/ml) 30.8 (10-83) 96.1 (8.6-100) <0.001 
C-reactive protein (mg/l) 134 (2-565) 108 (10-397) 0.097 
White cell count (10
9
/l) 11.7 (0.5-45.4) 12.7 (4.6-53.1) 0.133 
Albumin (g/l) 16 (10-39) 14 (10-35) 0.011 
Fluid balance (ml) 856 (-176-5182) 806 (-2420-6303) 0.416 
    
Insulin (U hour 
-1
)
 a 0.8 (0.0-9.3) 2.0 (0.0-9.6) <0.001 
Norepinephrine (mg hour
-1
)
 a 0.5 (0.0-4.1) 0.1 (0.0-4.9) <0.001 
Epinephrine (mg hour
-1
)
 a 0.1 (0.0-2.7) 0.01 (0.0-0.9) 0.003 
Hydrocortisone (mg hour
-1
)
 a 1.5 (0.0-16.0) 1.0 (0.0-8.0) 0.178 
Dobutamine (mg hour
-1
)
 a 3.4 (0.0-76.4) 0.5 (0.0-45.0) 0.015 
Median (range), a Mean (range), 
b
 Wilcoxon rank test. 
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Figure. 2-1:  Blood glucose control protocol, Insulin Protocol Ward 25 GRI (2006). 
Patients admitted to ICU are frequently hyperglycaemic.  This occurs for a number of reasons: reduced insulin production and sensitivity, 
severity of the acute illness, and the concurrent administration of other drugs affecting sensitivity to insulin. 
We know that maintenance of normoglycaemia reduces both morbidity and mortality.  The target for blood sugar of patients in ICU is 
4.4 to 6.9 mmol.l-1.  This will require most patients admitted to ICU to receive insulin.  The following guidelines aim to help us achieve 
this new target. 
Insulin infusion, the standard concentration is 50 units insulin in 50 ml 0.9% saline.  After ICU admission until normoglycaemia (4.4 to 
6.9 mmol.l-1) is reached 1-hourly blood sugar measurement is required. 
All patients with blood sugar < 10 mmol.l-1 require either enteral feed (> 30 ml.h-1) or 5% dextrose at 100 ml.h-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Start:  Measure blood 
sugar 
< 10.0 mmol.l
-1
 10.1 – 12.0 mmol.l
-1
 > 12.0 mmol.l
-1
 
Insulin 2 U / hour Insulin 4 U / hour No insulin 
Measure blood sugar hourly 
4.4 – 6.9 mmol.l-1 
> 9.0 mmol.l
-1
 7.0 – 9.0 mmol.l-1 
Increase infusion by 2 U / hour Increase infusion by 1 U / hour 
1 hourly BMs for 4 hours, 
2 hourly BMs for 4 hours, 
Then 4 hourly 
Hypoglycaemia at any time < 3.5 mmol.l
-1
 3.5 - 4.4 mmol.l
-1
 
Half the infusion 
rate, continue 
baseline glucose 
intake.   If insulin 
infusion was > 4 U 
/ h, cut to 2 U / h. 
 
Stop infusion, 
give 20 ml 50% 
dextrose i.v., 
check BM in 20 
min. 
Check blood 
sugar 4 hourly 
What is the 
blood glucose? 
If last blood glucose was > 10 mml.l-1, and it is now 
in range 4.4 – 6.9 mmol.l-1 cut infusion rate by 50% 
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3. The relationship between plasma asymmetrical dimethylarginine 
metabolism and patients with critical illness outcome. 
3.1. Introduction  
Patients with critical illness are often hypercatabolic and hyperglycaemic, and these 
metabolic disorders have been shown to have a significant influence on patient outcome 
(Siroen et al. 2005b).  Furthermore, several studies have reported the beneficial effect of 
the treatment of metabolic response and controlling hyperglycaemia that consequently 
reduce the morbidity and mortality (Van den Berghe et al. 2001; Siroen et al. 2005b).  
However, the mechanisms by which these beneficial effects are brought about remain 
unclear.  One possible mechanism is the amelioration of endothelial dysfunction related to 
endogenous nitric oxide synthase (NOS) inhibitors (Nijveldt et al. 2003; Siroen et al. 
2005a; Ellger et al. 2008). 
Endothelial dysfunction has been reported to be associated with an increase in insulin 
resistance and the circulating asymmetric dimethylarginine (ADMA).  This may lead to a 
reduction in the bioavailability of nitric oxide (NO) (Figure 3-1) (Blackwell 2010; Siervo 
et al. 2011).  An increase in ADMA concentrations and endothelial dysfunction have been 
associated with a broad range of several clinical disorders such as obesity, cardiovascular 
disease, chronic renal failure, diabetes  and hypertension (Boeger 2006; Blackwell 2010; 
Siervo et al. 2011).  Therefore, ADMA may play a role in developing of insulin resistance.  
This is consistent with the report that plasma ADMA concentration was increased in 
patients with impaired glucose tolerance (Nijveldt et al. 2003), diabetes (Can et al. 2011) 
and overweight individuals (Nijveldt et al. 2003).  In addition, weight loss was associated 
with  improved the insulin sensitivity and reduced plasma ADMA concentration (Nijveldt 
et al. 2003).  It is of interest that, in patients with critical illness an elevated ADMA 
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concentration was associated with increased  mortality (Nijveldt et al. 2003).  Also, 
significant reduction in ADMA concentrations in critically ill patients who received 
intensive insulin treatments compared with patients who were treated conventionally.  This 
reduction was associated with a significant improvement in mortality (Siroen et al. 2005b; 
Ellger et al. 2008).  Therefore, there is evidence that tight regulation of glucose levels by 
intensive insulin treatment preserves dimethylaminohydrolase (DDAH) activity (Siroen et 
al. 2005b).  Moreover, insulin may decrease the degradation of arginine and thereby reduce 
the production of ADMA (Siroen et al. 2005b).  In contrast, Iapichino and co-workers 
reported that intensive insulin treatments, while achieving tight glucose control, did not 
reduce ADMA levels in patients with septic shock who were fed with no more than 25 
kCal/kg per day (Iapichino et al. 2008). 
It has been reported during acute inflammatory response of elective surgery plasma 
ADMA concentration decreases rapidly in the first 48 hours (Blackwell et al. 2011).  It has 
also been shown that inflammatory markers, such as interleukin-6 (IL-6), CRP and tumour 
necrosis factor-α are inversely associated with ADMA concentrations and the 
ADMA:SDMA ratio, and this has been proposed to be the result of increased catabolism 
induced by an inflammatory response (Blackwell et al. 2009; Iapichino et al. 2010). 
The aims of the present study were to examine the relationships between the 
concentrations of plasma ADMA and related compounds (homoarginine, arginine, 
SDMA), length of stay and mortality in patients with critical illness.  
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3.2. Patients and methods 
Patients in the ICU of the Glasgow Royal Infirmary who were  18 years old, and had 
evidence of the systemic inflammatory response syndrome as per Bone’s criteria (Bone et 
al. 1992; Levy et al. 2003), were studied.  The study was approved by the ethics 
committees of the North Glasgow NHS Trust and Multicentre Research Ethics Committee 
(MREC) Scotland.  Where patients were unable to give signed informed consent, consent 
was obtained from the patients’ next of kin or welfare guardian in accordance with the 
requirements of the Adults with Incapacity Scotland (2000) Act (Appendix 1, 2). 
Blood samples for population references values were obtained from laboratory staff, from 
local health centres and from people attending a cardiovascular risk clinic.  None of the 
subjects were taking any vitamin supplements or evidence of a systemic inflammatory 
response (serum CRP <10 mg/ l) and previously reported (Blackwell et al. 2009) 
3.2.1. Data collection.  
Baseline demographics including age, ICU admission cause, and ICU length of stay were 
extracted from ICU computer using Carevue programme.  Such data was collected as part 
of routine clinical care including laboratory plasma glucose, CRP, white cell count, 
albumin, creatinine, alanine aminotransferase (ALT) and liver function tests.  Drugs and 
their dosages that may have influenced plasma glucose were also recorded such as insulin, 
epinephrine, norepinephrine, dobutamine and hydrocortisone.  APACHE II score and 
predicted hospital mortality and SOFA scores were recorded. 
  
  
95 
 
3.2.2. ICU insulin protocol  
Hyperglycaemia was treated according to a standardised insulin Protocol (Figure 2-1, p 
91).  The same protocol was used over the period of the study.  The target of plasma 
glucose concentration for critically ill patient in ICU was 4.4- 6.9 mmol/l.  In order to 
maintain this concentration, patients who required insulin infusion were infused with a 
standard concentration of 50 units of insulin in 50 ml 0.9% saline. 
There were several parenteral feeding preparations used in the ICU such as Jevity (1 
cal/ml), Jevity Plus (1.2 cal/ml), Jevity 1.5 (1.5 cal/ml) and Osmolite (1 cal/ml), Osmolite 
Plus (1.2 cal/ml), Peptisorb (1 cal/ml), Perative (1.31 cal/ml) and Nepro (2 cal/ml). Patients 
routinely receive 2L of one of these preparations per day, amounting to an intake of 2000-
2500 calories per day. 
3.2.3. Analytical methods  
Collection and preparation of blood samples. 
Venous blood samples (EDTA) were withdrawn on admission (day 1) and follow up 
sample which was the last day in ICU sample (died or discharge sample) (median 7, IQR 
6-8, rang 5-15) for the analysis of plasma ADMA, arginine, homoarginine and SDMA.  
Blood samples were centrifuged (2500 g, 10 minutes), the plasma removed and stored at -
70°C until analysis.  Blood samples that formed part of patients’ clinical care were handled 
in the usual way according to established standard operating procedures in the routine 
hospital laboratory. 
Laboratory analysis 
ADMA, arginine, homoarginine and SDMA were measured using isocratic high 
performance liquid chromatography (HPLC) with fluorescence detection as previously 
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described (Blackwell et al. 2009).  The inter-assay coefficients of variation (CV) were 
approximately 3.0%. Reference values for the studied analytes were derived from 86 
healthy people, and have already been published (Blackwell et al. 2009).  These were used 
to construct reference intervals with which to compare the present results in patients with 
critical illness. 
Plasma glucose level, white cell count, creatinine, alanine aminotransferase (ALT) were 
measured in accordance with the manufacturer’s instructions on an automated analyzer 
(Architect; Abbott Diagnostics, Abbott Park, Chicago, IL) in the routine biochemistry 
laboratory which is accredited (Clinical Pathology Accreditation UK).  For CRP, the limit 
of detection was 0.5 mg/L. 
Albumin was measured by a BCP dye-binding method and C-reactive protein was 
measured using an automated analyser (Architect, Abbott Diagnostics, USA).  For C-
reactive protein the limit of detection was 5 mg/l.  The inter-assay coefficient of variation 
was less than 3% and 5% over the sample concentration range for albumin and C-reactive 
protein respectively.  The limit of detection for albumin was 10 g/L. 
3.2.4. Statistical analysis 
As the data was not normally distributed and to use a consistent statistical approach 
throughout the thesis the data was presented as median (median, IQR) and non-parametric 
testing used as appropriate.  The relationship between patient characteristics and plasma 
arginine, homoarginine ADMA and SDMA concentrations were carried out with the use of 
the Mann-Whitney U test. Correlations between variables in the control and critically-ill 
groups were carried out using the Spearman rank correlation.  Data from different time 
points in the patient groups were tested for statistical significance with the use of the 
Wilcoxon signed rank test.  Outcome data were analysed by binary logistic regression 
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analysis.  Analysis was performed with the use of SPSS software (version 19; SPSS Inc., 
Chicago, IL).  
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3.3. Results 
In total, one hundred and four adult patients with critical illness (medical n=44, surgical 
n=60) admitted to Glasgow Royal Infirmary ICU in the period between September 2006 to 
March 2008 were studied.  The characteristics of the patients with critical illness on 
admission were shown in Table 3-1.  The majority of patients were male (69%) and had 
median age of 61 years.  The median APACHE II score was 21, predicted hospital 
mortality rate was 39% and SOFA score was 7, 10 and 5 patients were on severe sepsis and 
septic shock respectively.  Compared with controls (n=86), patients with critical illness had 
a lower median arginine and homoarginine concentrations and higher ADMA and SDMA 
concentrations (all p< 0.001).  Also, critically ill patients had lower ADMA: SDMA and 
arginine: ADMA ratios and higher total dimethylarginine (sum of ADMA and SDMA) 
concentrations (both p< 0.001). 
The median creatinine was close to the upper normal range, the median bilirubin was 
within the normal range and the median of alanine transaminase (ALT) was above the 
normal range.  The median of plasma glucose measurements was above the normal range 
and close to the upper limit of the target glucose concentration in the insulin protocol that 
was applied during the study period.  The median CRP concentration was elevated, median 
white cell count was close to the upper normal range, and the median albumin 
concentration was low.  The median daily fluid balance was positive 1034 ml. 
The mean infusion rate of insulin, norepinephrine, epinephrine, dobutamine and 
hydrocortisone were 0.9 Unit hour -1, 0.5 mg hour -1, 0.1 mg hour -1, 2.5 mg hour -1 and 
1.9 mg hour -1  respectively.  The administration of insulin ranged from zero to 9.3 units 
per hour, norepinephrine from zero to 6.0 mg per hour, epinephrine from zero to 2.7 mg 
per hour, dobutamine from zero to 76.4 mg per hour and hydrocortisone from zero to 16 
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mg per hour. The median ICU length of stay was 5.1 days.  Seventy eight patients survived 
and twenty six patients died in the ICU. 
The relationship between patient characteristics, plasma ADMA concentrations, other 
variables and ICU death was shown in Table 3-2.  Non-survivors had significantly higher 
SOFA scores (P < 0.001), higher ADMA, SDMA and total dimethylarginine 
concentrations (all P < 0.05), lower homoarginine concentrations (P < 0.028) and lower 
albumin concentrations (P < 0.017).  They also had a longer ICU length of stay (P < 
0.001). 
Univariate binary logistic regression analysis of clinical characteristics and 
dimethylarginine concentrations on admission to ICU and ICU death in critically ill 
patients was shown in Table 3-3.  On univariate binary logistic regression analysis of the 
significant variables identified in comparisons of survivors and non-survivors, only SOFA 
scores (P <0.011), ICU length of stay (P =0.007) and ADMA (P = 0.003) were 
independently associated with ICU mortality. 
Of the 104 patients who were admitted into the ICU, only 33 patients had last blood 
sample measurements of plasma ADMA concentrations (Table 3-4).  The rest of the 
patients did not have a last sample measurement due to discharge (n = 61) or death (n = 
10).  The median time between admission and the last sample was 7 (range 5-15, IQR 6-8) 
days.  There was a significant decrease in SOFA score (P < 0.02), arginine (P <0.008), 
homoarginine (P <0.001), ALT (P < 0.012), Lab-Glucose (P <0.012), and albumin (P 
<0.012).  There was a significant increase in ADMA (P <0.009), ADMA: SDMA ratio (P 
< 0.003), and the administration of norepinephrine (P < 0.017).  
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3.4. Discussion 
Plasma dimethylarginine, especially ADMA, have been previously reported to be 
associated with mortality in critically ill patients, and have been speculated to be a cause of 
endothelial dysfunction and multiple organ failure in this patient group (Blackwell et al. 
2009; Iapichino et al. 2010).  In the present study it was shown that plasma concentrations 
of ADMA and SDMA were significantly higher in critically ill patients compared with 
healthy controls and that both were significantly associated with disease severity and 
mortality.  This association supports the hypothesis that ADMA metabolism may play a 
causative role in endothelial dysfunction through impairment of NOS activity.  The 
strength of association between ADMA and mortality was striking (odds ratio of 31), and 
is consistent with a recent report in patients with severe sepsis (Blackwell et al. 2009; 
Iapichino et al. 2010). 
In the present study SDMA was also associated with increased mortality.  However, there 
was a strong association between SDMA and creatinine concentrations on admission (n= 
104, rs= 0.62, P<0.001) and on follow-up (n= 33, rs= 0.76, P<0.001) and therefore plasma 
SDMA concentrations, in part, reflect renal function; most likely due to renal elimination 
being the predominant route of SDMA clearance.  It has previously been speculated that by 
competing with arginine uptake at cationic amino acid transporters (CAT) SDMA can 
impair the delivery of the substrate arginine to NOS (Closs et al. 1997).  However, it has 
not been established whether the concentrations encountered in vivo are sufficient to have a 
significant effect.  Therefore, it may be that the association of SDMA with mortality is in 
part due to the effect of renal dysfunction on mortality. 
ADMA and SDMA are generated by the methylation of arginine residues in proteins by 
type 1 protein arginine methyltransferases (type 1 PRMTs) and from type 2 protein 
arginine methyl transferases (type 2 PRMTs) respectively. Daily production of ADMA is 
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approximately 300 µmol with about 10% of this amount excreted unchanged into the urine. 
The majority is metabolized by DDAH to citrulline and dimethylamine.  In contrast, 
SDMA is mainly excreted unchanged in urine and is increasingly being regarded as a 
sensitive marker of renal function (Kielstein et al. 2008; Can et al. 2011). 
In the present study the ADMA: SDMA ratio was significantly lower in patients with 
critical illness compared with controls.  The ADMA: SDMA ratio has previously been 
shown to be reduced in patients with acute infections, severe sepsis, post-operatively and 
in rats following lipopolysaccharide administration; it has been speculated that the 
reduction in ratio reflects an inflammation-induced increase in ADMA clearance through 
DDAH activity (Nijveldt et al. 2004; Zoccali et al. 2007; Iapichino et al. 2010; Blackwell 
et al. 2011).  However, in no such study has DDAH activity in vivo been assessed, and 
therefore no conclusion can be reached about this at the present time; indeed in the present 
study there was no direct association between CRP and ADMA concentration.  
Inflammatory cytokines have been shown to both increase and decrease DDAH activity in 
different models (Cardounel et al. 2007;Ueda et al. 2003), but the net effect in vivo, taking 
into account the confounding effects of oxidative stress and NO itself, is unclear. 
In the present study the ADMA concentration increased on subsequent sampling and is 
consistent with other studies.  This pattern has also been shown in patients undergoing 
elective surgery who had a significant inflammatory response, although in those patients 
this was following a significant reduction in ADMA concentration from baseline 
(Blackwell et al. 2011).  In these patients there was no change in SDMA concentrations, 
indicating differential handling of the dimethylarginines.  However, there was no clear 
evidence of increased ADMA metabolism, and it may be have been that ADMA transport 
via CATs was the more important factor (Blackwell et al. 2011).  This is an area which is 
worthy of further study in critical illness, as it is becoming clear that the plasma 
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concentrations may not reflect the pathophysiologically important tissue concentrations, 
which even in health are up to 10 – 20 times that found in plasma (Cardounel et al. 2007; 
Teerlink et al. 2009). 
There are two distinct isoforms of DDAH.  DDAH-1 is widely expressed, particularly in 
tissues such as liver, renal cortex, lung and immune tissues and cells.  There are large 
arterio-venous gradients across organs such as the liver and kidney, and DDAH-1 has been 
described as the “guardian” of circulating ADMA concentration (Palm et al. 2007).  In 
contrast, DDAH-2 is mainly found in tissues which express endothelial nitric oxide 
synthase (eNOS) and inducible nitric oxide synthase (iNOS) such as endothelium and 
smooth muscle cells of cardiovascular system (Blackwell 2010; Li et al. 2011).  As such, 
DDAH-2 appear to be more involved in the regulation of local endothelial responses (Palm 
et al. 2007).  Consequently, ADMA concentrations in plasma are regulated within fairly 
narrow limits in health, and it is clear that DDAH-mediated metabolism is the critical step 
in this regulation (Teerlink 2005; Blackwell 2010). 
The activity of dimethylaminohydrolase (DDAH) is highly dependent on a cysteine residue 
at its catalytic site.  This is susceptible to oxidation as a consequence of oxidative stress 
and may provide a mechanism that results in increased ADMA concentration and reduced 
NO formation (Blackwell 2010).  This has been observed with hyperglycaemia and 
hyperhomocystinaemia (Blackwell 2010).  Therefore, interaction between 
dimethylaminohydrolase (DDAH), ADMA and NOS may present a common pathway of 
several risk factors affecting the vascular endothelium. 
Indeed, a recent study in critically ill rabbits showed that tissue DDAH activity was a 
stronger determinant of plasma than tissue ADMA concentration, suggesting that CAT-
mediated exchange of ADMA between compartments might be even more important than 
changes in DDAH activity itself (Davids et al. 2012).  Previous work has documented 
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increased fractional excretion of ADMA by the liver during endotoxaemia (Nijveldt et al. 
2004), but, again, this does not differentiate between an increase in CAT-mediated uptake 
and a true increase in DDAH activity itself.  In this regard, it has also been shown that 
methylarginine uptake into endothelial cells and macrophages increases with cytokine 
stimulation (Teerlink et al. 2009).  With current limitations in knowledge, caution should 
be exercised when interpreting the ADMA: SDMA ratio that might not be useful as a 
simple surrogate marker of DDAH activity for these reasons. 
A novel aspect of the present study was the measurement of homoarginine.  Homoarginine 
is an amino acid largely generated from lysine and may promote endothelial function as a 
substrate for NO synthesis (Hecker et al. 1991), although it is probably present at too low a 
concentration for this to be important, given the relative concentration of arginine is about 
30 times greater (Blackwell et al. 2009).  A potentially more important role that has 
received some attention is in the inhibition of the enzyme arginase with consequent 
preservation of arginine for NOS (Yang and Ming 2006).  Indeed, low homoarginine 
concentrations have been recently shown to be associated with mortality and 
cardiovascular events (Maerz et al. 2010).  Furthermore, increased homoarginine 
concentrations during normal pregnancy are associated with increases in brachial artery 
diameter and flow-mediated dilatation (Valtonen et al. 2008).  In the present study, 
homoarginine was positively associated with arginine (rs = 0.641, P<0.001), that is 
consistent with the above concept.  Indeed, homoarginine was significantly inversely 
associated with CRP (rs= -0.349, P= 0.001) suggesting an effect of inflammation on 
homoarginine synthesis and/ or metabolism. 
Limitations of the present study were principally that it was a single centre study and there 
was no validation cohort.  Furthermore, the cohort was mixed in two of surgical and 
medical patients there was considerable variation in the severity of illness. 
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In summary, plasma ADMA and SDMA concentrations were higher in patients with 
critical illness and were associated with disease severity and mortality.  In contrast, plasma 
homoarginine concentrations were lower in patients with critical illness and were also 
associated with disease severity and mortality.  These results suggest that ADMA 
metabolism is perturbed with likely knock on effects on NOS and endothelial function.  
There is a need for further work on in vivo DDAH activity in critical illness and the effect 
of critical illness on the CAT-mediated exchange of ADMA between intra and extra-
cellular compartments.  
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Table 3-1:  Admission characteristics and arginine, homoarginine, ADMA and 
SDMA concentrations in normal subjects and patients with critical illness (n=104). 
 Reference 
Intervals 
(Control) (n=86) 
Patients with 
critical illness 
(n=104) 
P-value* 
Age (years)  61 (47-71)  
Gender (Male/Female) (%)  72 (69)/32 (31)  
Admission cause (Surgical/Medical) 
(%) 
 60 (58)/44 (42)  
APACHE II  21 (17-27)  
Predicted mortality rate (%)  38.9 (17.6-60.4)  
SOFA score  7.0  (4.0-9.0)  
Sever sepsis/septic shock (%)  10 (10)/5 (5)  
    
Arginine (µmol L
-1
)  65.7 (48.8-79.9) 18.4 (12.9-29.1) <0.001 
Homoarginine (µmol L
-1
)  1.9 (1.38-2.49) 0.58 (0.32-1.18) <0.001 
ADMA(µmol L
-1
)  0.45 (0.41-0.52) 0.54 (0.41-0.64) <0.001 
SDMA (µmol L
-1
)  0.38 (0.34-0.43) 0.75 (0.52-1.15) <0.001 
ADMA/SDMA ratio 1.20 (1.10-1.36) 0.73 (0.43-1.02) <0.001 
Arginine/ADMA ratio 125.7 (101.0-
171.5) 
36.7 (26.0-56.6) <0.001 
Total dimethylarginine 0.82 (0.76-0.88) 1.2 (1.0-1.83) <0.001 
    
Creatinine (umol/L)
§
 68-118  117 (78-171)  
Total Bilirubin (umol/l) 
§
 5.1–17.0 10.5 (7.0-21.0)  
ALT (U/L)
 §
 10-40  37 (18-115)  
Lab-Glucose (mmol/l)
 §
 3.5-5.5 6.4 (5.5-8.1)  
C-reactive protein (mg/l)
 §
 <10 119 (41-216)  
White cell count (10
9
/L)
 §
 4-11 x10
9
 11.4 (7.9-18.5)  
Albumin (g/l)
 §
 35-55 16 (12-21)  
Daily fluid balance (ml)  1034 (393-2343)  
    
Insulin (U hour 
-1
)
 a
  0.9 (0.0-9.3)  
Norepinephrine (mg hour
-1
)
 a
  0.5 (0.0-6.0)  
Epinephrine (mg hour
-1
)
 a
  0.1 (0.0-2.7)  
Dobutamine (mg hour
-1
)
 a
  2.5 (0.0-76.4)  
Hydrocortisone (mg hour
-1
)
 a
  1.9  (0.0-16.0)  
    
ICU length of stay (Days)  5.1 (2.0-13.6)  
ICU death No/Yes   78 (75%)/26 (25%)  
    
Median (interquartile range, IQR), §
 
reference interval, 
a 
Mean (range), * Mann-Whitney U.  
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Table 3-2:  Admission patient characteristics and measurements between survivors 
and non-survivors (n=104). 
Median (interquartile range, IQR), 
a 
Mean (range), * Mann-Whitney U. 
 Admission 
Survivors (n=78) 
Admission Non-
survivors (n=26) 
P-value* 
Age (years) 60 (43-69) 67 (48-74) 0.175 
Gender (Male/Female) (%) 55 (71)/23 (29) 17/9 0.625 
Admission cause 
(Surgical/Medical) (%) 
45 (58)/33 (42) 15 (58) /11 (42) 1.000 
APACHE II 21 (16-26) 24 (18-31) 0.174 
Predicted mortality rate (%) 35.3 (14.1-57.3) 45.6 (23.3-73.8) 0.061 
SOFA score 5 (4-8) 8 (7-11) 0.001 
Sever sepsis/septic shock (%) 7 (9)/5 (6) 3 (12)/0 (0)  
    
Arginine (µmol L
-1
) 17.5 (12.1-29.0) 19.6 (17.3-34.9) 0.281 
Homoarginine (µmol L
-1
)  0.70 (0.35-1.30) 0.50 (0.26-0.77) 0.028 
ADMA(µmol L
-1
) 0.49 (0.38-0.62) 0.59 (0.52-0.90) 0.003 
SDMA (µmol L
-1
) 0.69 (0.50-1.10) 0.94 (0.57-1.72) 0.047 
ADMA/SDMA ratio 0.72 (0.43-1.02) 0.79 (0.37-1.05) 0.866 
Arginine/ADMA ratio 38.5 (25.7-59.2) 33.3 (26.0-49.2) 0.218 
ADMA+SDMA 1.2 (0.92-1.68) 1.7 (1.2-2.5) 0.008 
    
eGFR  >30/ <30 10 (0-35) 11 (0-28) 0.747 
Creatinine (umol/L) 115 (73-169) 118 (79-249) 0.605 
Total Bilirubin (µmol/l) 10.5 (8-20) 10.5 (7-28) 0.980 
ALT 38.5 (19-129) 37 (15-115) 0.556 
Lab-Glucose (mmol/l) 6.4 (5.5-8.1) 6.8 (5.4-9.2) 0.642 
C-reactive protein (mg/l)  108 (40-218) 125 (42-169) 0.870 
White cell count (10
9
/L) 10.8 (7.6-16.9) 16.3 (7.9-20.0) 0.223 
Albumin (g/l) 17 (13-23) 13 (10-19) 0.017 
Daily fluid balance (ml) 1006 (393-2166) 4793 (-7-5113) 0.167 
    
Insulin (U hour 
-1
)
 a
 0.9 (0.0-9.3) 0.7 (0.0-4.8) 0.874 
Norepinephrine (mg hour-1)
 a
 0.4 (0.0-2.5) 0.8 (0.0-6.0) 0.292 
Epinephrine (mg hour
-1
)
 a
 0.1 (0.0-2.7) 0.1 (0.0-1.0) 0.894 
Dobutamine (mg hour
-1
)
 a
 2.4 (0.0-76.4) 2.7 (0.0-50.0) 0.431 
Hydrocortisone (mg hour-1)
 a
 2.2 (0.0-16.0) 1.2 (0.0-8.0) 0.276 
    
ICU length of stay (Days) 3 (1-10) 11.6 (6-19) <0.001 
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Table 3-3:  The relationship between clinical characteristics and ADMA on admission 
to ICU mortality in patients with critical illness.  Univariate binary logistic regression 
analysis. 
 Univariate analysis OR (95%CI) P-value 
Age (years) 1.02 (0.99-1.05) 0.292 
Sex (male/female) 1.27 (0.49-3.25) 0.624 
Patients (medical/surgical) 1.00 (0.41-2.46) 1.000 
APACHE II score 1.05 (0.99-1.12) 0.138 
Predicted mortality rate (%) 1.02 (0.99-1.03) 0.081 
SOFA score 1.34 (1.12-1.61) 0.002 
ICU length of stay (days) 1.05 (1.01-1.09) 0.007 
Arginine (µmol L-1) 1.02 (0.99-1.05) 0.241 
Homoarginine (µmol L-1) 0.39 (0.15-0.99) 0.048 
ADMA(µmol L-1) 31.31 (3.34-293.18) 0.003 
SDMA (µmol L-1) 1.54 (0.90-2.64) 0.118 
ADMA/SDMA ratio 1.10 (0.30-4.06) 0.887 
Arginine/ADMA ratio 0.99 (0.97-1.01) 0.243 
ADMA+SDMA 1.66 (1.02-2.70) 0.041 
eGFR  >30/ <30 0.99 (0.97-1.02) 0.771 
Creatinine (umol/L) 1.00 (0.99-1.00) 0.721 
Bilirubin (umol/l) 1.00 (0.99-1.01) 0.858 
ALT (u/l) 1.00 (1.00-1.00) 0.661 
Lab-Glucose mmol/l 1.05 (0.94-1.16) 0.413 
C-reactive protein (mg/l) 1.00 (0.99-1.01) 0.665 
Albumin (g/l) 0.92 (0.85- 1.00) 0.063 
Daily fluid balance (ml) 1.00 (1.00-1.00) 0.020 
Insulin (U hour -1) 0.93 (0.70-1.24) 0.623 
Norepinephrine (mg hour-1) 1.51 (0.95-2.40) 0.079 
Epinephrine (mg hour-1) 0.89 (0.25-3.23) 0.864 
Dobutamine (mg hour-1) 1.00 (0.96-1.05) 0.896 
Hydrocortisone (mg hour-1) 0.92 (0.800-1.06) 0.263 
OR, odd ratio   
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Table 3-4:  The relationship between patient characteristics and plasma arginine, 
homoarginine, ADMA, and SDMA concentrations in patients with critical illness on 
admission and (follow-up) last sample median day 7 (range 5-15) (IQR 6-8) 
 Patients with critical 
illness Admission (n=33) 
Patients with critical 
illness Follow-up (n=33)  
P-
value* 
Age (years) 64 (51-71)   
Sex (M/F) (%) 23 (70%) /10 (30%)   
Medical/ Surgical (%) 19 (58%) /14 (42%)   
APACHE II score 24 (18-29)   
Predicted mortality (%) 46.0 (21.8-71.9)   
SOFA score 8 (6-10) 6 (4-8) 0.002 
Sever sepsis/septic shock 2/1   
    
Arginine (µmol L
-1
) 19.1 (12.8-31.8) 24.3 (21.5-35.6) 0.008 
Homoarginine (µmol L
-1
) 0.56 (0.35-1.22) 0.33 (0.12-0.42) <0.001 
ADMA(µmol L
-1
) 0.60 (0.50-0.84) 0.71 (0.57-1.04) 0.009 
SDMA (µmol L
-1
) 0.87 (0.53-1.44) 0.94 (0.51-1.49) 0.829 
ADMA/SDMA ratio 0.75 (0.43-1.04) 0.89 (0.57-1.25) 0.003 
Arginine/ADMA ratio 31.2 (16.3-44.2) 40.0 (27.0-46.3) 0.236 
ADMA+SDMA 1.5 (1.04-2.44) 1.6 (1.16-2.52) 0.936 
    
eGFR   >30/ <30 20.0 (0.0-33.5) 17.0 (0.0-30.0) 0.604 
Creatinine (umol/L) 126 (93-204) 167 (91-278) 0.626 
Bilirubin (umol/l) 11 (7-20) 11 (6-27) 0.350 
ALT (u/l) 57 (1-171) 42 (21-96) 0.012 
Lab-Glucose mmol/l 7.4 (5.9-10.5) 6.2 (5.2-7.0) 0.012 
C-reactive protein (mg/ l) 72 (13-156) 131 (56-173) 0.597 
White cell count (10
9
/L) 10.6 (7.4-18) 12.0 (9.2-20.8) 0.320 
Albumin (g/ l) 15 (10-21) 13 (11-16) 0.012 
Daily fluid balance (ml) 469 (-21-2000) 1491 (-275-2148) 0.778 
    
Insulin (U hour 
-1
) 
a
 1.0 (0.0-9.3) 2.1 (0.0-10.9) 0.148 
Norepinephrine (mg hour
-1
)
 
a
 
0.4 (0.0-4.0) 0.5 (0.0-4.4) 0.017 
Epinephrine (mg hour
-1
)
 a
 0.1 (0.0-2.7) 0.07 (0.0-1.6) 0.028 
Dobutamine (mg hour
-1
)
 a
 3.9 (0.0-76.4) 4.5 (0.0-117) 0.028 
Hydrocortisone (mg hour
-1
)
 
a
 
2.1 (0.0-16.0) 2.4 (0.0-16.0) 0.058 
    
ICU length of stay (days) 16 (11-27)   
ICU death (no/ yes) (%) 17 (52)/16 (48)   
Median (interquartile range, IQR), 
a 
Mean (range), * Wilcoxon signed rank test. 
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Figure 3-1:  Interactions between oxidative stress, dimethylarginine 
dimethylaminohydrolase (DDAH), asymmetric dimethylarginine (ADMA) and nitric 
oxide synthase (NOS). SDMA, symmetric dimethylarginine; PRMTs, protein arginine 
methyltransferases; TNF-a, tumour necrosis factor-a (Blackwell, 2010) 
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4. The relationship between markers of the systemic inflammatory 
response and outcomes in patients with critical illness. 
4.1. Introduction  
Prediction of outcome in patients with critical illness by current scores such as APACHE II 
score and predicted mortality rate are complex and time consuming.  The systemic 
inflammatory response has long been recognised to be associated with many forms of 
tissue injuries including surgery, trauma, burns and infections.  It is composed of a number 
of stereotypical reactions that involve almost all organs in the human body such that the 
systemic inflammatory process is resolved and healing of tissue occurs (Gabay and 
Kushner 1999).  It is becoming increasingly recognised that the systemic inflammatory 
response is not only an epiphenomena of the tissue injury but is also key to the resolution 
or exacerbation of the injury. 
APACHE II score was applied to evaluate probabilities of hospital mortality which were 
compared with the actual mortality (Dieter et al, 1997).  Expected or predicted mortality 
rate (EMR) is calculated by summing the predicted probability of death for all of the 
patients and dividing by the number of patients (Edward et al, 2005), however, predicted 
mortality rate has been developed for estimating the probability of mortality among ICU 
patients and it is calculated automatically in the Royal Infirmary ICU computers by 
Carevue programme, such data was collected as part of routine clinical care.  It was 
calculated as described in Figure 1-1(see Chapter 1 p 27). 
CRP is an acute-phase protein that has been evaluated extensively in the clinical setting 
(Gabay and Kushner 1999; Ho et al. 2008).  Although CRP is not diagnostic of sepsis and 
in particular reflects a systemic inflammatory state, in the clinical context it is routinely 
used to raise suspicions of infection and further investigations such as imaging and blood 
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cultures.  Moreover, a change in CRP concentrations can however suggest a response to 
treatment (Povoa et al. 2006) and may a reliable marker of outcomes during the post-ICU 
period (Ho et al. 2008; Grander et al. 2010; Ranzani et al. 2013).  In addition to CRP, 
serum albumin may be an important short- and long-term marker for prognosis.  Serum 
albumin is a negative acute-phase protein; thus, the degree of hypoalbuminemia in 
critically ill patients correlates with the intensity of the systemic inflammatory response.   
The aim of the present study was to examine the relationship between the systemic 
inflammatory response, as evidenced by the combination of CRP and albumin, and 
mortality in patients with critical illness. 
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4.2. Patients and methods 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008 and who had evidence of the systemic inflammatory response syndrome as per 
Bone’s criteria (Bone et al. 1992; Levy et al. 2003), were studied.  Briefly, APACHE II 
score (Knaus et al. 1985)  and predicted hospital mortality, CRP and albumin were 
recorded. This cohort has been described previously (Vasilaki et al. 2008). 
This investigation was conducted with the intent of developing local guideline to aid in the 
interpretation of patient with critical illness outcomes results.  A selected prospective 
cohort arose from a prospective study of patients with critical illness.  The patient data 
from the cohort was anonymised and de-identified prior to analysis (Andrew Duncan and 
Donald C McMillan respectively).  In line with local ethical procedures written informed 
consent was obtained.  The latter study was approved by the ethics committees of the 
North Glasgow NHS Trust and Multicentre Research Ethics Committee (MREC) Scotland.  
Where patients were unable to give signed informed consent, consent was obtained from 
the patients’ next of kin or welfare guardian in accordance with the requirements of the 
Adults with Incapacity Scotland (2000) Act (Appendix 1, 2). 
4.2.1. Analytical methods 
Albumin was measured by a BCP dye-binding method and CRP was measured using an 
automated analyser (Architect, Abbott Diagnostics, USA).  For CRP the limit of detection 
was 5 mg/l.  The inter-assay coefficient of variation was less than 3% and 5% over the 
sample concentration range for albumin and CRP respectively.  The limit of detection for 
albumin was 10 g/L. 
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4.2.2. Statistical analysis 
Data was presented in median and range value.  Correlations between variables in the 
convenience sample were carried out using the Spearman rank correlation.  The cohorts 
were divided into three groups according to CRP concentrations ≤10, 11-80 and >80 mg/L 
as previously described (Marsik et al. 2008).  The patient outcome either alive or dead 
were grouped according to 3 categories of albumin concentrations ≥ 35, 25-34,< 25 g/Las 
previously described (Goldwasser and Feldman 1997).  Comparisons between the <50 and 
≥ 50 of predicted mortality rate groups were performed with the use of the Mann-Whitney 
U test.  Outcome data were analysed by binary logistic regression analysis.  A P- value < 
0.05 was considered significant and the analysis of the data was carried out using SPSS 
software (version 19; SPSS Inc, Chicago, Ill).  
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4.3. Result 
The APACHE II severity of disease classification system was shown in Figure 1-1 (see 
Chapter 1 p 27).  The characteristics of the patients with critical illness (n= 261) were 
shown in Table 4-1.  The majority were older than 50 years (median 60 years), 78% of the 
patients were males, an APACHE II score of 23 and the associated median predicted 
mortality was 46% and had plasma CRP concentrations were above the normal range and 
plasma albumin concentrations were below the normal range.  The median ICU stay was 7 
days; 168 patients survived and 93 (36%) patients died in the ICU and hospital outcome 
was 150 survived and 111 (45%) died. 
Sex was significant associated with APACHE II score (rs= 0.151, P =0.015), predicted 
mortality rate (rs= 0.205, P =0.001), ICU stay (rs= 0.155, P =0.012) and hospital mortality 
(rs= - 0.145, P =0.019).  APACHE II score was significantly associated with predicted 
mortality rate (rs= 0.906, P <0.001), ICU mortality (rs= - 0.196, P =0.001) and hospital 
mortality (rs= - 0.186, P =0.003).  Predicted mortality rate was significant associated with 
CRP (rs= 0.204, P =0.001), albumin (rs= -0.194, P =0.002), ICU stay (rs= 0.182, P 
=0.003), ICU mortality (rs= - 0.250, P <0.001) and hospital mortality (rs= - 0.266, P 
<0.001).  Duration of ICU stay was significant associated with CRP (rs= 0.152, P =0.014), 
albumin (rs= - 0.178, P =0.004) and hospital mortality (rs= - 0.143, P =0.021).  ICU 
mortality was significantly associated with albumin (rs= 0.169, P =0.006) and hospital 
mortality (rs= 0.849, P <0.001).  Hospital mortality was significant associated with 
albumin (rs= 0.152, P =0.014). 
A comparisons between the <50 and ≥ 50 of predicted mortality rate groups in the patients 
with critical illness cohort was shown in Table 4-2.  Predicted mortality rate has been 
developed for estimating the probability of mortality among ICU patients and it is 
calculated automatically in the Royal Infirmary ICU computers by Carevue programme, 
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such data was collected as part of routine clinical care.  Compared with patients with 
predicted mortality rate < 50%, patients with predicted mortality rate ≥50 % were older (P 
<0.001), more likely to be male (P =0.003), and had higher APACHE II score (P <0.001), 
higher CRP concentrations (P =0.009), lower albumin concentration (P =0.007) and higher 
CRP/albumin ratio (P =0.003).  The ICU and hospital mortality rate was also higher in 
those patients (P =0.015, P =0.002 respectively). 
A distribution of ICU survival rate according to CRP and albumin concentrations in the 
patients with critical illness cohort was shown in Table 4-3.  The mortality rate was higher 
in patients with CRP concentration > 80 mg/l and albumin concentration < 25 g/l. 
A distribution of hospital survival rate according to CRP and albumin concentrations in the 
patients with critical illness cohort was shown in Table 4-4.  The mortality rate was higher 
in patients with CRP concentration > 80 mg/l and albumin concentration < 25 g/l. 
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4.4. Discussion 
The results of the present study suggest that, the combination of CRP and albumin 
concentrations during critical illness were independently associated with outcome in 
patients with critical illness.  Compared with the complex APACHE II score the simple 
combination of CRP and albumin effectively predicted ICU and hospital mortality.  Given 
the widespread use of these blood protein markers it may be possible to rationalise the 
prediction of outcome in patients with critical illness. 
The results of the present study were consistent with previous work.  Ho and co-workers 
(2008) reported that in 603 unselected patients with critical illness a high CRP 
concentration at ICU discharge was an independent predictor of higher in-hospital 
mortality (Ho et al. 2008).  Similarly, Grander and co-workers (2010) reported that in 765 
nonsurgical patients with critical illness, CRP concentrations during critical illness were 
independently associated with poorer post-ICU survival (Grander et al. 2010).  In contrast, 
an observational study by Al-Subaie and co-workers (2010) reported that in 1487 medical 
and surgical patients with critical illness a higher CRP concentration and low albumin 
concentrations at the day of discharge were not associated with ICU readmissions and in-
hospital mortality (Al Subaie et al. 2010). 
Recently Ranzani and co-workers (2014) reported that in 334 patients with critical illness, 
a higher CRP / albumin ratio at ICU discharge independently predicted of mortality within 
90 days and that the combination had greater accuracy that CRP alone.  In particular, CRP 
and albumin concentration at discharge predicted long-term outcome after an episode of 
sepsis.  In the present study the CRP/ albumin ratio on admission was compared with that 
of the standard thresholds of CRP and albumin concentration in predicting ICU and 
hospital mortality. In the largest category (CRP >80 mg/l and albumin < 25 g/l, n=143) the 
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CRP/ albumin ratio afforded little additional prognostic value in predicting ICU mortality 
(P = 0.097) and no additional prognostic value in predicting hospital mortality (P = 0.287).  
Therefore, in the present study the CRP/ albumin ratio offers little additional prognostic 
value over the simple standard threshold measurement of and albumin in patients admitted 
to ICU. 
An APACHE II score is based on 12 physiological variables that mainly assist the function 
of cardiovascular, respiratory and urinary tract systems, and is not validated for certain 
diseases states such as patients with burns (Vincent and Moreno 2010).  Moreover, the 
APACHE II score does not assess liver function in patients with critical illness.  The 
results of the present study suggest that synthetic liver function may play an important role 
in determining ICU outcome.  The basis of such a relationship are unclear, however, an 
increased CRP is associated with a reduction of activity of a number of metabolically 
active detoxify enzymes such as cytochrome P450 (Morgan et al. 2008; Roberts and Hall 
2013).  Also a low albumin concentration is associated with a loss of colloid osmotic 
pressure and a reduction in the plasma availability of a number of micronutrients (Ghashut 
et al. 2013; Stefanowicz et al. 2013a; Ghashut et al. 2014). 
In summary, the combination of CRP and albumin concentrations during critical illness 
was independently associated with mortality outcome.  In this cohort, the combination of 
CRP and albumin predicted ICU and hospital mortality as effectively as APACHE II.  
Future research focusing on the association between the acute phase protein response post-
ICU outcomes is warranted in order to understand their role long-term survival of patients 
with critical illness particularly in septic patient.  
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Table 4-1:  Characteristics of patients with critical illness cohort (n=261). 
 Reference interval Patients with critical illness 
Age (years) N/A 60 (18-100) 
Sex (Male/Female) N/A 206 (78%) / 55 (22%) 
APACHE II score  N/A 23 (3-45) 
Predicted mortality rate (%) N/A 46 (0.2 -97) 
C-reactive protein (mg/l) <10 134 (<10-565) 
Albumin (g/l) 35-55 17 (<10-47) 
   
ICU stay (days) N/A 7 (<1 -76) 
ICU outcome (alive/ dead) N/A 168 (64%) / 93 (36%) 
Hospital outcome (alive/ dead) N/A 150 (55%) / 111 (45%) 
(Median and range)   
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Table 4-2:  Distribution of ICU and hospital mortality according to predicted 
mortality rate in the patients with critical illness cohort (n=261). 
Predicted mortality rate 
 <50% (n=147) ≥50% (n=114) P- value 
Age (years) 53 (18-86) 62 (10-100) <0.001 
Sex (Male/Female) 123 (84%) / 24 (16%) 83 (73%) / 31 (27) 0.033 
APACHE II score 18 (3-30) 29 (21-45) <0.001 
C-reactive protein (mg/l) 120 (<1-434) 153 (7 – 565) 0.009 
Albumin (g/l) 19 (5-47) 16 (<10-38) 0.007 
    
ICU outcome  
alive/ dead (%) 
104/ 43 (29%) 64 / 50 (44%) 0.015 
Hospital outcome 
alive/dead (%) 
97/50 (34%) 53 / 61 (54%) 0.002 
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Table 4-3:  Distribution of ICU mortality according to CRP and albumin concentrations in the patients with critical illness cohort (n=261). 
 CRP ≤10 (mg/l) 
n= (25) 
CRP 11-80 (mg/l) 
n= (69) 
CRP >80 (mg/l) 
n= (167) 
Mortality (%) according to albumin 
Albumin ≥35 (g/l) 
n= (14) 
APACHE II= 16 
PM= 2 % 
AM= 4/1 (20%) 
APACHE II= 20 
PM= 32% 
AM= 5/2 (40 %) 
APACHE II= 23 
PM= 42% 
AM= 2/0 (0 %) 
APACHE II= 19 
PM= 23% 
AM= 11/3 (21%) 
Albumin 25-34 (g /l) 
n= (47) 
APACHE II= 15 
PM= 14% 
AM= 8/3 (27 %) 
APACHE II= 21 
PM= 21% 
AM=10/4 (29 %) 
APACHE II= 24 
PM= 55% 
AM= 15/7 (32 %) 
APACHE II= 21 
PM= 32% 
AM= 33/14 (30%) 
Albumin <25 (g/l) 
n= (200) 
APACHE II= 21 
PM= 22% 
AM= 8/1 (11 %) 
APACHE II= 25 
PM= 50% 
AM=34/14 (29 %) 
APACHE II= 23 
PM= 53% 
AM= 82/61 (43 %) 
APACHE II= 23 
PM= 49% 
AM= 124/76 (38%) 
Mortality (%) according to CRP APACHE II= 17 
PM= 15% 
AM= 20/5 (19%) 
APACHE II= 24 
PM= 46% 
AM= 49/20 (29%) 
APACHE II= 23 
PM= 53% 
AM= 99/68 (41%) 
 
PM predicted mortality rate (Median), AM actual mortality (alive/ dead). 
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Table 4-4:  Distribution of hospital mortality according to CRP and albumin concentrations in the patients with critical illness cohort (n=261). 
 CRP ≤10 (mg/l) 
n= (25) 
CRP 11-80 (mg/l) 
n= (69) 
CRP >80 (mg/l) 
n= (167) 
Mortality (%) according to albumin 
Albumin ≥35 (g/l) 
n= (14) 
APACHE II= 16 
PM= 2% 
AM= 4/1 (20 %) 
APACHE II= 20 
PM= 32% 
AM= 5/2 (40 %) 
APACHE II= 23 
PM= 42% 
AM= 2/0 (0 %) 
APACHE II= 19 
PM= 23% 
AM= 11/3 (21%) 
Albumin 25-34 (g /l) 
n= (47) 
APACHE II= 15 
PM= 14% 
AM= 7/4 (36 %) 
APACHE II= 21 
PM= 21% 
AM= 8/6 (43 %) 
APACHE II= 24 
PM= 55% 
AM=14/8 (79 %) 
APACHE II= 21 
PM= 32% 
AM= 29/18 (39%) 
Albumin <25 (g/l) 
n= (200) 
APACHE II= 21 
PM= 22% 
AM= 7/2 (22 %) 
APACHE II= 25 
PM= 50% 
AM= 30/18 (38 %) 
APACHE II= 23 
PM= 53% 
AM= 73/70 (49 %) 
APACHE II= 23 
PM= 49% 
AM= 110/90 (45%) 
Mortality (%) according to CRP APACHE II= 17 
PM= 15% 
AM= 18/7 (28%) 
APACHE II= 23 
PM= 46% 
AM= 43/26 (38%) 
APACHE II= 24 
PM= 53% 
AM= 89/78 (47%) 
 
    PM predicted mortality rate (Median), AM actual mortality (alive/ dead). 
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5. The relationship between markers of the systemic inflammatory 
response and plasma glucose concentrations. 
5.1. Introduction 
Acute illness has a profound effect on the metabolic response.  As part of this metabolic 
response it has been reported that systemic inflammatory response is associated with the 
significant elevation of plasma glucose secondary to protein catabolism by the release of 
inflammatory cytokines and counter regulatory hormones (Hill 1999).  This may lead to 
hyperglycaemia and insulin resistance resulting in organ dysfunction and increased 
morbidity and mortality (Krinsley 2006; Egi et al. 2008; Kavanagh and McCowen 2010). 
However, it is not clear whether all patients are equally susceptible to the adverse effects of 
hyperglycaemia and whether all would have similar benefit from treatment (Falciglia et al. 
2009) also optimal glucose concentration targets in the patients with systemic 
inflammatory response have not been well defined (Schuetz et al. 2014).  In previous work 
there was evidence that insulin administration only accounted for a small part of the daily 
fluctuation of glucose concentrations in these patients with critical illness (Falciglia et al. 
2009).  Therefore, it would appear that regulation of plasma glucose concentrations, even 
within the context of an insulin protocol, is complex and multifactorial in patients with 
critical illness (Falciglia et al. 2009). 
The aim of the present study was to examine the relationships between plasma glucose and 
systemic inflammatory response, as evidenced by the elevation of CRP and albumin 
concentrations in a large cohort of patients referred for assessment and also examine these 
relationships in patients with critical illness receiving an insulin protocol.  
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5.2. Patients and methods 
5.2.1. Nutrition screen cohort 
A total of 5248 consecutive heparin-treated whole-blood samples from 5248 patients were 
received from hospitals throughout Scotland between January 2006 and March 2013 for 
routine analysis of plasma measurements of glucose concentrations.  If more than one set 
of plasma measurements of glucose results was available in a patient only the first sample 
was included into the analysis, leaving a total of 5248 plasma glucose results.  As a 
regional centre blood samples were sent for analysis if the patient was considered at 
nutrition risk and was often secondary to a number of disease states.  In addition, 
measurement of albumin and CRP was also recorded for these patients. 
5.2.2. Critical illness cohort 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008 and who had evidence of the systemic inflammatory response syndrome as per 
Bone’s criteria (Bone et al. 1992; Levy et al. 2003), were studied.  Briefly, APACHE II 
score (Knaus et al. 1985) and predicted hospital mortality and SOFA scores, CRP and 
albumin were recorded.  This cohort has been described previously (Vasilaki et al. 2008). 
This investigation was conducted with the intent of developing local guideline to aid in the 
interpretation of glucose results.  There were two cohorts studied.  The first (a large 
unselected retrospective cohort) arose from an audit of patients who had a sample sent to a 
regional laboratory for a nutrition screen.  Approval for audit purpose was obtained from 
the local ethics committee of the North Glasgow NHS Trust.  The second (a small selected 
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prospective cohort) arose from a prospective study of patients with critical illness.  The 
patient data from the two cohorts was anonymised and de-identified prior to analysis 
(Andrew Duncan and Donald C McMillan respectively).  In line with local ethical 
procedures written informed consent was obtained for the latter cohort only.  The latter 
study was approved by the ethics committees of the North Glasgow NHS Trust and 
Multicentre Research Ethics Committee (MREC) Scotland.  Where patients were unable to 
give signed informed consent, consent was obtained from the patients’ next of kin or 
welfare guardian in accordance with the requirements of the Adults with Incapacity 
Scotland (2000) Act (appendix 1, 2). 
5.2.3. Analytical methods 
Plasma glucose samples were collected into blood tubes containing sodium fluoride as an 
anticoagulant.  The sample was centrifuged at 3000 rpm for 10 minutes to separate the 
plasma from blood cells.  Plasma samples were analysed on an automated platform 
(ARCHITECT; Abbott Diagnostics) using a commercial kit (Abbott Diagnostics) 
according to manufacturer’s instructions.  The Limit of detection for plasma glucose is 
0.14 mmol/L with an inter assay Coefficient of Variation of ≤ 5%. 
Albumin was measured by a BCP dye-binding method and CRP was measured using an 
automated analyser (Architect, Abbott Diagnostics, USA).  For CRP the limit of detection 
was 5 mg/l.  The inter-assay coefficient of variation was less than 3% and 5% over the 
sample concentration range for albumin and CRP respectively.  The limit of detection for 
albumin was 10 g/L. 
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5.2.4. ICU insulin protocol  
In the ICU, Glasgow Royal Infirmary, hyperglycaemia was treated according to Insulin 
Protocol Ward 25 GRI as of July the 5th 2006 (Blood glucose control protocol Figure 2-1, 
p 91).  This continued to be used over the period of the study.  The target of plasma 
glucose concentration for critically ill patient in ICU was 4.4- 6.9 mmol/l.  In order to 
maintain this concentration, patients who required insulin infusion were infused with a 
standard concentration of 50 units of insulin in 50 ml 0.9% saline. 
5.2.5. Statistical analysis 
Data was presented in median and range value.  Correlations between variables in the 
convenience sample were carried out using the Spearman rank correlation.  The cohorts 
were divided into three groups according to CRP concentrations ≤10, 11-80 and >80 mg/L 
as previously described (Marsik et al. 2008).  The concentration of individual glucose 
measurments were grouped according to 3 categories of albumin concentrations ≥ 35, 25-
34,< 25 g/Las previously described (Goldwasser and Feldman 1997).  A P- value < 0.05 
was considered significant and the analysis of the data was carried out using SPSS 
software (version 19; SPSS Inc, Chicago, Ill).  
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5.3. Results 
5.3.1. Screen cohort  
The characteristics of the convenience sample for glucose (n= 5248) are shown in Table 5-
1.  The majority were younger than 50 years (median 35 years), female (57%) and had 
plasma albumin were below the normal range and plasma CRP and plasma glucose were 
above the normal range.  Plasma glucose was significantly associated with age (rs= 0.280, 
P <0.001) sex (rs= -0.122, P <0.001), CRP (rs= -0.217, P <0.001) and albumin (rs= -0.164, 
P <0.001).  CRP was significantly associated with age (rs= 0.256, P <0.001), sex (rs= -
0.003, P <0.001) and albumin (rs= -0.465, P <0.001).  Albumin was significantly 
associated with age (rs=-0.398, P <0.001) and sex (rs= -0.151, P <0.001). 
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
concentrations and albumin, on glucose are shown in Figure 5-1a, 5-1b and 5-1c.  
The median plasma concentrations of glucose grouped according to CRP concentrations 
≤10, 11-80 and >80 mg/L were 5.2, 5.5 and 6.0 mmol/l respectively (P <0.001) with an 
overall elevation of 13%.  The median plasma concentrations of glucose grouped 
according to albumin concentrations ≥35, 25-34 and <25 g/l were 5.3, 5.8 and 6.2 mmol/l 
respectively (P <0.001) with an overall elevation of 15%. 
A distribution of median plasma glucose concentration according to CRP and albumin 
concentrations in nutrition screen cohort was shown in Table 5-2.  When albumin 
concentrations were ≥ 35 g/L, the median plasma concentrations of plasma glucose 
grouped according to CRP concentrations ≤10 and 11-80 mg/L were 5.2, 5.4 and 5.6 
mmol/l (P <0.001) with an overall elevation of 7%.  When albumin concentrations were 
25-34 g/L, the median plasma concentrations of glucose grouped according to CRP 
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concentrations ≤10, 11-80 and >80 mg/L were 5.4, 5.9 and 6.0 mmol/l (P <0.001) with an 
overall elevation of 11%.  When albumin concentrations were < 25 g/L, the median plasma 
concentrations of glucose grouped according to CRP concentrations ≤10, 11-80 and >80 
mg/L were 5.6, 6.1 and 6.4 mmol/l (P =0.441) with an overall elevation of 14%.  The 
deference between glucose concentration when albumin concentration were ≥ 35 and <25 
g/l was 5.2 and 6.4 mmol/l with an elevation of 19% (P < 0.001). 
5.3.2. Patients with critical illness  
The characteristics of the critically ill cohort (n=116) are shown in Table 5-1.  The 
majority were older than 50 years (median 60 years), male (66%), an APACHE II score of 
21 and SOFA score of 7 and the associated median predicted mortality was 33.6%.  The 
majority of patients were surgical (56%) and had a median length of ICU stay of 4 days 
and median hospital stay of 19 days.  The median CRP and albumin concentrations were 
above and below the normal reference intervals respectively.  Approximately half had 
some renal impairment as evidence by eGFR of <60ml/min. 
The median plasma glucose was above the reference interval (6.4mmol/l), whereas patients 
with critical illness have low plasma glucose concentrations compared with general 
population of this nutrition screen cohort. CRP was significantly associated with albumin 
(rs=-0.345, P <0.001). 
The median plasma concentrations of glucose grouped according to CRP concentrations 
≤10, 11-80 and >80 mg/L were 7.2, 6.3 and 6.3 mmol/l respectively (88%, P <0.486).  The 
median plasma concentrations of glucose grouped according to albumin concentrations 
≥35, 25-34 and <25 g/l were 7.6, 6.1 and 6.4 mmol/l respectively (84%, P <0.128). 
A distribution of median plasma glucose concentration according to CRP and albumin 
concentrations in nutrition screen cohort was shown in Table 5-3.  The deference between 
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glucose concentration when albumin concentration were <25 g/l was increased from 6.0 to 
6.4 mmol/l with an elevation of 6% (P < 0.001). 
  
129 
 
Discussion 
The results of the present study showed that, in a cohort of patients referred for a plasma 
glucose assessment, plasma concentrations of glucose were significantly higher with 
increasing magnitude of the systemic inflammatory response as evidenced by both changes 
in CRP and albumin concentrations.  Furthermore, this effect was differential with 
increasing albumin concentration associated with a reduction in plasma glucose 
irrespective of the CRP concentrations.  As a result, albumin appears to have independent 
effect than CRP on plasma concentrations of glucose.  In contrast, in patients with critical 
illness the association of both CRP and albumin with glucose appeared weaker, this may 
related to the effect of the drugs supplementation such as insulin.  Nevertheless, these 
results provide a basis for the better understanding of the impact of the systemic 
inflammatory response on plasma glucose concentrations and for its assessment and 
interpretation. 
These results are consistent with the recent work of Schuetz and co-workers (2014) that 
reported elevation on plasma glucose in patients with non-critical-care setting was 
associated with a more pronounced inflammatory response (Schuetz et al. 2014).  Taken 
together with the present work although it would appear that the magnitude of the systemic 
inflammatory response is an important determinant of plasma glucose concentration or it 
may be that it is the glucose concentrations determine the magnitude of the systemic 
inflammatory response.  However, given that the administration of cortisol (an anti-
inflammatory agent) is often associated with an increase in glucose concentrations it may 
be that glucose concentrations enhance the systemic inflammatory response. 
The elevation in blood glucose concentrations may occur due to the increase of glucose 
production in liver and increase insulin resistance in skeletal muscle (Cuthbertson 1979).  
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Moreover, secretion of pituitary hormones and stimulation of sympathetic nervous system 
appears to have a secondary effect on both the release and action of cortisol, 
norepinephrine, and epinephrine (Van den Berghe et al. 2001; Vanhorebeek and Van den 
Berghe 2006), resulting in an increase in plasma glucose concentration by increasing 
glucagon secretion and reducing the insulin secretion.  Moreover, the use of some drugs in 
ICU such as exogenous catecholamines and glucocorticoids may suppress the secretion 
and the action of insulin, and in turn may inhibit glycogen synthesis, stimulate 
gluconeogenesis and alter insulin-mediated glucose uptake by tissues.  Clearly these 
exogenous hormones may exacerbate insulin resistance, nitrogen loss and hyperglycaemia 
(Saberi et al. 2008; Ead 2009; Kavanagh and McCowen 2010; Thomas et al. 2010) and 
complicate the relationship between plasma glucose concentration and the magnitude of 
the systemic inflammatory response. 
In summary, plasma concentrations of glucose appear to be independently associated with 
both CRP and albumin and consistent with the systemic inflammatory response as a major 
confounding factor in determining its status.  However, in patients with critical illness, 
within the context of an insulin protocol the relationship was more complex and 
multifactorial.  
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Table 5-1:  Characteristics of nutrition screening, patient with critical illness cohorts 
and plasma glucose concentrations. 
 Reference 
interval 
Nutrition screen 
cohort 
(n= 5248)  
Nutrition screen 
cohort 
(n= 116) 
P- value 
Age (years) NA 35 (18-99) 60 (18-100) 0.043 
Sex (Male/Female) NA 2241 (43%)/ 
2997 (57%) 
76 (66%)/ 40 
(34%) 
<0.001 
C-reactive protein (mg/l) <10 5 (<10- 568) 109.0 (1.0- 565.0) <0.001 
Albumin (g/l) 35-55 40 (4-59) 17 (9-45) <0.001 
Plasma Glucose (mmol/l) 3.5-5.5 5.3 (1.0-31.0) 6.4 (2.8-30.6) <0.001 
APACHE II score - - 21 (3-38) - 
(Median and range)  
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Table 5-2:  Distribution of median plasma glucose concentration according to CRP and albumin concentrations in the nutrition screen cohort 
(n=5248). 
Plasma glucose CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Plasma glucose according to albumin 
Albumin ≥35 (g/l) 5.2 (1.2-54.3) 
(n=3450) 
5.4 (3.3-25.3) 
(n=791) 
5.6 (3.9-18.5) 
(n=144) 
5.3 (1.2-54.3) 
(n=4385)  
34-25 (g/l) 5.4 (1.8-21.6) 
(n=253) 
5.9 (1.1-23.8) 
(n=281) 
6.0 (2.8-30.5) 
(n=188) 
5.8 (1.1-30.5) 
(n=722)  
<25 (g/l) 5.6 (3.6-18.3) 
(n=14) 
6.1 (0.6-18.8) 
(n=34) 
6.4 (0.1-41.4) 
(n=93) 
6.2 (0.1-41.4) 
(n=141)  
Plasma glucose according to CRP 5.2 (1.2-54.3) 
(n=3717)  
5.5 (0.6-25.3) 
(n=1106)  
6.0 (0.1-41.4) 
(n=425)  
 
    Median (range) (number of observation) 
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Table 5-3:  Distribution of median plasma glucose concentration according to CRP 
and albumin concentrations in patients with critical illness cohort in admission 
(n=116). 
Plasma glucose (mmol/l) CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) 
Albumin ≥35 (g/l) - (n=3) - (n=2) - (n=1) 
34-25 (g/l) 6.0 (n=6) 7.0 (n=8) 5.9 (n=5) 
<25 (g/l) 7.5 (n=8) 6.1 (n=23) 6.4 (n=60) 
   When n<5 median value was not calculated 
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Figure 5-1a:  The relationship between glucose (mmol/l) and CRP (log 10) (rs= 0.217, 
P <0.001). 
 
Figure 5-1b:  The relationship between glucose (mmol/l) and albumin (rs= - 0.164, P 
<0.001). 
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Figure 5-1c:  The relationship between CRP (log 10) and plasma glucose adjusted to 
albumin (rs= 0.407, P <0.001). 
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6. The relationship between markers of the systemic inflammatory 
response and plasma carotenoids concentrations. 
6.1. Introduction  
Carotenoids enhance immune function (Hughes 1999) and appear to have a protective 
effect against ageing and several common diseases such as cancer, cardiovascular disease 
and stroke (Mayne 1996; Krinsky and Johnson 2005).  The properties of carotenoids 
appear to be mediated by a reduction of oxygen derived radicals (Bast et al. 1998).  
Currently, assessment of carotenoid status is based on their direct measurement in plasma.  
However, acute and chronic inflammation is associated with an alteration in concentrations 
of carotenoids in plasma independently of tissue stores (Quasim et al. 2003; Ford et al. 
2003).  For example, patients with non-small cell lung cancer and a systemic inflammatory 
response, as evidenced by elevated CRP concentrations, were found to have decreased 
plasma concentrations of carotenoids (Talwar et al. 1997; Gray et al. 2004). 
Although the effect of the systemic inflammatory response on plasma carotenoids 
concentrations is known, it has not translated into widespread changes in clinical practice 
with regard to the routine interpretation and reporting of plasma micronutrient 
concentrations.  Recently, it has been shown that a range of plasma micronutrient 
concentrations are inversely associated with CRP, commonly used as a marker of the 
systemic inflammatory response (Duncan et al. 2012b).  In an unselected cohort of 1,303 
patients, the systemic inflammatory response was associated with a major reduction in 
plasma zinc, selenium, vitamin A, C, D and B6 concentrations (Duncan et al. 2012b).  As a 
result, it was concluded that the interpretation of plasma micronutrients should only be 
made when the CRP concentrations were known (Duncan et al. 2012b).  Whether such a 
conclusion is valid for carotenoids is unclear.  In particular, since carotenoids are carried in 
  
137 
 
cholesterol-rich lipoprotein, the effect of the systemic inflammatory response on plasma 
carotenoid concentrations may be corrected by calculating carotenoid / cholesterol ratios. 
Therefore, the aim of the present study was to examine the effect of the magnitude of 
systemic inflammatory response on plasma carotenoids concentrations in a large cohort of 
patients whose blood samples were referred to the Scottish Trace Element and 
Micronutrient Reference Laboratory for assessment of their carotenoids status.  This 
investigation was conducted with the aim of developing local guidelines to aid in the 
interpretation of results. 
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6.2. Patients and methods 
A total of 1665 consecutive heparin-treated whole-blood samples from 1074 patients were 
received from hospitals throughout Scotland between December 2005 and December 2010 
for nutrition analysis and routine carotenoid analysis.  The individual analytes measured in 
a carotenoid screen are lutein, lycopene, α-carotene and β-carotene.  If more than one set of 
carotenoid results was available for a patient, in order to reduce potential bias, only the 
most recent one was included into the analysis, leaving a total of 1074 carotenoid results.  
Of these patients 778 had cholesterol measured allowing carotenoids concentrations to be 
adjusted for cholesterol.  Blood samples were sent to a regional centre for analysis if the 
patient was considered at a nutrition risk, and was often secondary to a number of disease 
states including kidney disease and critical illness. 
Plasma lutein, lycopene, α-carotene and β-carotene concentrations were determined with 
an HPLC method (Talwar et al. 1998).  Plasma was deproteinized with ethanol containing 
internal standards, and carotenoids were extracted into hexane.  After a single hexane 
extraction the mean (±2 SD) linear recoveries of carotenoids added to plasma were as 
follows: lutein 94 (±5) %; lycopene 91 (±6) %; and α-carotene and β-carotene 89 (± 4) %.  
Analysis was carried out using reversed-phase HPLC (5-tam microbore; Phenomenex, 
Macclesfield, United Kingdom) and multiwavelength monitoring (Waters, Milford, MA).  
Carotenoids were detected at 450 mn.  The precision (CV) of this method was < 9% 
intrabatch and < 16% interbatch for all analytes. 
The laboratory participated in external quality assurance and proficiency testing programs 
(trace element quality assurance scheme; UK NEQAS for vitamin assays; UK NEQAS for 
CRP and cholesterol) throughout the time period of the study.  Performance was acceptable 
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throughout, which indicated adequate accuracy and analytical precision.  The limit of 
detection of the assays was ≤ 10ug/l for all carotenoids. 
CRP and cholesterol were measured by using routine laboratory procedures with an 
automated analyzer (Architect; Abbott Diagnostics).  The limit of detection or CRP varied 
from 0.2 mg/L (from 2007) to 1.0 mg/L (2006–2007) to 5.0 mg/L (2001–2006).  Intraassay 
imprecision was 4%. 
6.2.1. Statistics analysis 
The concentrations of individual carotenoids and carotenoids after adjusted to cholesterol 
were separated according to 6 categories of CRP concentrations < 5, 6–10, 11–20, 21–40, 
41–80, and >80 mg/L as previously described (Marsik et al. 2008).  For each CRP 
category, data is presented as medians and 5th, 10th, 25th, 75th, and 95th percentiles.  The 
concentration of each analyte was compared with the reference CRP category of ≤5 mg/L 
by using the Mann-Whitney U test.  Correlations of plasma carotenoid concentrations 
compared with CRP and cholesterol were expressed as Spearman correlation coefficients.  
For each category of CRP concentration, the percentage of individual carotenoid 
concentrations below the lower limit of our laboratory reference range was calculated.  The 
numerical proportions of low carotenoid concentrations for the categories were compared 
with that of ≤5 mg/L using a contingency table analysis, with the chi-square test (Kuskal-
Wallis) for trend as appropriate.  Due to the number of statistical comparisons carried out a 
P value <0.01 was considered to be significant.  The statistical analysis was performed 
with the use of SPSS software (version 19; SPSS Inc, Chicago, Ill). 
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6.3. Results  
The characteristics and the plasma concentrations of carotenoids of the cohort are shown in 
Table 6-1.  The median age was 52 years (range 18-99), 58% of the patients were female 
and the median CRP concentration was < 6 mg/l.  The median levels of plasma 
concentrations of lutein, lycopene and β-carotene carotenoids were above the limits of 
detection but below the laboratory reference interval.  In contrast, median α-carotene 
concentrations were at the limit of detection of the assay.  Circulating concentrations of 
lutein, lycopene, α-carotene and β-carotene were below the limit of detection in 165(15%), 
238 (21%), 580 (52%) and 228 (20%) respectively.  Therefore, α-carotene was not 
corrected for cholesterol. 
The effect of the magnitude of the systemic inflammatory response, as evidenced by CRP 
concentrations, on median percentage changes in concentration of lutein, lycopene and β-
carotene are shown in Figures 6-1a, 6-1b and 6-1c, respectively. 
The median and the 5th, 10th, 25th, 75th and 95th percentiles of lutein, lycopene, α-
carotene and β-carotene concentrations were grouped according to CRP categories and 
their statistical comparison are shown in Tables 6-2, 6-3, 6-4 and 6-5 respectively.  With 
increasing CRP concentrations, plasma concentrations of lutein, lycopene and β-carotene 
significantly decreased.  Median α-carotene results were at the limit of detection and the 
same trend was not evident; however, at the 75th percentile the same trend of decreasing 
results was found.  For lutein this decrease was significant (P <0.01) when CRP 
concentrations were elevated between 10 and 20 mg/L (Table 6-2).  For lycopene, α-
carotene and β-carotene this decrease was significant (P <0.01) when CRP concentrations 
were elevated between 20 and 40 mg/L (Tables 6-3, 6-4 and 6-5, respectively).  CRP 
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concentrations of >80 mg/L were associated with the largest median fall in lutein, lycopene 
and β-carotene in the range 60-70%. 
Cholesterol concentration were directly correlated with lutein (rs=0.330, P <0.001) 
lycopene (rs= 0.297, P <0.001), α-carotene (rs=0.233, P <0.001) and β-carotene (rs=0.250, 
P <0.001) and so their ratio to cholesterol concentrations were determined.  The same 
pattern of decreasing carotenoids / cholesterol concentration as CRP increased was 
observed in Figures 6-1d, e and f, respectively. 
In order to compare the carotenoid values with and without adjustment for cholesterol the 
percentage change from the median reference value (<5mg/l) was calculated.  For lutein 
there was a 69% reduction in median concentrations when CRP concentrations were > 
80mg/L and when adjusted for cholesterol this was 42%.  For lycopene there was a 68% 
reduction in lutein concentrations when CRP concentrations were >80mg/L and when 
adjusted for cholesterol this was 47%.  For β -carotene there was a 64% reduction in the 
median concentrations when CRP concentrations were >80mg/L and when adjusted for 
cholesterol this was a 44%. 
Levels of lutein, lycopene, beta-carotene, and alpha-carotene were strongly correlated with 
one another (rs=0.60-0.76, P <0.001).  Cholesterol was modestly correlated with the 
carotenoids (rs =0.23-0.33, P <0.001).  CRP was modestly correlated with the carotenoids 
(rs =0.14-0.19, P <0.001). 
The percentages of results below the lower end of the reference range at each CRP 
concentration category are shown in Table 6-6.  For lutein, lycopene and β-carotene there 
were significantly more results below the lower laboratory reference range limit as CRP 
concentrations increased.  For lutein these ranged from 60% to 90% (P <0.001). 
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6.4. Discussion  
The results of the present study show that, as the magnitude of the systemic inflammatory 
response increased, as categorised by increasing increments of CRP concentrations, there 
was a significant fall in plasma concentrations of lutein, lycopene and β-carotene.  The 
effect of the systemic inflammatory response in lowering plasma lutein, lycopene and β-
carotene was apparent with both moderate and severe elevations of CRP concentrations.  
Indeed, it was shown that, as the severity of systemic inflammatory response increased, the 
proportion of results below the lower reference limit increased.  Adjusting these carotenoid 
results for cholesterol reduced, but did not abrogate, this effect.  Therefore, there is a risk, 
in the presence of a systemic inflammatory response, of misinterpreting plasma carotenoid 
concentrations as indicating deficiency. 
In particular, the present data suggests that, in the presence of moderate or severe systemic 
inflammatory response (as indicated by a CRP concentration >20 mg/L), plasma 
concentrations of lutein, lycopene and β-carotene are not readily interpretable.  Low 
plasma carotenoids, in the presence of such elevated CRP concentrations, could be an 
indication of either dietary insufficiency or chronic inflammation, and may suggest that 
increased supplementation of carotenoids may be warranted.  In other words, low plasma 
values may be the first warning sign of carotenoid insufficiency, despite normal 
intracellular levels. 
In the present study, the magnitude of the systemic inflammatory response was assessed 
using the circulating CRP concentration.  CRP was then grouped into clinically meaningful 
thresholds in order to facilitate clinical recognition of such associations and to be 
consistent with the previous literature (Duncan et al. 2012b).  It may be argued that some 
information about the nature of the relationship is lost by such analysis.  However, the 
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present analysis does facilitate the recognition of the clinical impact of this important 
association. 
The interpretation of the effect of the systemic inflammatory response on plasma α-
carotene concentrations was problematical since the majority of observations were at the 
limit of detection of the assay.  Nevertheless, at the 75th percentile there was a significant 
reduction in α-carotenoid concentration.  Therefore, given the other carotenoid results it 
would not be surprising if a similar association was also true for α-carotene. 
The carotenoids that were included in the present study are lutein, lycopene, α-carotene 
and β-carotene.  Lycopene, α-carotene and β-carotene are hydrocarbons that are classified 
as very fat-soluble carotene.  In contrast, lutein has at least one hydroxyl group and it is 
more polar than carotenes.  As a result, in circulation, lycopene and β-carotene tend to be 
located mainly in the low-density lipoproteins (LDL), whereas lutein is more equally 
distributed between both low-density lipoproteins (LDL) and high-density lipoproteins 
(HDL) (Krinsky and Johnson 2005). 
Since these carotenoids are carried in cholesterol-rich lipoproteins, it was hypothesised that 
the effect of the systemic inflammatory response on plasma carotenoid concentration may 
be corrected by calculating carotenoid/cholesterol ratios.  However, this approach did not 
abrogate the effect of the systemic inflammatory response.  This may be due to the 
complex effects of systemic inflammatory response on both carotenoids and cholesterol 
metabolism.  The mechanisms are at present uncertain, and therefore in practice this means 
that correcting the carotenoid concentrations according to cholesterol in patients with 
systemic inflammatory response cannot be recommended. 
It was also of interest that the correlation coefficients of plasma CRP and individual 
carotenoids were all relatively weak, which confirms that the association is highly variable 
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from patient to patient.  This is perhaps not surprising because the data was accumulated 
from a wide cross-section of patients with differing types and severities of medical 
conditions, as well as varying degrees of carotenoids deficiencies.  Furthermore, it might 
be expected that, in addition to redistribution to the extra-vascular compartments, increased 
utilization and turnover of carotenoids may occur in conditions associated with a systemic 
inflammatory response. 
The results of the present study demonstrate the difficulty of interpreting plasma 
carotenoid concentrations in the presence of moderate or severe systemic inflammatory 
response; however, it does not help to find a better way to detect patients with real 
carotenoid deficiency.  Alternative approaches of assessing micronutrient status in the 
presence of systemic inflammatory response are required and measurements in red blood 
cells, correcting with carrier proteins or the use functional measurements have been 
suggested (Talwar et al. 2003b; Duncan et al. 2012b).  However, measurement of 
carotenoids in red cells is problematical and it remains to be determined what the optimal 
approach will be to detect carotenoid deficiency in patients.  These results, however, do 
raise the issue of whether there are carotenoids concentrations below which deficiency is 
present irrespective of the systemic inflammatory response; such patients may truly be 
deficient but go untreated because of elevated CRP concentrations. 
A potential effect of systemic inflammatory response on decreasing plasma concentrations 
of carotenoids has been previously reported (Ford et al. 2003; Gray et al. 2004; Galan et al. 
2005).  However, these studies did not clearly delineate such an association and there 
remains a general lack of awareness in routine clinical medicine.  The basis of the 
consistent association between the magnitude of the systemic inflammatory response and 
low plasma concentrations of a wide variety of micronutrients including carotenoids is not 
clear (Duncan et al. 2012b).  However, it is known that following an acute systemic 
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inflammatory response low plasma carotenoids concentrations return to normal levels 
(Talwar et al. 1997; Gray et al. 2004).  This would suggest that redistribution of 
carotenoids from extracellular to intracellular compartments is an important component of 
this association.  Alternative approaches of assessing micronutrient status in the presence 
of systemic inflammatory response are required.  For example, measurements in red blood 
cells although useful for some vitamins (Talwar et al. 2003b; Galan et al. 2008) 
measurement of carotenoids in red cells are problematical and it remains to be determined 
what the optimal approach will be to detect carotenoid deficiency in patients. 
The results of the present study, although clear because of their cross-sectional nature, 
cannot prove a causal effect of the systemic inflammatory response on carotenoids 
concentrations.   There may be an underlying physiologic process that alters both the 
carotenoids concentrations and the systemic inflammatory response, so that the observed 
relations could at times be indirect. 
In summary, the results of the present study indicate that the magnitude of the systemic 
inflammatory response is directly associated with a significant lowering effect on the 
plasma concentrations of carotenoids within the context of a routine clinical service.  The 
basis of this association is not clear and may not be causal and so caution should exercise 
in clinical interpretation.  Therefore, we recommend that clinical interpretation of plasma 
carotenoids only be made when the CRP concentration is known (an indicator of the 
inflammation) or the presence of systemic inflammatory response is excluded.  Our data 
suggest that, in the presence of moderate or severe systemic inflammatory response (as 
indicated by a CRP concentration >20 mg/L), plasma concentrations of lutein, lycopene 
and β-carotene are not readily interpretable. 
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Table 6-1:  Characteristics of nutrition screening cohort and plasma carotenoid 
concentrations (n=1074). 
 Limits of 
detection  
Reference 
intervals 
Carotenoids screening cohort 
(n=1074)  
Age (years) N/A N/A 52 (18-99) 
Sex groups (Male / Female) N/A N/A 455 (42%) / 619 (58%) 
C-reactive protein (mg/L) <0.02 <10 6 (0.2-464) 
Cholesterol (mg/L) <0.161  4.3 (0.95-10.4) 
Lutein (µg/L) ≤10  80-200 50.0 (<10-1088) 
< 80 / 80-200 / >200   725 (68%) / 294 (27%) / 54 (5%) 
Lutein/ cholesterol (µg/mmol)  N/A  12.1 (0.42-241.5) 
Lycopene (µg/L) ≤10  100-300 50.0 (<10-694) 
< 100 / 100-300 / >300   717 (67%) / 308 (29%) / 40 (4%) 
Lycopene/ cholesterol (µg/mmol) N/A  12.3 (0.73-135.3) 
α-carotene (µg/L)  ≤10  14-60 ≤10 (≤10-1120) 
< 14 / 14-60 / > 60   667 (62%) / 331 (31%) / 74 (7%) 
β-carotene (µg/L) ≤10  90-310 55.0 (<10-2167) 
< 90 / 90-310 / > 310   687 (64%) / 288 (28%) / 96 (9%) 
β -carotene/ cholesterol (µg/mmol) N/A  12.0 (1.1-386.3) 
Median (range), N/A not applicable  
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Table 6-2:  Distribution in percentiles of plasma lutein concentrations according to increments of CRP concentration (n=1074). 
Plasma Lutein (µg/L) 
CRP Subjects 5th Percentile 10th Percentile 25th Percentile Median 
(% change) 
75th Percentile 90th Percentile 95th Percentile P-value 
 n (%)         
≤5 mg/L 483(45) <10.0 <10.0 27.0 62.0 (100) 121.0 186.8 253.4 - 
>5-10 mg/L 191(18) <10.0 <10.0 28.0 70.0 (113) 117.0 159.6 206.6 0.680 
>10-20 mg/L 124 (12) <10.0 <10.0 17.0 49.0 (79) 87.5 136.5 169.0 0.004 
>20-40 mg/L 92 (9) <10.0 <10.0 14.0 42.0 (68) 76.5 109.1 131.8 <0.001 
>40-80 mg/L 67 (6) <10.0 <10.0 13.0 24.0 (39) 43.0 85.6 115.4 <0.001 
>80 mg/L 113 (11) <10.0 <10.0 <10.0 19.0 (31) 37.5 71.6 91.0 <0.001 
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Table 6-3:  Distribution in percentiles of plasma lycopene concentrations according to increments of CRP concentration (n=1074). 
Plasma lycopene (µg/L) 
CRP Subjects 5th Percentile 10th Percentile 25th Percentile Median 
(% change) 
75th Percentile 90th Percentile 95th Percentile P-value 
 n (%)         
≤5 mg/L 480 (45) <10.0 <10.0 19.0 70.0 (100) 154.8 241.8 293.9 - 
>5-10 mg/L 189 (18) <10.0 <10.0 15.0 75.0 (107) 176.0 282.0 327.0 0.441 
>10-20 mg/L 122 (11) <10.0 <10.0 <10.0 49.5 (71) 145.5 247.0 274.4 0.200 
>20-40 mg/L 92 (9) <10.0 <10.0 <10.0 29.0 (41) 94.0 172.5 238.5 <0.001 
>40-80 mg/L 67 (6) <10.0 <10.0 13.0 34.0 (49) 60.0 124.4 152.0 <0.001 
>80 mg/L 112(10) <10.0 <10.0 <10.0 22.5 (32) 45.0 92.0 137.4 <0.001 
  
149 
 
Table 6-4:  Distribution in percentiles of plasma α-Carotene concentrations according to increments of CRP concentration (n=1074). 
Plasma α-Carotene (µg/L) 
CRP Subjects 5th Percentile 10th Percentile 25th Percentile Median 75th Percentile 90th Percentile 95th Percentile P-value 
 n (%)         
≤5 mg/L 483 (45) <10.0 <10.0 <10.0 <10.0 28.0 58.0 87.8 - 
>5-10 mg/L 190 (18) <10.0 <10.0 <10.0 <10.0 25.5 50.9 69.0 0.737 
>10-20 mg/L 124(12) <10.0 <10.0 <10.0 <10.0 18.8 30.0 65.8 0.118 
>20-40 mg/L 92 (9) <10.0 <10.0 <10.0 <10.0 15.0 28.4 35.4 0.007 
>40-80 mg/L 67 (6) <10.0 <10.0 <10.0 <10.0 16.0 32.0 79.6 0.070 
>80 mg/L 113(11) <10.0 <10.0 <10.0 <10.0 15.0 31.4 59.9 0.004 
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Table 6-5:  Distribution in percentiles of plasma β-Carotene concentrations according to increments of CRP concentration (n=1074). 
Plasma β-Carotene (µg/L) 
CRP Subjects 5th Percentile 10th Percentile 25th Percentile Median 
(% change) 
75th Percentile 90th Percentile 95th Percentile P-value 
 n (%)         
≤5 mg/L 481 (45) <10.0 <10.0 18.0 72.0 (100) 173.5 335.8 4910 - 
>5-10 mg/L 190 (18) <10.0 <10.0 20.8 64.5 (90) 142.0 315.2 545.3 0.531 
>10-20 mg/L 124 (12) <10.0 <10.0 10.5 49.0 (68) 118.3 306.5 537.3 0.023 
>20-40 mg/L 92 (9) <10.0 <10.0 16.3 46.0 (64) 97.8 202.6 283.1 0.005 
>40-80 mg/L 68 (6) <10.0 <10.0 12.5 37.0 (51) 90.3 186.2 279.0 0.002 
>80 mg/L 113 (11) <10.0 <10.0 <10.0 26.0 (36) 61.5 142.8 229.6 <0.001 
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Table 6-6:  Plasma carotenoids below the lower plasma reference range according to CRP concentrations. 
Lower limits: Lutein, 80 (µg/L), lycopene, 100 (µg/L), β-Carotene, 90 (µg/L), aKuskal-Wallis 
  
CRP Lutein 
(n=722) 
Lutein/Cholesterol 
(n=527) 
Lycopene 
(n=714) 
Lycopene/Cholesterol 
(n=515) 
β-Carotene 
(n=685) 
Β-carotene/Cholesterol 
(n=503) 
 n (%) n (%) n (%) n (%) n (%) n (%) 
≤5 mg/L 288(60) 234(61) 295 (61) 236(62) 276 (57) 228(60) 
>5-10 mg/L 106 (55) 73 (38) 107 (57) 73 (62) 115 (61) 75 (64) 
>10-20 mg/L 92 (74) 64 (72) 80 (66) 56 (64) 83 (67) 58 (65) 
>20-40 mg/L 72 (78) 51 (77) 73 (79) 49 (74) 68 (74) 48 (73) 
>40-80mg/L 59 (88) 40 (91) 57 (85) 37 (84) 51 (75) 36 (80) 
>80 mg/L 105 (93) 65 (89) 102 (91) 64 (89) 92 (81) 58 (79) 
a
P value <0.001 0.427 0.141 0.636 0.113 0.854 
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Figure 6-1a, 6-1b, 6-1c:  Percentage changes in lutein (Figure 6-1a), lycopene (Figure 
6-1c) and β-carotene (Figure 6-1e) with increasing increments of CRP Error bars 
represent the upper and the lower quartiles.  CRP; C- reactive protein, n, number of 
patients. 
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Figure 6-1d, 6-1e and 6-1f:  Percentage changes in lutein/ cholesterol ratio (Figure 6-
1b), lycopene/cholesterol ratio (Figure 6-1d) and β-carotene/cholesterol ratio (Figure 
6-1f) with increasing increments of CRP Error bars represent the upper and the 
lower quartiles. CRP, C- reactive protein; n, number of patients. 
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7. The relationship between markers of the systemic inflammatory 
response and plasma vitamin 25 (OH) D concentrations. 
7.1. Introduction  
It has been recognised for some time that plasma 25-hydroxyvitamin D (25 (OH) D) 
deficiencies are associated with increased risks in relation to several diseases such as 
diabetes, hypertension, stroke, and heart disease (Danik and Manson 2012).  However, 
there is the potential for confounding factors, since the presence of a systemic 
inflammatory response has been consistently reported to be associated with low plasma 
micronutrient concentrations (Galloway et al. 2000; Duncan et al. 2012b; Ghashut et al. 
2013).  In particular, it has recently been reported that the magnitude of systemic 
inflammatory response, as evidenced CRP, is a major factor associated with the lowering 
of circulating concentrations of the important lipid soluble vitamins, such as 25 (OH) D 
(Reid et al. 2011; Waldron et al. 2013). 
Duncan and co-workers (Duncan et al. 2012b) reported the presence of an elevated 
systemic inflammatory response was associated with a significant reduction (41%)  in 
plasma vitamin D concentration when CRP concentrations were > 80 mg/L compared to 
≤5 mg/L.  However, the variability of the association was such that plasma 25(OH) D 
concentrations were not readily adjusted for CRP concentrations (Duncan et al. 2012b). 
In the blood 25 (OH )D is transported primarily bound to vitamin D binding protein 
(VDBP) but also to albumin and these fall as part of the systemic inflammatory response 
(Reid et al. 2011; Waldron et al. 2013).  Quantitatively, albumin is the most important 
protein in the plasma and binds most plasma micronutrients, including 25 (OH) D.  
Moreover, albumin may be considered as a surrogate measure for other plasma binding 
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proteins, such as VDBP, and is routinely measured.  Therefore, it may be useful in 
adjusting plasma 25 (OH) D concentrations for the effect of the systemic inflammatory 
response. 
The aim of the present study was to examine the relationships between plasma 25 (OH) D, 
CRP and albumin concentrations in a large cohort of patients referred for vitamin D 
assessment, and also to examine these relationships in patients with critical illness. 
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7.2. Patients and methods 
7.2.1. Nutrition screen cohort 
A total of 7646 consecutive heparin-treated whole-blood samples from 5327 patients were 
received from hospitals throughout Scotland between January 2000 and March 2013 for 
routine analysis of plasma 25 (OH) D concentrations.  If more than one set of plasma 
25(OH) D results was available in a patient only the first sample was included in the 
analysis, leaving a total of 5327 plasma 25 (OH) D results.  Blood samples were sent to a 
regional centre for analysis if the patient was considered at nutrition risk and was often 
secondary to a number of disease states.  In addition, measurement of CRP and albumin 
was also recorded for these patients. 
7.2.2. Critical illness cohort 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008 and had evidence of the systemic inflammatory response syndrome as per Bone’s 
criteria (Bone et al. 1992; Levy et al. 2003), and admitted in the period from September 
2006 to December 2008 were studied.  Briefly, APACHE II score (Knaus et al. 1985)  and 
predicted hospital mortality and SOFA scores, CRP and albumin were recorded.  This 
cohort have been described previously; their purpose was to study micronutrients 
concentrations in the critically ill (Stefanowicz et al. 2013a). 
This investigation was conducted with the intent of developing local guidelines to aid in 
the interpretation of vitamin 25 (OH) D results.  There were two cohorts studied.  The first 
(a large convenience retrospective sample) arose from an audit of patients who had a 
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sample sent to a regional laboratory for a nutrition screen.  The second (a small selected 
prospective cohort) arose from a prospective study of patients with critical illness.  The 
patient data from the two cohorts was anonymised and de-identified prior to analysis 
(Andrew Duncan and Donald C McMillan respectively).  In line with local ethical 
procedures written informed consent was obtained for the latter cohort only.  The latter 
study was approved by the Ethics Committees of the North Glasgow NHS Trust and the 
Multicentre Research Ethics Committee (MREC) Scotland.  Where patients were unable to 
provide signed informed consent, this was obtained from the patients’ next of kin or 
welfare guardian in accordance with the requirements of the Adults with Incapacity 
Scotland (2000) Act. 
7.2.3. Analytical methods  
Plasma 25 (OH) D was measured by enzyme immunoassay kit (Immunodiagnostic 
Systems Ltd) until 2009, when tandem mass spectrometry was used (Waters Acuity; UPLC 
and TQD).  Using routine standards and quality control, intra- and between assay 
imprecision was <10% in both methods over the concentration range of 25 to 120 nmol/L.  
Both methods had a similar lower limit of sensitivity of ~ 4 nmol/L.  
Albumin was measured by a BCP dye-binding method and C-reactive protein was 
measured using an automated analyser (Architect, Abbott Diagnostics, USA).  For CRP the 
limit of detection was 5 mg/l.  The inter-assay coefficient of variation was less than 3% 
and 5% over the sample concentration range for albumin and CRP respectively.  The limit 
of detection for albumin was 10 g/L. 
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7.2.4. Statistical analysis 
Data was presented in median and range.  Correlations between variables in the nutrition 
screen and critically-ill groups were carried out using the Spearman rank correlation.  The 
large cohort was divided into three groups according to CRP concentrations ≤ 10, 11-80 
and >80 mg/L as previously described (Marsik et al. 2008).  The concentrations of 
individual 25(OH) D were grouped according to 3 categories of albumin concentrations (≤ 
25, 25-34, ≥ 35 g/L) as previously described (Goldwasser and Feldman 1997).  For each 
albumin category, data are presented as medians and 5th, 10th, 25th, 75th, and 95th 
percentiles.  The concentration of each analyte was compared with the reference albumin 
category of ≥ 35 g/L by using the Mann-Whitney U test.  With each CRP and albumin 
category the Kruskal-Wallis test was used for the comparison of more than two groups.  A 
P- Value < 0.05 was considered significant and the analysis of the data was carried out 
using SPSS software (version 19; SPSS Inc, Chicago, Ill). 
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7.3. Results  
7.3.1. Nutrition screen cohort  
The characteristics of the convenience sample (n= 5327) are shown in Table 7-1.  The 
majority were older than 50 years (median 58 years), female (67%) and had plasma CRP, 
albumin and 25 (OH) D in the normal range (median 31 µmol/l).  Plasma 25 (OH) D was 
significantly associated with age (rs=0.052, P <0.001), sex (males median 29nmol/l, 
females median 33nmol/l, P <0.001), CRP (rs= -0.113, P <0.001) and albumin (rs=0.192, P 
<0.001).  Age was significantly associated with CRP (rs= 0.275, P <0.001) and albumin 
(rs=-0.292, P <0.001).  CRP was significantly associated with albumin (rs=-0.496, P 
<0.001). 
The association between the magnitude of the systemic inflammatory response, as 
evidenced by CRP and albumin concentrations, on 25 (OH) D are shown in Figure 7-1a 
and 7-1b.  The association of CRP and 25 (OH) D/ albumin ratio is shown in Figure 7-1c; 
the association of albumin and 25 (OH) D/ CRP ratio is shown in Figure 7-1d. 
The median plasma concentrations of 25 (OH) D grouped according to CRP concentrations 
≤10, 11-80 and >80 mg/L were 34, 27 and 22 nmol/l respectively (P <0.001) with an 
overall reduction of 35%.  The median plasma concentrations of 25 (OH) D grouped 
according to albumin concentrations ≥35, 25-34 and <25 g/l were 34, 25 and 20 nmol/l 
respectively (P <0.001) with an overall reduction of 41%. 
The median and the 5th, 10th, 25th, 75th, and 95th percentiles of plasma 25 (OH) D 
concentrations grouped according to albumin concentrations ≥35, 25-34 and <25 g/l for 
CRP concentrations ≤10, 11-80 and >80 mg/L are shown in Table 7-2.  3711 patients had 
CRP concentrations ≤ 10 mg/L; with decreasing albumin concentrations ≥35, 25-34 and 
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<25 g/l, median plasma concentrations of 25 (OH) D were significantly lower from 35 to 
28 to 14 nmol/l (P <0.001).  This decrease was significant when albumin concentrations 
were between 25-34 g/L (P <0.001) and when albumin concentrations were <25 g/L (P < 
0.001).  1271 patients had CRP concentrations between 11-80 mg/L; with decreasing 
albumin concentrations ≥35, 25-34 and <25 g/l, median plasma concentrations of 25 (OH) 
D were significantly lower from 31 to 24 to 19 nmol/l (P <0.001).  This decrease was 
significant when albumin concentration were 25-34 g/L (P <0.001) and when albumin 
concentrations were <25 g/L (P < 0.001).  345 patients had CRP concentrations >80 mg/L; 
with decreasing albumin concentrations ≥35, 25-34 and <25 g/l, median plasma 
concentrations of 25 (OH) D were not significantly altered varying from 19 to 23 to 
23nmol/l. 
When albumin concentrations were ≥35 g/L, the median plasma concentrations of 25 (OH) 
D grouped according to CRP concentrations ≤ 10, 11-80 and >80 mg/L were 35, 31 and 
19.0 nmol/l (P <0.001) with an overall reduction of 46%.  When albumin concentrations 
were 25-34 g/L, the median plasma concentrations of 25 (OH) D grouped according to 
CRP concentrations ≤ 10, 11-80 and >80 mg/L were 28, 24 and 23.0 nmol/l (P =0.013) 
with an overall reduction of 18%.  When albumin concentrations were <25 g/L, the median 
plasma concentrations of 25 (OH) D grouped according to CRP concentrations ≤ 10, 11-80 
and >80 mg/L were 14, 19.0 and 23.0 nmol/l (P =0.082).  The median 25 (OH) D/ albumin 
ratio x100 for CRP concentrations ≤ 10, 11-80 and >80 mg/L were 85.0, 84.2 and 90.9 (P 
=0.002). 
7.3.2. Patients with critical illness  
The characteristics of the critically ill cohort (n=117) are shown in Table 7-3.  The 
majority were older than 50 years (median 60 years), male (65%), an APACHE II score of 
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21 and SOFA score of 7 and the associated median predicted mortality was 34%.  The 
majority of patients were surgical (55%) and had a median length ICU stay of 5 days and 
median hospital stay of 22 days.  The median CRP and albumin concentrations were above 
and below the normal reference intervals respectively.  Median adjusted calcium, and 
median urea and creatinine concentrations were within the normal reference interval.  
Approximately half had some renal impairment eGFR of <60ml/min.  The median plasma 
25(OH) D was 33 nmol/l.  Plasma 25 (OH) D was significantly associated with age (rs= 
0.052, P <0.001), sex (rs = 0.082, P <0.001), CRP (rs = -0.113, P <0.001), albumin (rs 
=0.192, P <0.001).  Age was significantly associated with sex (rs =0.030, P =0.029), CRP 
(rs= -0.275, P <0.001) and albumin (rs= -0.292, P <0.001).  CRP was significantly 
associated with sex (rs= -0.040, P =0.003) albumin (rs=-0.496, P <0.001). 
The association between the magnitude of the systemic inflammatory response, as 
evidenced by CRP and albumin concentrations, on 25 (OH) D in patients with critical 
illness were shown in Figure 7-2a and 7-2b.  The association of CRP and 25 (OH) D/ 
albumin ratio was shown in Figure 7-2c; the association of albumin and 25 (OH) D/ CRP 
ratio is shown in Figure 7-2d. 
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7.4. Discussion  
The results of the present study show that, in two different patient cohorts, plasma 
concentrations of 25 (OH) D were associated with the magnitude of the systemic 
inflammatory response as evidenced by both changes in CRP and albumin concentrations.  
This effect was differential with CRP most strongly associated with a reduction in plasma 
25 (OH) D, where albumin concentrations were in the normal range (>35g/l) and with a 
much weaker association where albumin concentrations were very low (<25g/l).  With 
normal CRP concentrations (≤ 10 mg/L), albumin had an independent effect on plasma 
concentrations of 25 (OH) D.  These results provide a basis for the better understanding of 
the impact of the systemic inflammatory response on plasma vitamin D concentrations and 
for their assessment and interpretation. 
There is now a wealth of data from observational studies that have shown associations 
between low concentrations of plasma 25 (OH) D and increased risks of cardiovascular 
disease, cancer, neurodegenerative diseases, disorders of glucose metabolism and death.  
Many factors, such as ageing, ethnicity, season, latitude, adiposity, physical activity, 
smoking and diet may impact on the link between low 25 (OH) D and the above health 
outcomes.  In the present study of patients referred for a nutrition screen, some or all of the 
above factors may have impacted on plasma 25 (OH) D concentrations.  However, all of 
the above potential confounding factors appear to be dependent on inflammatory processes 
for their effect on plasma 25 (OH) D concentrations.  This is well illustrated in a recent 
study of the effect of elective knee arthroplasty on plasma 25 (OH) D concentrations (Reid 
et al. 2011).  Indeed, inflammatory processes have been proposed as a major reason behind 
the discrepancy in effect of normal vs deficient plasma 25 (OH) D concentrations on health 
outcomes in observational studies (beneficial effect) and interventional (no effect) studies 
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of health outcomes (Autier et al. 2014).  Similar associations seen in the critical illness 
cohort in the present study are also consistent with such a concept. 
In the present study, the basis of the relatively low median plasma concentrations of 
25(OH) D concentrations in those patients with normal CRP and albumin concentrations is 
not clear.  However, at northerly latitudes, such as Scotland plasma concentrations of 
25(OH) D concentrations are lower (Zgaga et al. 2011).  Indeed, it is recognized that the 
majority of the Scottish population have plasma 25 (OH) D concentrations less than 50 
nmol/l, considered to be borderline vitamin D status (Zgaga et al. 2011).  In such patients 
with albumin concentrations in the normal range the basis of the inverse relationship 
between CRP and plasma 25 (OH) D might be due to consumption of vitamin D since the 
concentrations of other binding proteins such as VDBP are also likely to be in the normal 
range (Reid et al. 2011; Waldron et al. 2013).  Further, there is some evidence that 
25(OH)D can be actively taken up by inflammatory cells, particularly macrophages 
(Hewison 2010).  In contrast, in those patients with low plasma albumin concentrations, 
the lack of such a relationship between CRP and plasma 25 (OH) D might be due to loss of 
vitamin D from the plasma compartment due to redistribution of its binding proteins 
vitamin D binding protein and albumin (Reid et al. 2011).  More generally the associations 
of plasma concentrations of CRP, albumin and vitamin D may reflect the redistribution and 
/or the consumption of body stores by a chronic ongoing systemic inflammatory response.  
If this were the case it is likely that similar associations would apply to other 
micronutrients. 
In order to confirm whether the combination of CRP and albumin can better account for 
the variability of plasma of 25 (OH) D, it would be important to have access to direct 
intracellular measurements.  For example, red blood cells have been shown to be useful for 
vitamin B6, vitamin E, B2 zinc and selenium concentrations in subjects undergoing an 
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elective knee arthroplasty with a consequent acute systemic inflammatory response (Gray 
et al. 2004; Gray et al. 2005; Oakes et al. 2008) and in patients with critical illness 
(Vasilaki et al. 2008; Vasilaki et al. 2009; Vasilaki et al. 2010; Stefanowicz et al. 2013a).  
Whereas plasma concentrations of these vitamins deceased rapidly on activation of the 
systemic inflammatory response, red blood cell concentrations remained stable.  Therefore, 
alongside the present measurements of plasma 25 (OH) D, CRP and albumin 
concentrations it would be important to examine intracellular concentrations of 25 (OH) D 
to better inform the effect of CRP and albumin on plasma 25 (OH) D.  Also, this may 
provide insight into the nature of the effect, i.e. whether redistribution or consumption. 
In summary, it is now recognized that plasma concentrations of 25 (OH) D were 
confounded in the presence of a systemic inflammatory response, as evidenced by CRP.  
The results of the present study show that albumin concentration also has an independent 
effect on plasma concentrations of 25 (OH) D.  Therefore, plasma concentrations of 25 
(OH) D may not be reliably interpreted in the presence of abnormal CRP (>10mg/l) and 
albumin concentrations (<35g/l).  It may be that plasma concentrations of 25 (OH) D in the 
presence of normal CRP and albumin concentrations reliably indicate nutrition status of 
vitamin D and the need for supplementation. 
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Table 7-1:  Characteristics of nutrition screen cohort and plasma 25 (OH) D 
concentrations. 
 Reference interval Nutrition screen cohort (n= 5327)  
Age (years) NA 58 (16-109) 
Sex (Male/Female) NA 1773 (33%)/ 3554 (67%) 
CRP (mg/l) <10 5.0 (0.19- 565.0) 
Albumin (g/l) 35-55 38 (9-52) 
25 (OH)  D (nmol/l) <25/25-50/>50 31 (6-1140) 
(Median and range) 
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Table 7-2:  Distribution in percentiles of plasma 25 (OH) D according to CRP and albumin concentrations (n=5327). 
CRP concentrations ≤10 mg/L (n= 3711) 
Albumin Subjects 
n (%) 
5th 
Percentile 
10th 
Percentile 
25th 
Percentile 
Median 
(% change) 
75th 
Percentile 
90th 
Percentile 
95th 
Percentile 
P-value 
≥ 35 g/L 3294(89) 14.0 14.0 20.0 35.0 (100) 57.0 85.0 102.0 <0.001 a 
25-34g/L  378 (10) 14.0 14.0 15.0 28.0 (80) 46.0 75.0 88.0 <0.001 b 
<25g/L 39 (1) 14.0 14.0 14.0 14.0 (40) 34.0 64.0 67.0 <0.001 b 
25 (OH) D/ albumin 
ratio x100 
 34.12 36.59 50.00 85.0 141.86 210.33 259.68  
CRP concentrations 11-80 mg/L (n= 1271) 
≥ 35 g/L 649 (51) 14.0 14.0 18.0 31.0 (100) 52.0 80.0 101.0 <0.001 a 
25-34g/L  476 (37) 14.0 14.0 14.0 24.0 (77) 49.0 82.0 105.0 <0.001 b 
<25g/L 146 (11) 14.0 14.0 14.0 19.0 (61) 37.8 76.7 138.5 <0.001 b 
25 (OH) D/ albumin 
ratio x100 
 36.82 39.97 51.81 84.2 148.48 242.36 105.71  
CRP concentrations ≥ 80 mg/L (n= 345) 
≥ 35 g/L 42 (12 ) 14.0 14.0 14.0 19.0 (100) 26.5 52.6 72.5 0.284 a 
25-34g/L  150 (43) 10.6 14.0 14.0 23.0 (121) 38.0 58.8 82.8 0.277 b 
<25g/L 153 (44) 14.0 14.0 14.0 23.0 (121) 33.0 55.2 78.3 0.093 b 
25 (OH) D/ albumin 
ratio x100 
 37.81 42.39 56.55 90.9 169.23 265.24 422.29  
a Kruskal Wallis, b Mann-Whitney U test. When n<5 median value was not calculated.
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Table 7-3:  Characteristics of ICU cohort and plasma vitamin D concentrations. 
 Reference interval Nutrition screen cohort (n= 117)  
Age (years) NA 60 (18-100) 
Sex (Male/Female) NA 76 (65%)/ 41 (35%) 
C-reactive protein (mg/l) <10 109.0 (1.0- 565.0) 
Albumin (g/l) 35-55 17 (9-45) 
25 (OH) D (nmol/l) <25/25-50/>50 33 (13-1140) 
(Median and range)  
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Figure 7-1a:  The relationship between CRP (log 10) and 25 (OH) D in the nutrition 
screen cohort (rs= -0.113, P <0.001). 
 
Figure 7-1b:  The relationship between albumin and 25 (OH) D in the nutrition 
screen cohort (rs= 0.192, P <0.001). 
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Figure 7-1c:  The relationship between CRP (log 10) and 25 (OH) D adjusted to 
albumin in the nutrition screen cohort (rs=- 0.053, P <0.001). 
 
 
Figure 7-1d:  The relationship between albumin and 25 (OH) D adjusted to CRP in 
the nutrition screen cohort (rs=0.507, P <0.001). 
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Figure 7-2a:  The relationship between CRP (log 10) and 25 (OH) D in patients with 
critical illness (rs= -0.221, P =0.017). 
 
Figure 7-2b:  The relationship between albumin and 25 (OH) D in patients with 
critical illness (rs= 0.166, P =0.073). 
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Figure 7-2c:  The relationship between CRP (log 10) and 25 (OH) D adjusted to 
albumin in patients with critical illness (rs= 0.016, P =0.863). 
 
Figure 7-2d:  The relationship between albumin and 25 (OH) D adjusted to CRP in 
patients with critical illness (rs= 0.363, P <0.001). 
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8. The relationship between the markers of the systemic inflammatory 
response and plasma vitamin E and C concentrations. 
8.1. Introduction  
Vitamin E (α-tocopherol), a fat-soluble vitamin, and vitamin C (ascorbic acid), a water-
soluble vitamin, both have complimentary and anti-oxidative properties (Padayatty et al. 
2003).  Vitamins E and C are chain-breaking antioxidants that prevent the peroxidation of 
lipids in cell membranes and lipoproteins (Nogueira et al. 2013).  Vitamins E and C also 
act synergistically, as a peroxyl radical scavenger, preventing the propagation of free 
radicals in tissues, by reacting with them to form an α-tocopheroxyl radical that is then 
reduced back to α-tocopherol by a hydrogen donor such as vitamin C (Crimi et al. 2004; 
Nogueira et al. 2013).  Vitamin E, because it is fat-soluble, is incorporated into cell 
membranes, which protects them from oxidative damage.  It is also essential with 
cholesterol for the cell membranes structural stability (Chow 1975). 
Vitamin E and C status is usually assessed by plasma measurement of α-tocopherol and 
ascorbic acid respectively, although their correlation with concentrations in tissues is not 
clearly established.  Moreover, plasma concentrations of vitamin E are strongly associated 
with their carrier lipids, principally lipoprotein complexes, such as high density lipoprotein 
(HDL), very low density lipoprotein (VLDL) and chylomicrons.  To overcome this 
limitation it has been proposed that the plasma α-tocopherol concentrations should be 
expressed in relation to plasma lipid concentrations, usually cholesterol (Thurnham et al. 
1986; Doise et al. 2008; Vasilaki et al. 2009).  Some workers have proposed either 
expressing plasma vitamin concentrations per lipid concentrations (Thumham et al. 2008) 
or measurement of intracellular vitamin concentrations (Talwar et al. 2003b).  Indeed, in 
healthy subjects undergoing elective surgery, there is a significant transient decrease in 
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both α-tocopherol and cholesterol concentrations during the evolution of the systemic 
inflammatory response (Gray et al. 2005).  Consistent with the above, when plasma α-
tocopherol/ cholesterol, was applied there was no significant alteration in plasma α-
tocopherol concentrations (Gray et al. 2005). 
Duncan and co-workers (2012) reported that the impact of systemic inflammatory response 
on plasma α-tocopherol not adjusted for cholesterol and ascorbic acid concentrations when 
CRP concentrations were > 80 mg/L were associated with a 8% and 78% reduction (Louw 
et al. 1992; Galloway et al. 2000; Duncan et al. 2012b).  However, the variability of the 
association was such that plasma α-tocopherol and ascorbic acid concentrations were not 
readily adjustable for CRP concentrations.  Furthermore, Ghashut and co-workers (2014) 
have recently reported that plasma concentrations of fat soluble micronutrients such as 25 
(OH) D may be confounded in the presence of a systemic inflammatory response with both 
CRP and albumin having an  independent effect on plasma 25 (OH) D concentrations 
(Ghashut et al. 2014). 
The aim of the present study was to examine the relationships between plasma α-
tocopherol, ascorbic acid, CRP and albumin concentrations in a large cohort of patients 
referred for assessment and also examine these relationships in patients with critical 
illness.  
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8.2. Patients and methods  
8.2.1. Nutrition screen cohort 
A total of 359 consecutive heparin-treated whole-blood samples from 684 patients, and a 
total of 494 consecutive heparin-treated whole-blood samples from 916 patients, were 
received from hospitals throughout Scotland between January 2000 and March 2013 for 
routine analysis of plasma α-tocopherol and ascorbic acid concentrations.  If more than one 
set of plasma α-tocopherol and ascorbic acid results was available in a patient, only the 
first sample was included in the analysis, leaving a total of 359 and 494 plasma α-
tocopherol and ascorbic acid results, respectively.  In the nutrition screen cohort < 20 % of 
patients had both vitamin E and C measurements.  In order to have enough observations to 
examine the relationship between markers of the systemic inflammatory response and 
measurements of vitamin E and C we used the present approach.  Blood samples were sent 
to a regional centre for analysis if the patient was considered at nutrition risk and was often 
secondary to a number of disease states.  In addition, measurement of albumin and CRP 
was also recorded for these patients. 
8.2.2. Critical illness cohort 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008 and had evidence of the systemic inflammatory response syndrome as per Bone’s 
criteria (Bone et al. 1992; Levy et al. 2003), were studied.  Briefly, APACHE II score 
(Knaus et al. 1985)  and predicted hospital mortality and SOFA scores, CRP and albumin 
were recorded. This cohort has been described previously (Vasilaki et al. 2008). 
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This investigation was conducted with the intent of developing local guidelines to aid in 
the interpretation of α-tocopherol and ascorbic acid results.  Two cohorts were studied:  the 
first (a large unselected retrospective cohort) arose from an audit of patients who had a 
sample sent to a regional laboratory for a nutrition screen.  Approval for audit purpose was 
obtained from the local Ethics Committee of the North Glasgow NHS Trust.  The second 
(a small selected prospective cohort) arose from a prospective study of patients with 
critical illness.  The patient data from the two cohorts was anonymised and de-identified 
prior to analysis (Andrew Duncan and Donald C McMillan respectively).  In line with 
local ethical procedures written informed consent was obtained for the latter cohort only.  
The latter study was approved by the ethics committees of the North Glasgow NHS Trust 
and Multicentre Research Ethics Committee (MREC) Scotland.  Where patients were 
unable to give signed informed consent, consent was obtained from the patients’ next of 
kin or welfare guardian in accordance with the requirements of the Adults with Incapacity 
Scotland (2000) Act (Appendix 1, 2). 
8.2.3. Analytical methods 
The within-batch imprecision was 3.7% at a concentration of 38 mol/L. α-tocopherol was 
measured by HPLC (Talwar et al. 1998).  The intra-assay CV was, 9% for both analytes 
over the sample concentration range.  The intra-assay imprecision was 4.9% at 59 nmol/L. 
Ascorbic acid was only measured if the plasma sample was prepared within 4 h and 
stabilized by diluting it with an equal volume of 6% metaphosphoric acid.  Plasma ascorbic 
acid status was assessed by using a method based on that of Margolis and Davis (Margolis 
and Davis 1988).  Briefly, plasma was stabilized and deproteinized with 60 g 
metaphosphoric acid/L (stored at 4–8 ̊C and prepared fresh every 2 weeks) and centrifuged 
and an aliquot of supernatant fluid was injected on a C18 reversed-phase analytic column 
(Nucleosil).  After separation, ascorbic acid was determined by coulometric 
  
176 
 
electrochemical detection (ESA 5100A).  The within-batch imprecision was 3.7% at a 
concentration of 38 μmol/L. 
8.2.4. Statistical analysis 
Data was presented in median and range value.  Correlations between variables in the 
convenience sample were carried out using the Spearman rank correlation.  The cohorts 
were divided into three groups according to CRP concentrations ≤ 10, 11-80 and >80 mg/L 
as previously described (Marsik et al. 2008).  The concentration of individual α-
tocopherol/ cholesterol  and ascorbic acid were grouped according to 3 categories of 
albumin concentrations ≥ 35, 25-34, < 25 g/L as previously described (Goldwasser and 
Feldman 1997).  A P- value < 0.05 was considered significant and the analysis of the data 
was carried out using SPSS software (version 19; SPSS Inc, Chicago, Ill).  
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8.3. Results 
The characteristics of the convenience sample for α-tocopherol (n= 359) are shown in 
Table 8-1.  The majority were older than 50 years (median 52 years), male (52%) and had 
plasma albumin and cholesterol below the normal range, while plasma CRP and plasma α-
tocopherol were in the normal range.  Plasma α-tocopherol was significantly associated 
with sex (rs=-0.342, P =0.001), cholesterol (rs= -0.311, P =0.005) and albumin (rs=0.491, 
P <0.001).  CRP was significantly associated with cholesterol (rs=-0.334, P =0.003). 
Albumin was significantly associated with cholesterol (rs=-0.464, P <0.001). 
The characteristics of the convenience sample for ascorbic acid (n= 494) are also shown in 
Table 8-1.  The majority were older than 50 years (median 54 years), female (53%), and 
had plasma CRP and albumin and plasma ascorbic acid in the normal range.  Plasma 
ascorbic acid was significantly associated with age (rs=-0.268, P <0.001), CRP (rs= -0.333, 
P <0.001) and albumin (rs=0.588, P <0.001).  Age was significantly associated with CRP 
(rs= 0.259, P <0.001) and albumin (rs=-0.251, P <0.001).  CRP was significantly 
associated with albumin (rs=-0.643, P <0.001). 
8.3.1. Nutrition screen cohort for α-tocopherol / cholesterol ratio 
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
concentrations and albumin, on α-tocopherol/ cholesterol ratio are shown in Figure 8-1a 
and 8-1b. 
The median α-tocopherol/ cholesterol ratio grouped according to CRP concentrations ≤10, 
11-80 and >80 mg/L were 5.9, 4.6 and 2.1 umol/l respectively (P <0.001) with an overall 
reduction of 64%.  The median α-tocopherol/cholesterol ratio grouped according to 
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albumin concentrations ≥35, 25-34 and <25 g/l were 6.0, 5.5 and 2.1 umol/l respectively (P 
<0.001) with an overall reduction of 65%. 
When albumin concentrations were ≥ 35 g/L, the median α-tocopherol/ cholesterol ratio 
grouped according to CRP concentrations ≤10 and 11-80 mg/L were 6.2 and 5.4 (P 
=0.134).  When albumin concentrations were 25-34 g/L, the median α-tocopherol/ 
cholesterol ratio grouped according to CRP concentrations ≤10, 11-80 and >80 mg/L were 
5.2, 6.0 and 4.6 (P =0.518) with an overall reduction of 12%.  When albumin 
concentrations were < 25 g/L, the median α-tocopherol/ cholesterol ratio grouped 
according to CRP concentrations ≤10, 11-80 and >80 mg/L were 3.8, 2.4 and 1.7 (P 
=0.032) with an overall reduction of 55%. 
8.3.2. Nutrition screen cohort for ascorbic acid. 
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
and albumin concentrations, on ascorbic acid are shown in Figure 8-2a and 8-2b.  The 
effect of the CRP on ascorbic acid/ albumin ratio is shown in Figure 8-2c. 
The median plasma concentrations of ascorbic acid grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/L were 25.0, 15.0 and 6.0 µmol/l respectively (P 
<0.001) with an overall reduction of 78%.  The median plasma concentrations of ascorbic 
acid grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 32.0, 13.0 
and 5.0 µmol/l respectively (P <0.001) with an overall reduction of 84%. 
When albumin concentrations were ≥ 35 g/L, the median plasma concentrations of 
ascorbic acid grouped according to CRP concentrations ≤10, 11-80 and >80 mg/L were 
33.0, 30 and 31µmol/l (P =0.765).  When albumin concentrations were 25-34 g/L, the 
median plasma concentrations of ascorbic acid grouped according to CRP concentrations 
≤10, 11-80 and >80 mg/L were 12.0, 15 and 10.0 µmol/l (P =0.409) with an overall 
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reduction of 17%.  When albumin concentrations were < 25 g/L, the median plasma 
concentrations of ascorbic acid grouped according to CRP concentrations ≤10, 11-80 and 
>80 mg/L were 3, 10 and 5.0 µmol/l (P =0.121).  The median vitamin C/ albumin ration x 
100 for CRP concentrations ≤10, 11-80 and >80 mg/L were 71.8, 53. 5 and 37.3 
respectively (48%, p=0.050).  The median vitamin C/ CRP ratio x 100 for albumin 
concentrations ≥35, 25-34 and <25 g/l were 711.5, 65.8 and 10.3 (99%, p<0.001). 
8.3.3. Patients with critical illness  
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
and albumin concentrations, on α-tocopherol/ cholesterol ratio are shown in Figure 8-1a 
and 8-1b; the effects on ascorbic acid are shown in Figure 8-2a and 8-2b, while the effect 
of the CRP on ascorbic acid/ albumin ratio is shown in Figure 8-2c. 
The characteristics of the critically ill cohort (n=82) are shown in Table 8-1.  The majority 
were older than 50 years (median 58 years), male (62%), with an APACHE II score of 21 
and a SOFA score of 7; the associated median predicted mortality was 33.6%.  The 
majority of patients were surgical (56%) and had a median length ICU stay of 4 days, and 
median hospital stay of 19 days.  The median CRP and albumin concentrations were above 
and below the normal reference intervals respectively.  Approximately half had some renal 
impairment as evidenced by eGFR of <60ml/min. 
The median plasma α-tocopherol was within the normal reference interval (14.5umol/l), 
whereas patients with critical illness have extremely low α-tocopherol concentrations 
compared with the general population of this nutrition screen cohort, median plasma 
cholesterol concentration was slightly elevated.  Plasma α-tocopherol was significantly 
associated with sex (rs =0.211, P =0.022), CRP (rs = -0.270, P =0.003) and with albumin 
(rs =0.5847, P <0.001).  Age was significant associated with albumin (rs = -0.207, P 
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=0.024).  CRP was significantly associated with albumin (rs=-0.358, P <0.001) and 
cholesterol (rs =0.366, P <0.001).  Albumin was significantly associated with cholesterol 
(rs =-0.416, P <0.001). 
The median α-tocopherol/ cholesterol ratio grouped according to CRP concentrations ≤10, 
11-80 and >80 mg/L were 4.0, 2.4 and 1.6 µmol/l respectively (85%, P <0.001).  The 
median α-tocopherol / cholesterol ratio grouped according to albumin concentrations ≥35, 
25-34 and <25 g/l were 4.8, 3.9 and 1.7 µmol/l respectively (65%, P <0.001). 
The median plasma ascorbic acid was below the normal reference interval (4.0µmol/l), 
whereas patients with critical illness had extremely low vitamin C concentrations 
compared with the general population of this nutrition screen cohort.  Plasma ascorbic acid 
was significantly associated with white cell ascorbic acid (rs =0.327, P =0.035).  CRP was 
significantly associated with albumin (rs=-0.393, P <0.001). 
The median plasma concentrations of ascorbic acid grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/L were 2.0, 5.0 and 5.0 µmol/l respectively (P 
=0.052).  The median plasma concentrations of ascorbic acid grouped according to 
albumin concentrations ≥35, 25-34 and <25 g/l were 6.0, 8.0 and 4.0 µmol/l respectively 
(p=0.490). 
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8.4. Discussion  
The results of this study show that, in two cohorts of patients referred for a nutrition 
screen, plasma concentrations of α-tocopherol/ cholesterol ratio and ascorbic acid were 
significantly altered by magnitude of the systemic inflammatory response as evidenced by 
both changes in CRP and albumin concentrations.  Furthermore, this effect was 
differential, with albumin associated with a reduction in plasma α-tocopherol/ cholesterol 
ratio and ascorbic acid irrespective of the CRP concentrations.  As a result, albumin 
appears to have a larger effect than CRP on α-tocopherol/ cholesterol ratio and ascorbic 
acid.  Moreover, vitamin C concentrations were more profoundly affected by the presence 
of a systemic inflammatory response.  These results provide a basis for the better 
understanding of the impact of the systemic inflammatory response on α-tocopherol/ 
cholesterol ratio and ascorbic acid concentrations, and for their assessment and 
interpretation. 
In particular, the results of the present study question the use of the α-tocopherol/ 
cholesterol ratio, as proposed by Thurnham and co-workers (1986), to adjust for the effect 
of the systemic inflammatory response. Since, when expressed per mmol of cholesterol, α-
tocopherol, concentrations were lower with decreasing concentrations of albumin. 
The role of vitamin C in alleviating the oxidant stress and recycling the oxidized α-
tocopherol is well recognised.  Plasma α-tocopherol concentrations, in addition to being 
redistributed as part of the systemic inflammatory response, have been reported to be 
regenerated by vitamin C.  Early work on fat autoxidation performed by Golumbic and 
Mattill (1941) reported the antioxygenic action of ascorbate in association with tocopherols 
(Golumbic and Mattill 1941).  More recently, in vitro studies have shown that ascorbic 
acid reduces the tocopheroxyl radical (Packer et al. 1979) and thereby restores the radical-
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scavenging activity of tocopherol (Niki et al. 1982; Doba et al. 1985; Lambelet et al. 1985; 
Niki 1987; Wayner et al. 1987).  It would appear that the tocopheroxyl radical that forms in 
membranes reacts with ascorbic acid to yield tocopherol and the ascorbyl radical, the result 
of which is to maintain radical scavenging potential within the membrane by regenerating 
tocopherol and to transfer the oxidative challenge to the aqueous phase.  This scheme is 
consistent with the observation in the present study that plasma vitamin C concentrations 
were lower compared with vitamin E concentrations for the same magnitude of the 
systemic inflammatory response, even in patients with critical illness in whom vitamin C 
concentrations were recognised to be profoundly low (Schorah et al. 1996; Nathens et al. 
2002; Mishra et al. 2005). 
The importance of the systemic inflammatory response in determining plasma vitamin C 
concentrations is highlighted by the relative inefficiency, whereby supplementation can 
prevent low concentrations following an inflammatory insult.  For example, in healthy 
patients with normal pre–operative plasma concentrations of ascorbic acid, a single oral 
supplementation with 1,000 mg of ascorbic acid was unable to prevent the fall in 
postoperative plasma concentrations (Ruemelin et al. 2002).  Therefore, it is reasonable to 
conclude that ascorbic acid deficiency and the need for supplementation should only be 
considered on the basis of low plasma ascorbic acid concentrations in the presence of 
plasma CRP and albumin concentrations in the normal range. 
In summary, the results of the present study show that plasma concentrations of α-
tocopherol/ cholesterol ratio and ascorbic acid are independently associated with both CRP 
and albumin and consistent with the systemic inflammatory response as a major 
confounding factor in determining their status.  In particular, vitamin C concentrations 
were more profoundly affected by the presence of systemic inflammatory response.  These 
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results provide a basis for the better understanding of the impact of the systemic 
inflammatory response on plasma vitamin E and C. 
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Table 8-1:  Characteristics of nutrition screening, patient with critical illness cohorts and plasma vitamin E (α-tocopherol) and C (ascorbic acid) 
concentrations. 
 Reference 
interval 
Vitamin E nutrition screen  
(n=359) 
Vitamin C nutrition screen  
(n=494)  
Critical illness cohort  
(n= 82) 
P-value 
Age (years) N/A 52 (15-100) 54 (16-90) 58 (18-86) <0.001a 
Sex (Male/Female) N/A 185 (52%)/ 174 (48%) 234 (47%)/ 260 (53%) 51 (62%)/ 31 (38%) <0.001a 
C-reactive protein (mg/l) <10 9.0 (0.20- 565.0) 10.0 (0.20- 565.0) 85.0 (1.0- 565.0) <0.001a 
Albumin (g/l) 35-55 31 (9-50) 33 (9-50) 18 (9-45) <0.001a 
      
Plasma α-tocopherol (umol/l) 12 - 46 21.0 (2.9-58.0)  15.1 (5.0 -36.0) <0.001b 
Cholesterol (mmol/l) <5.2 4.5 (1.1-15.7)  2.2 (0.53-6.4) <0.001b 
α-tocopherol/ cholesterol ratio 
(μmol/ mmol) 
5.2 (3.5-8.7)  5.2 (0.4-19.5)  6.6 (2.1-15.7) <0.001b 
Plasma ascorbic acid (µmol/l) 11-114  17.0 (0.9-262.0) 4.0 (0.9-136.0) <0.001b 
Median (Range) a Kruskal Wallis, b Mann-Whitney U test   
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Table 8-2:  Distribution of plasma α-tocopherol adjusted to cholesterol according to CRP and albumin concentrations (n=359). 
Plasma α-tocopherol/ cholesterol ratio CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Plasma α-tocopherol/ cholesterol ratio 
according to albumin 
Albumin ≥35 (g/l) 6.2 (3.2-10.7) 
(n=131) 
5.4 (3.3-10.8) 
(n=18) 
- 
(n=1) 
6.0 (3.2-10.8) 
(n=150)  
34-25 (g/l) 5.2 (0.97-10.4) 
(n=48) 
6.0 (1.2-9.7) 
(n=38) 
4.6 (1.3-8.3) 
 (n=12) 
5.5 (1.0-10.4) 
(n=98)  
<25 (g/l) 3.8 (1.1-7.6) 
(n=15) 
2.4 (0.9-17.0) 
(n=31) 
1.7 (0.4-19.4) 
(n=65) 
2.1 (0.4-19.5) 
(n=111)  
Plasma α-tocopherol/ cholesterol ratio 
according to CRP 
5.9 (1.0-10.7) 
(n=194)  
4.6 (0.9-17.0) 
(n=87)  
2.1 (0.4-19.5) 
(n=78)  
 
     Median (range) (number of observation)  
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Table 8-3:  Distribution of plasma vitamin C (ascorbic acid) (µmol/l) according to CRP and albumin concentrations (n=494). 
Plasma vitamin C (ascorbic acid) 
(µmol/l) 
CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Plasma C (ascorbic acid) 
according to albumin 
Albumin ≥35 (g/l) 33 (0.99-235) 
(n=175) 
30 (0.99-79.0) 
(n=44) 
31 (17.0-66.0) 
(n=4) 
32 (0.99-235) 
(n=223)  
34-25 (g/l) 12 (0.90-126) 
(n=61) 
15 (0.99-136) 
(n=66) 
10 (0.99-61.0) 
 (n=19) 
13 (0.90-136) 
(n=146)  
<25 (g/l) 3 (0.90-40.0) 
(n=12) 
10 (0.90-262) 
(n=50) 
5.0 (0.90-102.0) 
(n=63) 
5 (0.90-262) 
(n=125)  
Plasma C (ascorbic acid) according to 
CRP 
25 (0.90-235) 
(n=248)  
15 (0.90-262.0) 
(n=160)  
6.0 (0.90-102.0) 
(n=86)  
 
Median (range) (number of observation) 
  
187 
 
Figure 8-1a:  The relationship between α-tocopherol adjusted to cholesterol and CRP 
(log 10) (rs= - 0.424, P <0.001) and ) in patients with critical illness (rs= - 0.391, P 
<0.001). 
 
Figure 8-1b:  The relationship between α-tocopherol adjusted to cholesterol and 
albumin (rs=  0.531, P <0.001) and in patients with critical illness (rs=  0.693, P 
<0.001). 
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Figure 8-2a:  The relationship between CRP (log 10) and vitamin C (µmol/l) (rs= - 
0.333, P<0.001) and in patients with critical illness (rs= - 0.174, P=0.117). 
 
Figure 8-2b:  The relationship between albumin and vitamin C (µmol/l) (rs= 0.427, 
P<0.001) and in patients with critical illness (rs= 0.205, P=0.064). 
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Figure 8-2c:  The relationship between CRP (log 10) and vitamin C adjusted to 
albumin (rs= - 0.179, P<0.001) and in patients with critical illness (rs= - 0.266, 
P=0.016). 
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9. The relationship between markers of the systemic inflammatory 
response and plasma zinc and selenium concentrations. 
9.1. Introduction 
Trace elements are of vital importance in human health acting as cofactors in many 
catalytic processes and particularly, in the case of zinc, they have a structural role. 
Selenium is essential for the catalytic activity of glutathione peroxidase activity (GSH-Px) 
protecting against membrane lipid peroxidation (Thomas et al. 1990) while zinc also 
combats oxidative stress as cofactors in zinc superoxide dismutase.  Zinc and selenium 
both play important functions in immune regulation (Fraker et al. 2000).  With such roles, 
adequate trace element status is considered to be of particular importance in critically ill 
patients who have significantly reduced circulating and body stores of antioxidants, such as 
zinc superoxide dismutase and glutathione peroxidase activity, therefore compromise of 
reactive oxygen species (Heyland et al. 2005). 
Concentrations of some circulating trace elements such as zinc and selenium are known to 
decrease significantly following severe trauma, surgery, sepsis and severe systemic 
inflammatory response and remain low for several days and weeks (Berger et al. 1998; 
Heyland et al. 2006).  It has been proposed that this reduction in trace element 
concentrations may deplete circulating antioxidants leading to an elevation of reactive 
oxygen species and so exacerbating the severity of illness (Berger and Chiolero 2007).  
Other groups have also suggested that decreased plasma trace elements concentrations are 
associated with severity of critical illness (Goode et al. 1995; Metnitz et al. 1999; Rinaldi 
et al. 2009). 
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However, the presence of a systemic inflammatory response has been reported to be 
associated with low plasma antioxidant concentrations (Galloway et al. 2000; Duncan et al. 
2012b).  In particular, it has recently been reported that the magnitude of systemic 
inflammatory response, as evidenced by CRP, is associated with lower circulating 
concentrations of zinc and selenium (Duncan et al. 2012b). 
Duncan and co-workers (2012) reported that the systemic inflammatory response was 
associated with a 20% and 50% reduction in plasma zinc and selenium concentration 
respectively when CRP concentrations were > 80 mg/l.  However, the variability of the 
association was such that plasma zinc and selenium concentrations were not readily 
adjusted for CRP concentrations (Duncan et al. 2012b). 
Oakes and co-workers (2008) reported that during the acute systemic inflammatory 
response plasma zinc fell by 36%, plasma selenium fell by 26%  and albumin by 19% 
(Oakes et al. 2008).  Therefore, it is of interest that albumin is quantitatively the most 
important protein in the plasma and binds several plasma micronutrients, including zinc 
and selenium (Blindauer et al. 2009).  Albumin is routinely measured and may be 
considered as a surrogate measure for some plasma binding proteins of similar molecular 
weight.  Therefore, albumin may be useful in adjusting plasma zinc and selenium 
concentrations for the effect of the systemic inflammatory response and it may be useful in 
assessing zinc and selenium status. 
The aim of the present study was to examine the relationships between plasma zinc, 
selenium and the systemic inflammatory response in a large cohort of patients referred for 
zinc and selenium assessment and also examine these relationships in patients from critical 
illness cohort.  
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9.2. Patients and methods 
9.2.1. Nutrition screen cohort  
Plasma zinc measurements were obtained from an unselected cohort of 1305 consecutive 
heparin-treated whole- blood samples from 743 patients referred for nutrition assessment 
between January 2000 and March 2013.  Similarly, plasma selenium measurements were 
obtained from an unselected cohort of 1244 samples from 833 patients.  If more than one 
set of plasma zinc or selenium results was available in a patient only the first sample was 
included into the analysis, leaving a total of 743 and 833 plasma zinc and selenium results 
respectively.  In the nutrition screen cohort < 20 % of patients had both zinc and selenium 
measurements.  In order to have enough observations to examine the relationship between 
markers of the systemic inflammatory response and measurements of zinc and selenium we 
used the present approach.  As a regional centre blood samples were sent for analysis if the 
patient was considered at nutrition risk and was often secondary to a number of disease 
states.  In addition, measurement of CRP and albumin was also recorded for these patients. 
9.2.2. Critical illness cohort 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008 and who had evidence of the systemic inflammatory response syndrome as per 
Bone’s criteria (Bone et al. 1992; Levy et al. 2003), and admitted in the period from 
September 2006 to December 2008 were studied.  Briefly, APACHE II score (Knaus et al. 
1985) and predicted hospital mortality and SOFA scores, CRP and albumin were recorded.  
This cohort has been described previously and the basic purpose of this cohort was to study 
micronutrients concentrations (Stefanowicz et al. 2013a). 
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This investigation was conducted with the intent of developing local guideline to aid in the 
interpretation of zinc and selenium results.  There were two cohorts studied, the first (a 
large unselected retrospective cohort) arose from an audit of patients who had a sample 
sent to a regional laboratory for a nutrition screen.  Approval for audit purpose was 
obtained from the local ethics committee of the North Glasgow NHS Trust.  The second (a 
small selected prospective cohort) arose from a prospective study of patients with critical 
illness.  The patient data from the two cohorts was anonymised and de-identified prior to 
analysis (Andrew D and Donald C McMillan respectively).  In line with local ethical 
procedures written informed consent was obtained for the latter cohort only.  The latter 
study was approved by the ethics committees of the North Glasgow NHS Trust and 
Multicentre Research Ethics Committee (MREC) Scotland.  Where patients were unable to 
give signed informed consent, consent was obtained from the patients’ next of kin or 
welfare guardian in accordance with the requirements of the Adults with Incapacity 
Scotland (2000) Act (Appendix 1, 2). 
9.2.3. Analytical methods  
Plasma zinc and selenium were measured by atomic absorption spectrometry (Perkin-
Elmer) until 2006, and then it was measured by inductively coupled plasma mass 
spectrometry (Agilent Technologies).  Intra-assay imprecision was 4% for these analyses. 
Samples were centrifuged (500 g, 4˚C, 10 minutes) and the plasma removed for analysis. 
Samples were stored at -70 ˚C prior to analysis.  Plasma was simultaneously analysed for 
zinc and selenium using a 7500 CE inductively-coupled plasma mass spectrometer 
(Agilent, USA) operated in reaction cell mode.  Prior to analysis plasma was diluted 1 in 
10 with a solution containing 2% butan-1-ol, 0.05% EDTA, 0.05% Triton-X-100, 1% 
ammonia and 25 ug/l of germanium which served as internal standard.  The dried sample 
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was then digested in 500 μl of 60% ultrapure nitric acid at 70˚C for 4 hours and diluted 
with 4.5 mL of 1% nitric acid containing 25 ug/l of germanium. Plasma internal quality 
controls (Seronorm, Billingstad, Norway) and plasma and whole blood external quality 
assurance samples (TEQAS, Guildford, UK) were analysed. 
Albumin was measured by a BCP dye-binding method and C-reactive protein was 
measured using an automated analyser (Architect, Abbott Diagnostics, USA).  For C-
reactive protein the limit of detection was 5 mg/l.  The inter-assay coefficient of variation 
was less than 3% and 5% over the sample concentration range for albumin and C-reactive 
protein respectively.  The limit of detection for albumin was 10 g/L. 
9.2.4. Statistical analysis 
Data was presented in median and range.  Correlations between variables in the 
convenience sample were carried out using the Spearman rank correlation.  The cohorts 
were divided into three groups according to CRP concentrations < 10, 11-80 and >80 mg/l 
as previously described (Marsik et al. 2008).  Plasma CRP is recognised to be produced in 
an exponential manner and have a skewd distribution.  Therefore taking the logarithm of 
CRP is a recognised approach to normalise the distribution prior to examining relationships 
The concentration of individual zinc and selenium were grouped according to 3 categories 
of albumin concentrations ≤ 25, 25-34, ≥ 35 g/l as previously described (Goldwasser and 
Feldman 1997).  A P- value < 0.05 was considered significant and the analysis of the data 
was carried out using SPSS software (version 19; SPSS Inc, Chicago, Ill). 
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9.3. Results  
9.3.1. Nutrition screen cohort for zinc and selenium 
The characteristics of the zinc convenience sample (n= 743) are shown in Table 9-1.  The 
majority were older than 50 years (median 55 years), female (52%) and had plasma CRP 
was elevated, albumin concentrations were low and zinc in the normal range.  Plasma zinc 
was significantly associated with age (rs=-0.118, P =0.001), sex (males median 9.7 µmol/l, 
females median 10.9 µmol/l, P <0.001), CRP (rs= -0.404, P <0.001) and albumin 
(rs=0.588, P <0.001).  Age was significantly associated with CRP (rs= 0.308, P <0.001) 
and albumin (rs=-0.294, P <0.001).  CRP was significantly associated with albumin (rs=-
0.606, P <0.001). 
The association between the magnitude of the systemic inflammatory response, as 
evidenced by CRP and albumin concentrations and zinc are shown in Figure 9-1a and 9-
1b.  The association of CRP and zinc/ albumin ratio is shown in Figure 9-1c. 
The median plasma concentrations of zinc grouped according to CRP concentrations ≤10, 
11-80 and >80 mg/l were 11.4, 10.0 and 7.0µmol/l respectively (P <0.001) with an overall 
reduction of 39%.  The median plasma concentrations of zinc grouped according to 
albumin concentrations ≥35, 25-34 and <25 g/l were 11.9, 10.0 and 6.3µmol/l respectively 
(P <0.001) with an overall reduction of 47%. 
The characteristics of the selenium convenience sample (n= 833) are shown in Table 9-1.  
The majority were older than 50 years (median 56 years), female (54%) and had plasma 
CRP and albumin in the normal range, and selenium was slightly below the normal range 
(median 0.74 µmol/l).  Plasma selenium was significantly associated with age (rs=0.073, P 
=0.036), sex (males median 0.69 µmol/l, females median 0.78 µmol/l, P =0.008), CRP (rs= 
-0.489, P <0.001) and albumin (rs=0.600, P <0.001).  Age was significantly associated 
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with CRP (rs= 0.279, P <0.001) and albumin (rs=-0.191, P <0.001).  CRP was significantly 
associated with albumin (rs=-0.599, P <0.001). 
The association between the magnitude of the systemic inflammatory response, as 
evidenced by CRP and albumin concentrations and selenium are shown in Figure 9-2a and 
9-2b.  The association of CRP and selenium/ albumin ratio is shown in Figure 9-2c. 
The median plasma concentrations of selenium grouped according to CRP concentrations 
<10, 11-80 and >80 mg/l were 0.86, 0.66 and 0.37µmol/l respectively (P <0.001) with an 
overall reduction of 57%.  The median plasma concentrations of selenium grouped 
according to albumin concentrations ≥35, 25-34 and <25 g/l were 0.90, 0.63 and 0.34 
µmol/l respectively (P <0.001) with an overall reduction of 62%. 
The median distributions of plasma zinc according to CRP and albumin concentrations are 
shown in Table 9-2.  The median plasma concentrations of zinc grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/l were 11.4, 10.0 and 7.0µmol/l respectively (P 
<0.001) with an overall reduction of 39%.  The median plasma concentrations of zinc 
grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 11.9, 10.0 and 
6.3µmol/l respectively (P <0.001) with an overall reduction of 47%. 
When albumin concentrations were ≥ 35 g/l, the median plasma concentrations of zinc 
grouped according to CRP concentrations ≤10, 11-80 and >80 mg/l were 12.1, 11.5 and 9.0 
µmol/l (P =0.006) with an overall reduction of 26%.  When albumin concentrations were 
25-34 g/l, the median plasma concentrations of zinc grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/l were 9.6, 10.5 and 9.7µmol/l (P =0.031) with an 
overall reduction of <1%.  When albumin concentrations were < 25 g/l, the median plasma 
concentrations of zinc grouped according to CRP concentrations ≤10, 11-80 and >80 mg/l 
were 7.2, 7.0 and 5.5 µmol/l (P =0.016) with an overall reduction of 24%.  The median 
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zinc/ albumin ratio x 100 for CRP concentrations ≤10, 11-80 and >80 mg/l were 31, 33 and 
32 (P =0.029).  The median Zinc / CRP ratio x 100 for albumin concentrations ≥35, 25-34 
and <25 g/l were 25.1, 59.4 and 8.4 (P <0.001). 
The median distributions of plasma selenium according to CRP and albumin 
concentrations are shown in Table 9-3.  The median plasma concentrations of selenium 
grouped according to CRP concentrations <10, 11-80 and >80 mg/l were 0.89, 0.66 and 
0.37µmol/l respectively (P <0.001) with an overall reduction of 57%.  The median plasma 
concentrations of selenium grouped according to albumin concentrations ≥35, 25-34 and 
<25 g/l were 0.90, 0.63 and 0.34 µmol/l respectively (P <0.001) with an overall reduction 
of 62%. 
When albumin concentrations were ≥ 35g/l, the median plasma concentrations of selenium 
grouped according to CRP concentrations ≤10, 11-80 and >80 mg/l were 0.93, 0.85 and 
0.87µmol/l (P =0.013) with an overall reduction of 6%.  When albumin concentrations 
were 25-34 g/l, the median plasma concentrations of selenium grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/l were 0.71, 0.66 and 0.48 µmol/l (P =0.001) with 
an overall reduction of 32%.  When albumin concentrations were <25g/l, the median 
plasma concentrations of selenium grouped according to CRP concentrations ≤10, 11-80 
and >80 mg/l were 0.43, 0.39 and 0.29 µmol/l (P =0.002) with an overall reduction of 
33%.  The median selenium /albumin ratio x 100 for CRP concentrations ≤10, 11-80 and 
>80 mg/l were 2.3, 2.1 and 1.8 (p<0.001).  The median selenium / CRP ratio x 100 for 
albumin concentrations ≥35, 25-34 and <25 g/l were 0.54, 3.9 and 21.5 (P <0.001). 
9.3.1. Patients with critical illness. 
The characteristics of the critically ill cohort (n=114) are shown in Table 9-1.  The 
majority were older than 50 years (median 60 years), male (65%), an APACHE II score of 
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21 and SOFA score of 7 and the associated median predicted mortality was 35.1%.  The 
majority of patients were surgical (56%) and had a median length of ICU stay of 4 days 
and median hospital stay of 19 days.  The median CRP and albumin concentrations were 
above and below the normal reference intervals respectively.  Approximately half had 
some renal impairment as evidence by eGFR of <60ml/min.  The median plasma zinc and 
selenium was 4.5 µmol/l and 0.29µmol/l respectively. 
Plasma zinc was significantly associated with CRP (rs= - 0.266, P =0.004) and albumin (rs 
=0.348, P <0.001).  Age was significantly associated with albumin (rs = - 0.233, P =0.013).  
CRP was significantly associated with albumin (rs =-0.377, P <0.001).  Plasma selenium 
was significantly associated with CRP (rs = -0.322, P <0.001) and Albumin (rs =0.580, P 
<0.001).  Age was significantly associated with albumin (rs =-0.212, P =0.022).  CRP was 
significantly associated with albumin (rs =-0.362, P <0.001). 
The association between the magnitude of the systemic inflammatory response, as 
evidenced by CRP and albumin concentrations, on zinc and selenium in patients with 
critical illness were shown in Figures 9-1a, 9-1b and 9-2a, 9-2b.  The association of CRP 
and zinc/ albumin ratio and selenium/ albumin ratio were shown in Figure 9-1c and 9-2c 
respectively. 
The median plasma concentrations of zinc grouped according to CRP concentrations ≤10, 
11-80 and >80 mg/L were 6.8, 5.5 and 4.0 µmol/l respectively (P =0.007).  The median 
plasma concentrations of zinc grouped according to albumin concentrations ≥35, 25-34 and 
<25 g/l were 8.0, 6.1 and 4.0 µmol/l respectively (P <0.001). 
The median plasma concentrations of selenium grouped according to CRP concentrations 
≤10, 11-80 and >80 mg/L were 0.51, 0.30 and 0.22 µmol/l respectively (P <0.001).  The 
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median plasma concentrations of selenium grouped according to albumin concentrations 
≥35, 25-34 and <25 g/l were 0.63, 0.52 and 0.22 µmol/l respectively (P <0.001).  
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9.4. Discussion 
The results of the present study show that, in nutrition screen and critical illness patient 
cohorts, plasma zinc and selenium concentrations were independently associations with 
CRP and albumin as markers of systemic inflammatory response.  In the case of zinc the 
effect was mainly associated with lower albumin concentrations and so the impact of the 
systemic inflammatory response (as evidenced by elevated CRP concentrations) could 
largely be adjusted to the albumin concentration. In the case of selenium the effect was 
associated with both CRP and albumin and so the impact of the systemic inflammatory 
response (as evidenced by elevation of CRP concentrations) could not be reasonably 
adjusted by either CRP or albumin concentrations alone. 
One of the important implications of the present study is that when one encounters patients 
who have low plasma concentrations of zinc or selenium, it is difficult to differentiate real 
deficiencies of these trace elements from redistribution caused by systemic inflammation 
and therefore independent of nutrition deficiency.  However, recognition of such a 
relationship would suggest that, in those patients who have a low plasma concentration of 
zinc or selenium and who have a CRP and albumin concentration in the normal range, such 
patients are likely to be deficient.  In the case of those patients who have low plasma 
concentration of zinc or selenium and who have CRP and albumin concentrations out with 
the normal range it is difficult to determine whether deficiency is real or apparent.  In these 
patients a number of approaches could be used to determine whether there was real 
deficiency. Firstly, serial measurements could be used to examine the changes in zinc or 
selenium and in CRP and albumin.  Secondly, functional tests may be useful e.g. 
glutathione peroxidase activity (GSH-Px) in the case of selenium.  Thirdly, intracellular 
measurements could be carried out e.g. red cell zinc or selenium measurements.  Fourthly, 
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potential correction of zinc and selenium plasma levels for their carrier proteins (i.e. 
albumin for zinc and albumin/selenoproteins for selenium). 
The reasons for the differential association of CRP and albumin with zinc and selenium are 
unclear.  However, approximately 70 % of plasma zinc is bound to albumin while 
approximately 53% and 9% of plasma selenium is bound to selenoprotein P (SePP) or 
albumin respectively (Deagen et al. 1993; Harrison et al. 1996; Mostert et al. 1998; 
Nicholson et al. 2000; Stefanowicz et al. 2013b).  Indeed, in the blood less than 1% of 
selenium is in free form.  The concentrations of all these fall as part of the systemic 
inflammatory response (Oakes et al. 2008; Alhazzani et al. 2013) and therefore 
interpretation of plasma selenium remains problematical.  Therefore, it is of interest that 
Stefanowicz and co-workers (2013) recently reported that erythrocyte GSH-Px activity was 
associated with plasma and erythrocyte selenium concentrations to a threshold point after 
which activity of the enzyme was found to reach a maximum and plateau.  Further work 
examining the relationship between plasma selenium and erythrocyte GSH-Px activity in 
the presence of a systemic inflammatory response may shed some light on the importance 
of low plasma selenium concentrations. 
The results of the present study examining the effect of the systemic inflammatory 
response on plasma zinc and selenium concentrations may also have implications for other 
trace elements and vitamins in plasma that fall as part of the systemic inflammatory 
response (Duncan et al. 2012b; Ghashut et al. 2013).  Indeed, CRP is recognised to be the 
prototypical marker of the systemic inflammatory response (Gabay and Kushner 1999).  In 
contrast, plasma albumin not only reflects the systemic inflammatory response but also 
reflects lean body mass and thus can be considered as a general marker of nutritional status 
(McMillan et al. 1998; Richards et al. 2012).  Therefore, examining the different effects of 
these acute phase proteins gives an important insight into the basis of low plasma zinc and 
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selenium concentrations.  Also albumin is a carrier protein for zinc and selenium in plasma 
and may reflect the extent of redistribution of these trace elements in the presence of 
systemic inflammatory response.  Further work is required to determine whether both CRP 
and albumin have an independent impact on circulating concentrations of such 
micronutrients. 
The present study has a number of limitations.  In particular there was no information on 
the presence of chronic disease, co-morbidity or on BMI.  Nevertheless, it is likely that the 
impact of these clinical factors on metabolic trace elements will have involved the 
systemic inflammatory response, at least in part (Hotamisligiil 2006; Jensen 2014). 
In summary, the results of the present study show that plasma concentrations of zinc were 
associated with both CRP and albumin.  Moreover, that the impact of the systemic 
inflammatory response (as evidenced by elevation of CRP) on plasma zinc concentration 
may be largely adjusted by the albumin concentrations.  Plasma concentrations of selenium 
were associated with both CRP and albumin.  However, the impact of the systemic 
inflammatory response (as evidenced by elevation in CRP) may not be readily adjusted by 
the albumin concentration.  Similar relationships were also observed in the cohort of 
patients with critical illness.  
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Table 9-1:  Characteristics of nutrition screening, patient with critical illness cohorts and plasma zinc and selenium. 
 Reference 
interval 
Nutrition screen cohort (Zinc) 
(n=743)  
Nutrition screen cohort (Selenium)  
(n=833 ) 
Critical illness patients 
(n= 114)  
P- value 
a
 
Age (years) N/A 55 (16-100) 56 (16-100) 60 (18-100) 0.068 
Sex (Male/Female) N/A 359 (48%)/ 384 (52%) 387 (46%)/ 446 (54%) 74 (65%)/ 40 (35%) <0.001 
C-reactive protein (mg/l) <10 12.0 (0.19- 565.0) 10.0 (0.19- 565.0) 100.0 (1.0- 565.0) <0.001 
Albumin (g/l) 35-55 32 (<10-50) 35 (<10-50) 17 (9-45) <0.001 
      
Zinc (µmol/l) 12.0-18.0 10.5 (0.6-30.1)  4.5 (0.6-27.0) <0.001 
Selenium (µmol/l) 0.8-2.0  0.74 (0.1-5.68) 0.29 (0.01-5.68) <0.001 
Median (Range), 
a
 Mann-Whiney U Test. 
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Table 9-2:  Distribution of plasma zinc (µmol/l) according to CRP (mg/l) and albumin (g/l) concentrations (n=743). 
Plasma Zinc (µmol/l) CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Plasma zinc according to 
albumin 
Albumin ≥35 (g/l) 12.1 (6.5-30.1) 
(n=242) 
11.5 (7.0-23.0) 
(n=70) 
9.0 (5.5-15.5) 
(n=9) 
11.9 (5.5-30.1) 
(n=321)  
34-25 (g/l) 9.6 (3.5-25.5) 
(n=87) 
10.5 (3.5-27.8) 
(n=100) 
9.7 (3.0-15.5) 
 (n=40) 
10.0 (3.0-27.8) 
(n=227)  
<25 (g/l) 7.2 (3.0-27.9) 
(n=26) 
7.0 (0.6-27.0) 
(n=71) 
5.5 (1.0-15.5) 
(n=98) 
6.3 (0.6-27.9) 
(n=195)  
Plasma zinc according to 
CRP 
11.4 (3.0-30.1) 
(n=355)  
10.0 (0.6-27.8) 
(n=241)  
7.0 (1.0-15.5) 
(n=147)  
 
      Median (range) (number of observation) 
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Table 9-3:  Distribution in plasma selenium (µmol/l) according to CRP (mg/l) and albumin (g/l) concentrations (n=833). 
Plasma Selenium (µmol/l) CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Plasma selenium 
according to albumin 
Albumin ≥35 (g/l) 0.93 (0.1-3.4) 
(n=315) 
0.85 (0.3-2.6) 
(n=99) 
0.87 (0.6-1.2) 
(n=8) 
0.90 (0.1-0.3) 
(n=422)  
34-25 (g/l) 0.71 (0.2-1.7) 
(n=86) 
0.66 (0.1-1.4) 
(n=100) 
0.48 (0.02-1.3) 
(n=41) 
0.63 (0.02-1.7) 
(n=227)  
<25 (g/l) 0.43 (0.1-1.1)  
(n=26) 
0.39 (0.01-1.7) 
(n=70) 
0.29 (0.04-5.7) 
(n=88) 
0.34 (0.01-5.7) 
(n=184)  
Plasma selenium 
according to CRP 
0.89 (0.1-3.4) 
(n=427)  
0.66 (0.01-2.6) 
(n=269)  
0.37 (0.02-5.7) 
(n=137)  
 
      Median (range) (number of observation) 
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Figure 9-1a:  The relationship between CRP (log 10) and zinc (µmol/l) in the nutrition 
screen cohort  (rs= - 0.404, P <0.001) and in the critical illness cohort  (rs= -0.266, 
P=0.004). 
 
 
Figure 9-1b:  The relationship between albumin and zinc (µmol/l) in the nutrition 
screen cohort (rs= 0.588, P<0.001) and in the critical illness cohort (rs= 0.348, 
P<0.001). 
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Figure 9-1c:  The relationship between CRP (log 10) and zinc adjusted to albumin in 
the nutrition screen cohort (rs= 0.074, P=0.045) and in the critical illness cohort (rs= 
0.038, P=0.114). 
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Figure 9-2a:  The relationship between CRP (log 10) and selenium (µmol/l) in the 
nutrition screen cohort (rs= -0.489, P<0.001) and in the critical illness cohort (rs= -
0.336, P<0.001). 
 
Figure 9-2b:  The relationship between albumin and selenium (µmol/l) in the 
nutrition screen cohort (rs= 0.600, P<0.001) and in the critical illness cohort (rs= 
0.588, P<0.001). 
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Figure 9-2c:  The relationship between CRP (log 10) and selenium adjusted to 
albumin in the nutrition screen cohort (rs= - 0.207, P<0.001) and in the critical illness 
cohort (rs= - 0.163, P=0.081) 
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10. The relationship between markers of the systemic inflammatory 
response and plasma and red cell trace element concentrations, 
disease severity and outcome in patients with critical illness. 
10.1. Introduction 
Trace elements are of vital importance in human health acting as cofactors in many 
catalytic processes and particularly, in the case of zinc, they have a structural role. 
Selenium is essential for the catalytic activity of glutathione peroxidase (GSH-Px) 
protecting against membrane lipid peroxidation (Thomas et al. 1990) while copper and 
zinc also combat oxidative stress as cofactors in copper-zinc superoxide dismutase.  Zinc 
and selenium both play important functions in immune regulation (Fraker et al. 2000).  
With such roles, adequate trace element status is considered to be of particular importance 
in critically ill patients who have significantly reduced circulating and body stores of 
antioxidants, such as copper-zinc superoxide dismutase and glutathione peroxidase, so 
impeding detoxification of reactive oxygen species (Heyland et al. 2005). 
Concentrations of some circulating trace elements such as zinc and selenium, are known to 
decrease significantly following severe trauma, surgery, sepsis and severe systemic 
inflammatory response and remain low for several days and weeks (Berger et al. 1998; 
Heyland et al. 2006).  It has been proposed that this reduction in trace element 
concentrations may deplete circulating antioxidants leading to an elevation of reactive 
oxygen species and so exacerbating the severity of illness (Berger and Chiolero 2007).  
Other groups have also suggested that decreased plasma trace elements concentrations are 
associated with severity of critical illness (Goode et al. 1995; Metnitz et al. 1999; Rinaldi 
et al. 2009). 
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A recent study of patients presenting to ICU reported that plasma zinc concentrations were 
inversely associated with Sequential Organ Failure Assessment scores (SOFA) (Cander et 
al. 2011).  Furthermore, a study examining zinc metabolism in patients in ICU found 
plasma concentrations were lower in septic compared with non-septic adults after 
admission to ICU (Besecker et al. 2011).  Similarly, a low plasma selenium concentration 
found after admission to ICU was associated with the systemic inflammatory response, 
multiorgan dysfunction (Manzanares et al. 2009) and an increase in mortality (Forceville et 
al. 1998). 
Perhaps unwittingly such reports suggest a causative role of low circulating concentrations 
of plasma trace elements in these processes.  In clinical practice a significant percentage of 
UK ICUs routinely request such measurements and low plasma zinc concentrations, 
purportedly indicating deficiency, has resulted in a significant minority of UK ICUs 
supplementing with high-dose zinc supplementation (Duncan et al. 2012a). 
Although the direct measurement of essential trace elements in plasma is the most 
predominant method used to assess nutrition deficiency, interpretation of plasma 
concentrations of trace elements can be difficult in patients with a systemic inflammatory 
response.  Rather than being indicative of nutrition deficiency, decreasing concentrations 
of plasma trace elements concentrations such as zinc, selenium, vitamin E, C and B6 are 
associated with the magnitude of inflammatory response as evidenced by increased CRP 
concentrations (Galloway et al. 2000; Duncan et al. 2012b).  This relationship can be 
readily demonstrated by studying the evolution of the systemic inflammatory response 
following an elective knee arthroplasty (Oakes et al. 2008; Defi et al. 2011); plasma 
selenium and zinc concentrations initially decreased from baseline in association with a 
rise in CRP concentrations while the copper increased.  Plasma concentration changes 
were transient and normalised without supplementation as CRP concentrations returned to 
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normal as the patient recovers.  Erythrocyte trace element concentrations such as zinc and 
selenium, however, did not change significantly throughout the development of the 
systemic inflammatory response (Oakes et al. 2008). 
This study was carried out to further investigate the value of plasma trace element 
measurement in ICU patients by investigating their association with the severity of illness 
and mortality.  Glutathione peroxidase activity was also measured as an alternative marker 
of selenium status.  Since erythrocyte concentrations of trace elements remained stable 
during elective surgery we also took the opportunity to similarly examine their relationship 
with severity of illness and outcome. 
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10.2. Patients and methods 
10.2.1. Patients and study design 
Patients admitted to ICU at the Glasgow Royal Infirmary, between September 2006 and 
April 2008 and who had respiratory failure requiring ventilatory support, were ≥18 years 
old, and who had evidence of the systemic inflammatory response syndrome as per Bone’s 
criteria, (Bone et al. 1992) were studied.  The systemic inflammatory response is a 
systemic response to a variety of severe clinical insults.  The syndrome is manifested by 2 
or more of the following conditions: temperature >38C or < 36C, heart rate > 90 beats/min, 
respiratory rate > 20 breath/min or PaCO2< 4.3 kPa, and white cell count > 12000 or < 
4000 cells/mm
3
 or > 10% immature forms (Bone et al. 1992).  Only two patients had been 
diagnosed with liver failure and the frequency and use of red cell transfusion was not 
recorded. 
Venous blood was collected into heparinised trace element free tubes on admission to the 
ICU and, depending on the length of stay, on day four and day seven (± one day).  
APACHE II and SOFA scores were also recorded.  Enteral feeding was usually started on 
day two using either Jevity (Abbott, US); 10mg/L zinc, 5.30μg/L selenium, 95 mg/L 
copper) or Osmolite (Abbott, US): 1.50mg/L zinc, 50μg/L selenium, 1.2 mg/L copper).  
Patients routinely receive 2L of one of these preparations per day, amounting to an intake 
of 2.2 to 2.60 mg zinc, 10.6 to 12.0 μg selenium, and 0.19 to 0.22 g copper.  The reference 
nutrient intakes are: copper, 1.2 mg/day; zinc 9.5 mg/day; selenium 75 μg/day (males) and 
60 μg/day (females) (Expert group on vitamins and minerals 2003). 
The study was approved by the Multicentre Research Ethics Committee, Scotland.  In 
cases where patients were unable to provide consent, it was obtained from their next of kin 
  
214 
 
or welfare guardian in accordance with the Adults with Incapacity Scotland (2000) Act 
(Appendix 1, 2). 
10.2.2. Analytical Methods 
Samples were centrifuged (500 g, 4˚C, 10 minutes) and the plasma removed for analysis. 
Packed erythrocytes were prepared by removing any residual plasma and the buffy layer. 
Samples were stored at -70 ˚C prior to analysis. 
Plasma and packed erythrocytes were simultaneously analysed for copper, zinc, selenium 
and iron using a 7500 CE inductively-coupled plasma mass spectrometer (Agilent, USA) 
operated in reaction cell mode.  Prior to analysis plasma was diluted 1 in 10 with a solution 
containing 2% butan-1-ol, 0.05% EDTA, 0.05% Triton-X-100, 1% ammonia and 25 ug/L 
of germanium which served as internal standard.  Packed erythrocytes were prepared for 
analysis by drying a 50 μl aliquot at 80˚C for 90 minutes.  The dried sample was then 
digested in 500 μl of 60% ultrapure nitric acid at 70˚C for 4 hours and diluted with 4.5 mL 
of 1% nitric acid containing 25 ug/L of germanium.  Plasma and whole blood internal 
quality controls (Seronorm, Billingstad, Norway) and plasma and whole blood external 
quality assurance samples (TEQAS, Guildford, UK) were analysed.  No external quality 
assurance scheme was available for erythrocyte trace elements or GSH-Px.  Erythrocyte 
trace elements were reported as a ratio to haemoglobin concentration to correct for 
inaccuracies associated with pipetting packed red blood cells.  Iron was measured as a 
surrogate for haemoglobin (Oakes et al. 2008) whose concentration was calculated using 
the following equation where 64,456 is the molecular weight of haemoglobin in g and the 
denominator is the number of atoms of iron per haemoglobin molecule. 
Hb (g/L) = Iron (mol/L) x 64 456 
                       4 
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GSH-Px activity in plasma and erythrocytes was measured on an analytical platform 
(Sapphire 350, Audit Diagnostics, Ireland) using a commercially available kit (Randox, 
Co. Antrim, UK).  Haemoglobin was measured colorimetrically on a Sapphire 350 by 
Drabkin’s method (Drabkin and Austin 1935).  Glutathione peroxidase activities, measured 
as glutathione peroxidase 1, were reported as IU/g Hb. 
Albumin and CRP were measured in plasma by bromocresol purple and turbidimetric 
methods respectively using an automated analyzer (Architect; Abbot Diagnosis, 
Maidenhead, UK). 
10.2.3. Statistics 
Data was presented as median and range.  Correlations between variables in the critically 
ill group were performed using the Spearman’s rank correlation.  Data from different time 
points in the patient group were tested for significance using Friedman’s signed-rank test. 
Data from survivors and non-survivors were tested for statistical significance using the 
Mann-Whitney U-test. Outcome data were analysed by binary logistic regression analysis. 
Because of the large number of statistical comparisons, a p value of <0.01 was considered 
to be significant.  Analysis was performed with the use of SPSS software (version 19; 
SPSS Inc, Chicago, IL). 
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10.3. Results 
125 critically ill patients were recruited; 81 (66%) were male, the median age was 60 
(range: 18 to 100), and the medical / surgical proportion was 55/70 (44%/56%).  The 
median (lower and upper 2.5th percentiles) APACHE II score, SOFA score and length of 
stay and mortality were 21 (16 to 26), 7 (4 to 9), 3.7 days (1.5 to 11.1) and 19% 
respectively. 
Laboratory results on admission are shown in Table 10-1.  Median concentrations of 
albumin were low compared to the reference range whilst those of CRP and glucose were 
high. Median plasma concentrations of zinc and selenium were low while copper and 
glutathione peroxidase concentrations in plasma and concentrations of zinc, selenium, 
copper and glutathione peroxidase in erythrocyte were within the laboratory reference 
range.  Plasma zinc and selenium concentrations were below the lower limit of the 
reference interval in 86% and 90% of patients respectively.  Only plasma zinc and 
selenium concentrations were inversely associated with CRP (rs= -0.266, P = 0,004, rs = -
0.322, P <0.001 respectively). 
Thirty-one of the 125 patients had two further samples taken (Table 10-2); the remainder 
did not have additional samples due to discharge or death (n = 70).  Plasma zinc (P = 
0.004), plasma selenium (P = 0.003) increased significantly during the ICU stay although 
they remained below the reference interval.  There were no significant changes in the 
SOFA score or in erythrocyte analytes or any of the remaining plasma analytes. Plasma 
selenium concentrations were directly associated with plasma glutathione peroxidase 
activity (rs = 0.325, P = 0.001) and red cell selenium concentrations (rs= 0.582, P = 0.001).  
Red cell selenium concentrations were directly associated with red cell glutathione 
peroxidase activities (rs= 0.567, P = 0.001). 
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Twenty-four (19%) patients died in ICU following their admission.  Compared with 
survivors, non-survivors had significantly longer (P <0.001) ICU lengths of stay and lower 
plasma albumin concentrations: median length of stay (upper and lower 2.5% percentile):  
2.9 days (1.0 to 8.9) in survivors and 11.6 days (7.1 to 17.3) in non-survivors; and albumin 
concentrations: 19 g/L (14 to 26) in survivors and 13 g/L (10 to 17) in non-survivors.  No 
statistically significant difference of plasma zinc or selenium between survivors and non-
survivors was found (P <0.01) although selenium concentrations tended to be lower in 
non-survivors (P =0.04) (Table 10-3). 
When admission patient SOFA and APACHE II scores and analyte concentrations were 
compared to mortality by univariate analysis, only length of stay and albumin 
concentrations showed significant differences, Odd Ratio (95% confidence intervals), 
length of stay: 1.05 (1.01-1.08, P = 0.007); and albumin concentration: 0.89 (0.82- 0.96).  
On multivariate logistic regression analysis neither of these significant variables was 
independently associated with mortality (Table 10-4). 
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10.4. Discussion 
The results of the present study showed profoundly low plasma concentrations of selenium 
and zinc in ICU on admission compared with our Laboratory reference intervals.  These 
results are in accordance with previous findings in critically ill patients (Berger et al. 1998; 
Heyland et al. 2006).  Rather than suggesting deficiency of these trace elements, this 
finding can be explained by the existence of the systemic inflammatory response in these 
patients as evidenced by the high CRP concentrations.  In a recent study it was 
demonstrated that plasma concentrations of essential trace elements are strongly directly 
associated with the systemic inflammatory response; as measured by CRP concentrations, 
the plasma concentrations of zinc and selenium element fall while copper initially rises and 
only falls with more a severe systemic inflammatory response.  These changes are largely 
predictable when the metabolic dynamics of the systemic inflammatory response are 
considered and are unlikely to represent tissue status to any appreciable degree.  Cytokines 
produced during the systemic inflammatory response increase capillary permeability 
allowing albumin, selenoprotein P (SePP) and other low molecular weight proteins to 
redistribute into the interstitium.  As the plasma concentrations of these proteins fall any 
trace elements carried by them such as selenium and zinc will also fall (Fleck et al. 1985). 
It is generally accepted that plasma albumin concentration is determined by rates of 
synthesis and breakdown, and its distribution across fluid compartments (Buerk et al. 
1973).  Approximately 70 % of serum zinc is bound to albumin while approximately 53% 
and 9% of plasma selenium is bound to SePP or albumin respectively (Buerk et al. 1973; 
Deagen et al. 1993; Harrison et al. 1996; Nichol et al. 1998; Mostert et al. 1998).  In 
addition, whilst selenium and copper may be bound to albumin, these elements are actually 
integral components of SePP and caeruloplasmin, respectively.  The reduction in SePP 
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may be a result of down-regulation of synthesis by the liver as well as protein 
redistribution (Dreher et al. 1997; Mostert et al. 1998). 
In the present study unlike plasma selenium and zinc concentrations, we found plasma 
copper concentrations remained within the reference interval at admission.  Around 95% of 
plasma copper is bound to caeruloplasmin which is a positive acute phase reactant.  Its 
concentration initially increases in response to the systemic inflammatory response 
although as its severity increases concentrations fall (Duncan et al. 2012b) as the capacity 
of the liver to synthesise caeruloplasmin falls.  So again the finding of unchanged plasma 
copper concentrations may be explained as a manifestation of the systemic inflammatory 
response (DiSilvestro 1989). 
Our conclusion that low plasma zinc and selenium concentrations in ICU patients can be 
largely explained by the systemic inflammatory response is corroborated by a similar 
response in well-nourished patients admitted for elective knee surgery.  As the 
inflammatory response develops in these individuals plasma zinc and selenium fall 
abruptly but normalise in approximately 7 days without dietary intervention or 
supplementation (Oakes et al. 2008). 
Plasma glutathione peroxidase activity can be used as an alternative to plasma selenium as 
a marker of selenium status.  It is a measure of functional catalytic activity that, in one 
study was unaffected by the systemic inflammatory response (Defi et al. 2011) and in 
another study produced a small but significant increase (Nichol et al. 1998).  The findings 
in the present study of normal activities of plasma glutathione peroxidase on admission to 
ICU and unchanging activities during the patients’ stay in ICU, serve as a reliable 
indication that the nutrition status of selenium remained normal throughout.  This finding 
consequently provides additional confirmation that the changes of plasma selenium 
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concentrations observed are due to the systemic inflammatory response rather than 
nutrition status. 
There is strong evidence to recommend the use of erythrocyte selenium as a marker of 
status.  Erythrocyte concentrations fall as deficiency develops (Daniels et al. 1996) and 
increase on supplementation (Jacobson and Plantin 1985; Neve et al. 1988).  In healthy 
volunteers and patients who are not critically ill, there is a close correlation with plasma 
selenium concentrations and glutathione peroxidase activity (Rea et al. 1979) and this 
correlation is maintained in individuals who have sub-normal and supra-normal selenium 
intakes (Stefanowicz et al. 2013b).  Therefore, the finding in the present study of normal 
red cell selenium concentrations on admission would tend to suggest that the patients’ 
selenium status was normal in the previous 6 to 12 weeks. 
The same cannot be inferred with respect to zinc; in several studies in which zinc 
deficiency is produced in healthy individuals, erythrocyte concentrations show little (Buerk 
et al. 1973) or no change (Prasad et al. 1978; Baer and King 1984) whereas plasma zinc 
levels fall quickly and significantly.  Fewer studies have investigated the response of 
erythrocyte copper during depletion, however, in a hypocupraemic patient erythrocyte 
concentrations returned to normal after replacement therapy (Okahata et al. 1980). 
An unexpected finding of this study was the slight improvement of plasma zinc and 
selenium concentrations with duration of stay in ICU; although both remained severely low 
at day 7, their concentrations had increased significantly whereas markers of the systemic 
inflammatory response remained unchanged.  This may be due to faster recovery rates of 
plasma trace elements, or more specifically proteins which carry or are complexed with 
trace elements, compared with CRP, albumin and other markers of the systemic 
inflammatory response.  Unfortunately only 31 patients remained in ICU for follow-up 
samples, and this low number is a limitation of this aspect of the study. 
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The early literature reports of low plasma selenium concentrations in ICU patients were 
taken to represent deficiency and prompted several trials of selenium supplementation 
(Berger et al. 1998; Berger et al. 2001; Berger et al. 2004).  This hypothesis was supported 
by the anti-oxidant properties of selenium-dependent enzymes and the proposal that 
critically ill patients have significant reductions in body antioxidant stores, reduced 
intracellular cofactor concentrations, reduced activities of enzymes involved in 
detoxification of reactive oxygen species, and that the severity of critical illness may be 
exacerbated by such reductions of the antioxidant.  Given our findings that low plasma 
selenium concentrations in ICU patients do not represent deficiency, this concept may in 
retrospect be misguided.  Indeed, a recent meta-analysis of selenium supplementation and a 
Cochrane Review (Avenell et al. 2004) were unable to demonstrate convincing data 
supporting a beneficial effect of supplementation (Andrews et al. 2011).  Despite the lack 
of evidence, zinc supplementation is still routinely given in some UK ICUs (Duncan et al. 
2012b). 
In summary, the low plasma zinc and selenium concentrations and elevated plasma copper 
concentrations observed in the present study on admission of critically ill patients to ICU 
are in keeping with our knowledge of the systemic inflammatory response and are a 
consequence of it rather than an indicator of trace element status. 
  
222 
 
Table 10-1:  Laboratory concentrations on admission (day 1). 
Analyte Median Concentration (Range) Reference Interval 
Albumin (g/l) 18 (9-47) 32-45 
CRP (mg/l) 108 (<1-565) <10 
Lab-Glucose (mmol/l) 6.4 (2.8-30.6) 3.5-5.5 
Plasma Copper (µmol/l) 12 (4.5-28.5) 10-22 
Red cell Copper (nmol/g Hb) 33.3 (13.1-46.2) 27.9-53.4  
Plasma Zinc (µmol/l) 4.5 (0.6-27.0) 12.0-18.0  
Red cell Zinc (nmol/g Hb) 581 (399-812) 423-781 
Plasma Selenium (µmol/l) 0.31 (0.01-5.68) 0.8-2.0 
Plasma GSH-Px (IU/L) 346 (30-740) 180-760 
Red cell Selenium (nmol/g Hb) 5.3 (2.48-10.62) 3.66-10.56 
Red cell GSH-Px (IU/g Hb) 27.0 (11.6-42.8) 20-55 
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Table 10-2:  Characteristics, clinical scores and laboratory concentrations on 
admission (day 1) and follow-up (day 4 and day 7).
 
Characteristic 
Clinical Score 
 
Numbers or Medians (ranges) 
Admission 
day 1 
Follow-up 
day 4 
Follow-up 
day 7 
P-value 
a
 
Number of recruits 31    
Sex (male/female) 23/9    
Age (years) 63 (20-81)    
Patients (medical/surgical) 14/18    
APACHE II score 24 (7-38)    
ICU length of stay (days) 16.1 (5.1-76.4)    
ICU mortality (%) 45.2 (18/14)    
SOFA score 7 (1-13) 8 (1-12) 6 (2-11) 0.067 
Albumin (g/l) 14 (9-32) 14 (9-29) 13 (9-31) 0.085 
CRP (mg/l) 111 (<6-565) 132 (20-356) 121 (15-455) 0.529 
Lab-Glucose (mmol/l) 6.6 (2.8-30.6) 6.2 (3.7-12.5) 6.2 (2.3-12.0) 0.839 
Plasma Copper (µmol/l) 10.5 (10.5-28.5) 10.8 (5.3-22.0) 13.3 (6.5-21.5) 0.295 
Red cell Copper (nmol/g Hb) 32 (22-41) 32 (22-49) 32 (26-48) 0.962 
Plasma Zinc (µmol/l) 4.0 (1.5-18.5) 5.0 (1.5-12.5) 6.5 (2.0-12.5) 0.004 
Red cell Zinc (nmol/b Hb) 606 (493-779) 611 (482-777) 622 (477-791) 0.241 
Plasma Selenium (µmol/l) 0.24 (0.01-0.83) 0.26 (0.01-5.65) 0.35 (0.04-0.99) 0.003 
Plasma GSH-Px (IU/L) 344 (30-739) 316 (17-7831) 365 (74-874) 0.310 
Red cell Selenium (nmol/g Hb) 5.3 (3.7-9.6) 5.5 (3.2-10.4) 5.6 (3.94-9.97) 0.080 
Red cell GSH-Px (IU/g Hb) 28 (12-43) 25 (14-48) 27.0 (12-43) 0.236 
a Friedman’s signed-rank test  
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Table 10-3:  Characteristics and trace element concentrations in survivors and non-
survivors on admission to ICU 
Characteristic/ Clinical score/ 
Analyte 
Number / Median (range) 
Survivors Non-survivors P-value* 
Number 101 24  
Age (years) 56 (22-100) 67 (18-81) 0.042 
Sex (male/female) 65/36 16/8 0.807 
Patients (medical/surgical) 44/57 11/13 0.802 
APACHE II score 20 (3-38) 25 (10-34) 0.014 
SOFA score 6 (0-18) 8 (1-14) 0.022 
ICU length of stay (days) 2.9 (0.2-76.2) 11.6 (1.8-59.5) <0.001 
Albumin (g/l) 19 (9-47) 13 (9-33) <0.001 
CRP (mg/l) 84.5 (0.6-438) 122 (2-565) 0.406 
Lab-Glucose (mmol/l) 6.4 (2.8-30.6) 6.8 (4.1-26.4) 0.480 
Plasma Copper (µmol/l) 12.0 (4.5-113.5) 12.0 (4.5-22.0) 0.255 
Red cell Copper (nmol/g Hb) 32.4 (13.1-46.2) 30.31 (13.8-45.3) 0.655 
Plasma Zinc (µmol/l) 5.0 (1.0-27.0) 3.5 (0.60-19.0) 0.306 
Red cell Zinc (nmol/L Hb) 574 (399-812) 631 (492-779) 0.016 
Plasma Selenium (µmol/l) 0.35 (0.01-5.68) 0.22 (0.04-0.72) 0.043 
Plasma GSH-Px (IU/L) 376.3 (29.7-739.2) 272.8 (36.3-456.5) 0.286 
Red cell Selenium (nmol/g Hb) 5.26 (2.48-10.62) 5.27 (2.63-9.62) 0.868 
Red cell GSH-Px (IU/g Hb) 28.4 (13.9-37.1) 24.3 (11.6-42.8) 0.086 
* Mann-Whitney U-test   
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Table 10-4:  The relationship between admission characteristics, trace elements and 
ICU mortality. 
 Univariate analysis Multivariate analysis 
 OR (95%CI) P-value OR (95%CI) P-value
 a
 
Age (years) 1.02 (0.99-1.05) 0.104 1.02 (0.97-1.06) 0.497 
Sex (male/female) 0.89 (0.35-2.28) 0.806   
Patients (medical/surgical) 0.89 (0.36-2.18) 0.802   
APACHE II score 1.09 (1.02-1.16) 0.014   
SOFA score 1.14 (1.00-1.29) 0.440   
ICU length of stay (days) 1.05 (1.01-1.08) 0.007 1.04 (1.003-1.076) 0.035 
Albumin (g/l) 0.89 (0.82- 0.96) 0.003   
CRP (mg/l) 1.00 (1.00-1.01) 0.446   
Lab-Glucose (mmol/l) 1.06 (0.95-1.17) 0.295   
Plasma Copper (µmol/l) 0.93 (0.84-1.03) 0.159   
Red cell Copper (nmol/g Hb) 0.98 (0.90-1.06) 0.584   
Plasma Zinc (µmol/l) 1.00 (0.89-1.12) 0.990   
Red cell Zinc (nmol/g Hb) 1.01 (1.001-1.011)  0.026   
Plasma Selenium (µmol/ l) 0.10 (0.01-1.09) 0.059   
Plasma GSH-Px (IU/L) 0.997 (0.992-1.002) 0.204   
Red cell Selenium (nmol/ g Hb) 1.00 (0.69-1.44) 0.984   
Red cell GSH-Px (IU/g Hb) 0.931 (0.824-1.053) 0.255   
a
 Binary logistic regression analysis.  
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11. The relationship between markers of the systemic inflammatory 
response and red cell vitamins B1, B2 and B6 concentrations. 
11.1. Introduction 
Vitamins B1, B2 and B6 serve as cofactors for several enzymes important in energy 
metabolism.  Vitamin B1, also known as thiamine, was the first B vitamin to be identified.  
The B1 is an important cofactor for enzymes involved on carbohydrate metabolism, also it 
is a cofactor for several enzymes, such as pyruvate dehydrogenase, oxoglutarate 
dehydrogenase and transketolase (Gray et al. 2004; Fattal-Valevski A 2011).  It also 
important for the biosynthesis of neurotransmitters and for the production of reducing 
substances used in oxidant stress defences (Fattal-Valevski A 2011).  Vitamin B2 and its 
two cofactors flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).  FAD 
is mainly found in red blood cells, FMN and FAD act as cofactors in oxidation-reduction 
reaction and in the respiratory chain and are thus involved in energy production (e.g. 
cytochrome, glutathione reductase, glutathione peroxidase, xanthine oxidase and 
methylene tetrahydrofolate reductase) (Talwar et al. 2003b; Talwar et al. 2005).  Vitamin 
B2 is required for normal immune function, by maintenance of glutathione status (Grimble 
1997).  It also has  a suppressive effect on the production of tissue inflammatory mediators 
and decreases plasma elevated nitric oxide levels (Kodama K et al. 2005).  Vitamin B6, 
also known as  pyridoxal phosphate, acts as cofactor for a wide variety of enzymes of 
intermediary metabolism, particularly proteins, carbohydrates, fats and homocysteine and 
synthesis of several neurotransmitters and heam (Leklem 1991; Quasim et al. 2005).  
These vitamins have an essential biological function, which acts as a cofactor for many 
enzymes that regulate glucose, lipid and amino acid metabolism and neurotransmitter 
synthesis (O'Connell 2001). 
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In contrast to functional tests, direct measurements of thiamine, FAD and PLP 
concentrations in blood are thought to more reliably reflect nutritional status of vitamin B1, 
B2 and B6 (Bates 1977).  However, as part of the systemic inflammatory response, plasma 
concentrations, in contrast to red cells, are reduced such that the relationship between 
plasma and red cell B1, B2 and B6 concentrations are disturbed (Talwar et al. 2003b; Gray 
et al. 2004; Quasim et al. 2005; Duncan et al. 2012b).  Duncan and co-workers (2012) have 
recently shown in a large cohort that plasma concentrations of B6 may be confounded in 
the presence of a systemic inflammatory response as evidenced by CRP (Duncan et al. 
2012b). 
The aim of the present study was to examine the effect of the systemic inflammatory 
response, as evidenced by both CRP and albumin, on red cell measurements of vitamins 
B1, B2 and B6 and also examine these effects in patients with critical illness.  
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11.2. Patients and methods 
11.2.1. Nutrition screen cohort 
A total of 553, 251 and 313 consecutive heparin-treated whole-blood samples that had B1, 
B2 and B6 respectively with CRP and albumin measurements were received from hospitals 
throughout Scotland between January2008 and March 2013 for routine analysis of red cell 
measurements.  As a regional centre blood samples were sent for analysis if the patient was 
considered at nutritional risk and was often secondary to a number of disease states.  In 
addition, measurement of albumin and CRP was also recorded for these patients. 
11.2.2. Critical illness cohort 
Data and stored samples were available from cohorts which had been defined previously.  
The critical illness cohort comprised of medical or surgical patients ≥ 18 years admitted to 
the ICU of the Glasgow Royal Infirmary (GRI) between September 2006 and December 
2008, and who had evidence of the systemic inflammatory response syndrome as per 
Bone’s criteria (Bone et al. 1992; Levy et al. 2003), were studied.  Briefly, APACHE II 
score (Knaus et al. 1985) and predicted hospital mortality and SOFA scores, CRP and 
albumin were recorded.  This cohort has been described previously (Vasilaki et al. 2008). 
This investigation was conducted with the intent of developing local guideline to aid in the 
interpretation of vitamin B1, B2 and B6 results.  There were two cohorts studied.  The first 
(a large unselected retrospective cohort) arose from an audit of patients who had a sample 
sent to a regional laboratory for a nutrition screen.  The second (a small selected 
prospective cohort) arose from a prospective study of patients with critical illness.  The 
patient data from the two cohorts was anonymised and de-identified prior to analysis 
(Andrew Duncan and Donald C McMillan respectively).  In line with local ethical 
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procedures written informed consent was obtained for the latter cohort only.  The latter 
study was approved by the ethics committees of the North Glasgow NHS Trust and 
Multicentre Research Ethics Committee (MREC) Scotland.  Where patients were unable to 
give signed informed consent, consent was obtained from the patients’ next of kin or 
welfare guardian in accordance with the requirements of the Adults with Incapacity 
Scotland (2000) Act (Appendix 1, 2). 
11.2.3. Analytical methods 
Consecutive heparin-treated whole-blood samples were received for routine analysis of 
Vitamin B1, B2 and B6 status was assessed by measuring TDP, FAD and PLP respectively 
in red blood cells by HPLC using established routine laboratory methods.  Within- and 
between-assay precision <10% for all methods.  
Albumin was measured by a BCP dye-binding method and C-reactive protein was 
measured using an automated analyser (Architect, Abbott Diagnostics, USA).  For C-
reactive protein the limit of detection was 5 mg/l.  The inter-assay coefficient of variation 
was less than 3% and 5% over the sample concentration range for albumin and C-reactive 
protein respectively.  The limit of detection for albumin was 10 g/L. 
11.2.4. Statistical analysis 
Data was presented in median and (range) value.  Correlations between variables in the 
convenience sample were carried out using the Spearman rank correlation.  The cohorts 
were divided into three groups according to CRP concentrations≤10, 11-80 and >80 mg/L 
as previously described (Marsik et al. 2008).  The concentration of individual vitamins B1, 
B2 and B6 were grouped according to 3 categories of albumin concentrations ≥ 35, 25-
34,< 25 g/Las previously described (Goldwasser and Feldman 1997).  A P- value < 0.05 
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was considered significant and the analysis of the data was carried out using SPSS 
software (version 19; SPSS Inc, Chicago, Ill). 
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11.3. Result 
11.3.1. Nutrition screen cohort  
The characteristics of the convenience sample for vitamin B1 (n=553) are shown in Table 
11-1.  The majority were older than 50 years (median 54 years), male (50%) and had 
plasma albumin were below the normal range and plasma CRP and whole blood vitamin 
B1were in the normal range.  Vitamin B1 was significantly associated with sex (rs=-0.094, 
P =0.027), CRP (rs= 0.290, P <0.001) and albumin (rs= -0.265, P <0.001).  CRP was 
significantly associated with age (rs=0.253, P <0.001), sex (rs=-0.123, P =0.004) and 
albumin (rs=-0.651, P <0.001).  Albumin was significantly associated with age (rs=-0.255, 
P <0.001). 
The characteristics of the convenience sample for red cells vitamin B2 (n=251) are shown 
in Table 11-1.  The majority were older than 50 years (median 51 years), female (56%) and 
had plasma albumin were below the normal range and plasma CRP and red cell vitamin B2 
in the normal range.  Red cells vitamin B2 was significantly associated with sex (rs=-
0.335, P <0.001), CRP (rs= -0.318, P <0.001), sex (rs= -0.123, P =0.004) and albumin (rs= 
-0.651, P <0.001).  Albumin was significantly associated with age (rs= - 0.255, P <0.001). 
The characteristics of the convenience sample for red cells vitamin B6 (n=313) are shown 
in Table 11-1.  The majority were older than 50 years (median 51 years), female (60%) and 
had plasma albumin were below the normal range and plasma CRP and red cells vitamin 
B6 in the normal range.  Red cells vitamin B6 was significantly associated with sex (rs=-
0.254, P =0.013).  CRP was significantly associated with age (rs= 0.253, P <0.001), sex 
(rs=-0.123, P =0.004) and albumin (rs=-0.651, P <0.001).  Albumin was significantly 
associated with age (rs=-0.255, P <0.001).  
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11.3.2. Nutrition screen cohort for red cell vitamin B1 
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
concentrations and albumin, on vitamin B1 are shown in Figure 11-1a and 11-1b. 
The median concentrations of vitamin B1 (Table 11-2) grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/L were 542.5, 664.0 and 765.5 ng/g Hb respectively 
(P <0.001) with an overall elevation of 41%.  The median whole blood concentrations of 
vitamin B1 grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 
547.0, 664.0 and 701.0 ng/g Hb respectively (P <0.001) with an overall elevation of 28%. 
When albumin concentrations were ≥ 35 g/L, the median concentrations of vitamin B1 
grouped according to CRP concentrations ≤10, 11-80 and >80 were 535.0, 619.0 and 811.5 
ng/g Hb respectively (P =0.003) with an overall elevation of 52%.  When albumin 
concentrations were 25-34 g/L, the median concentrations of vitamin B1 grouped 
according to CRP concentrations ≤10, 11-80 and >80 mg/L were 611.0, 693.0 and 776.0 
ng/g Hb respectively (P =0.011) with an overall elevation of 27%.  When albumin 
concentrations were < 25 g/L, the median concentrations of vitamin B1 grouped according 
to CRP concentrations ≤10, 11-80 and >80 mg/L were 574.0, 671.0 and 745.0 ng/g Hb 
respectively (P =0.118) with an overall elevation of 30%. Median concentrations of 
vitamin B1 / albumin x100 ratio were significantly increased from 1450 to 2250 to 4030 
respectively (P <0.001). 
11.3.3. Nutrition screen cohort for red cell vitamin B2 
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
concentrations and albumin, on vitamin B2 were shown in Figure 11-2a and 11-2b. 
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The median concentrations of red cell vitamin B2 (Table 11-3) grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/L were 2.2, 2.3 and 2.4 nmol/g Hb respectively (P 
<0.001) with an overall elevation of 9%.  The median red cell concentrations of vitamin B2 
grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 2.1, 2.4 and 2.3 
nmol/g Hb respectively (P <0.001). 
When albumin concentrations were ≥ 35 g/L, The median red cell concentrations of 
vitamin B2 grouped according to CRP concentrations ≤10 and 11-80 were 2.1 and 2.2 
nmol/g Hb respectively (P =0.147) with an overall elevation of 4%.  When albumin 
concentrations were 25-34 g/L, the median red cell concentrations of vitamin B2 grouped 
according to CRP concentrations ≤10 and 11-80 mg/L were 2.4 and 2.4 nmol/g Hb 
respectively (P =0.265).  When albumin concentrations were < 25 g/L, the median red cell 
concentrations of vitamin B2 grouped according to CRP concentrations ≤10, 11-80 and 
>80 mg/L were 2.5, 2.3 and 2.5 nmol/g Hb respectively (P =0.334).  Median red cell 
concentrations of vitamin B2 / albumin x100 ratio were significantly increased from 6 to 8 
to 14 respectively (P <0.001). 
11.3.4. Nutrition screen cohort for red cell vitamin B6 
The effects of the magnitude of the systemic inflammatory response, as evidenced by CRP 
concentrations and albumin, on vitamin B6 were shown in Figure 11-3a and 11-3b. 
The median concentrations of red cell vitamin B6 (Table 11-4) grouped according to CRP 
concentrations ≤10, 11-80 and >80 mg/L were 534, 548 and 767 pmol/g Hb respectively (P 
<0.001) with an overall elevation of 9%.  The median red cell concentrations of vitamin B2 
grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 462, 644 and 
840 pmol/g Hb respectively (P <0.001). 
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When albumin concentrations were ≥ 35 g/L, the median red cell concentrations of vitamin 
B6 grouped according to CRP concentrations ≤10 and 11-80 were 478 and 413 pmol/g Hb 
respectively were not significantly different (P =0.286).  When albumin concentrations 
were 25-34 g/L, the median red cell concentrations of vitamin B6 grouped according to 
CRP concentrations ≤10 and 11-80 mg/L were 818, 547 and 669 pmol/g Hb respectively 
(P =0.056).  When albumin concentrations were < 25 g/L, the median red cell 
concentrations of vitamin B6 grouped according to CRP concentrations ≤10, 11-80 and 
>80 mg/L were 1037, 822 and 81 pmol/g Hb respectively (P =0.802).  Median red cell 
concentrations of vitamin B6/ albumin x100 ratio were significantly increased from 1380 
to 2030 to 3560 respectively (P <0.001). 
11.3.5. Patients with critical illness  
The characteristics of the critically ill cohort (n=94) are shown in Table 11-1.  The 
majority were older than 50 years (median 60 years), male (64%), an APACHE II score of 
21 and SOFA score of 7 and the associated median predicted mortality was 34%.  The 
majority of patients were surgical (55%) and had a median length of ICU stay of 5 days 
and median hospital stay of 22 days.  The median CRP and albumin concentrations were 
above and below the normal reference intervals respectively.  Approximately half had 
some renal impairment as evidence by eGFR of <60ml/min. 
The median whole blood vitamin B1 was elevated compared with the normal reference 
interval (783.5 ng/g Hb); whereas patients with critical illness have also extremely high 
whole blood vitamin B1 concentrations compared with general population of this nutrition 
screen cohort.  Age was significant associated with albumin (rs = -0.212, P =0.021).  CRP 
was significantly associated with albumin (rs=-0.374, P <0.001).The median whole blood 
concentrations of B1 grouped according to CRP concentrations ≤10, 11-80 and >80 mg/L 
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were 665.5, 800.0 and 768.0 ng/g Hb respectively (15%, P =0.348).  The median whole 
blood concentrations of B1 grouped according to albumin concentrations ≥35, 25-34 and 
<25 g/l were 851.0, 789.0 and 727 ng/g Hb respectively (15%, P =0.361). 
The median red cell concentrations of vitamin B2 was below the normal reference interval 
(19.7 nmol/g Hb), whereas patients with critical illness have higher vitamin B2 
concentrations compared with general population of this nutrition screen cohort.red cell 
vitamin B2 was significantly associated with age (rs =-0.179, P =0.053), sex (rs =-0.322, P 
<0.001), CRP (rs =-0.353, P <0.001) and albumin (rs =0.334, P <0.001). Age was 
significantly associated with albumin (rs=-0.212, P =0.021).CRP was significantly 
associated with albumin (rs =-0.347, P <0.001). The median red cell concentrations of 
vitamin B2 grouped according to CRP concentrations ≤10, 11-80 and >80 mg/L were 40.8, 
23.5 and 13.1 nmol/g Hb respectively (P <0.001).  The median red cell concentrations of 
vitamin B2 grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 
36.7, 29.8 and 16.9 nmol/g Hb respectively (P =0.010). 
The median red cell concentrations of vitamin B6 was below the normal reference interval 
(23.5 pmol/g Hb), whereas patients with critical illness have lower vitamin B6 
concentrations compared with general population of this nutrition screen cohort.red cell 
vitamin B6 was significantly associated with sex (rs =-0.240, P =0.019).  Age was 
significantly associated with albumin (rs=-0.212, P =0.021).  CRP was significantly 
associated with albumin (rs =-0.347, P <0.001).  The median red cell concentrations of 
vitamin B6 grouped according to CRP concentrations ≤10, 11-80 and >80 mg/L were 21.4, 
24.2 and 24.1 pmol/g Hb respectively (P =0.250).  The median red cell concentrations of 
vitamin B6 grouped according to albumin concentrations ≥35, 25-34 and <25 g/l were 
14.6, 24.2 and 22.9 pmol/g Hb respectively (P =0.525).  
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11.4. Discussion 
The results of the present study show that, in contrast to previous reported plasma values, 
in three cohorts of patients referred for a nutrition screen, red cell concentrations of 
vitamin B1, B2 and B6 were not lower with an increasing magnitude of the systemic 
inflammatory response as evidenced by both CRP and albumin concentrations.  Indeed, 
there was a relatively small but significant increase in red cell B1, B2 and B6 
concentrations with an increasing magnitude of the systemic inflammatory response.  
Therefore, in contrast to plasma measurements, red cell measurements prevent 
misclassification of vitamin B1, B2 and B6 deficiency in the presence of systemic 
inflammatory response. 
These results of the present study are consistent with those of Vasilaki and co-workers 
(2008, 2010) who reported that plasma and red cell concentrations of B2 and B6 in patients 
with critical illness, red cell concentrations were less perturbed (Vasilaki et al. 2008; 
Vasilaki et al. 2010).  Therefore, it would appear that during the systemic inflammatory 
response there is mobilisation of vitamin B1, B2 and B6 from the plasma into the cells, 
including red cells. 
The results of the present study are consistent with previous reports.  Louw and co-workers 
(1992) reported that in patients undergoing elective surgery vitamin B2 concentrations in 
the plasma were affected by albumin redistribution due to the systemic inflammatory 
response.  Furthermore, in patients with critical illness, supplementation with pyridoxine 
was associated with an increase in concentrations of vitamin B6 in the red cell, but not in 
the plasma (Quasim et al. 2005).  Indeed, it is recognised that, in plasma, riboflavin is 
extensively bound to proteins such as albumin and globulins, primarily immunoglobulins 
(Innis et al. 1986).  This is consistent with the observation that plasma concentrations of 
vitamin B6 are transiently decreased in subjects undergoing elective surgery (Gray et al. 
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2004) and that vitamin-B6 supplementation in patients with critical illness was unable to 
increase plasma vitamin B6 concentration (Louw et al. 1992; Huang et al. 2002; Quasim et 
al. 2005). 
Patients admitted to intensive care are under severe metabolic stress and may have 
increased utilization and consumption of vitamin B1, B2 and B6 and therefore some 
workers have advocated supplementation of these vitamins in these patients, which appears 
to have a beneficial effect on immune responses (Huang et al. 2005; Cheng et al. 2006).  
However, the results of the present study do not address the question of increased 
utilization and metabolic turnover of plasma vitamin ns B1, B2 and B6. 
The present study has a number of limitations.  In particular there was no information on 
the presence of chronic disease, co-morbidity or on body composition.  Nevertheless, it is 
likely that the impact of these clinical factors on metabolic vitamins will involve the 
systemic inflammatory response, at least in part. 
In summary, the results of the present study show that, unlike plasma concentrations, red 
cell concentrations of vitamin B1, B2 and B6 were not significantly affected by the 
systemic inflammatory response as a major confounding factor in determining their status.  
Therefore, red cell B1, B2 and B6 concentrations are likely to be a more reliable measure 
of status in patients with evidence of a systemic inflammatory response.   
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Table 11-1:  Characteristics of nutrition screen cohort and vitamins B1, B2 and B6 concentrations. 
 Reference 
interval 
Nutrition screen cohort Whole 
blood vitamins B1 (n=553) 
Nutrition screen cohort 
vitamins B2 (n=251) 
Nutrition screen cohort 
vitamins B6 (n=313) 
Critical illness cohort  
(n= 94) 
P-value 
Age (years) NA 54 (18-100) 51 (16-82) 51 (16-82) 60 (18-100) 0.001 a 
Sex (Male/Female) NA 276 (50%)/ 277 (50%) 111 (44%)/ 140 (56%) 125 (40%)/ 188 (60%) 60 (64%)/ 34 (36%) <0.001 a 
C-reactive protein 
(mg/l) 
<10 14.0 (<10- 565.0) 5.0 (<10- 565.0) 4.3 (<10- 301.0) 105 (<10- 565.0) <0.001 a 
Albumin (g/l) 35-55 32 (6-50) 36 (9-49) 35 (9-49) 18 (9-45) <0.001 a 
B1 (ng/g Hb) 275- 675 613 (175-3650)   783.5 (196-3650) <0.001 b 
B2 (nmol/g Hb) 1.0 – 3.4  2.2 (1.2-27.3)  19.7 (1.2-332.6) <0.001 b 
B6 (pmol/g Hb) 250 – 680    540 (79-100755) 23.5 (8.7-2140.3) <0.001 b 
(Median and range) a Kruskal-Wallis Test, b Mann-Whitney Test  
  
239 
 
Table 11-2:  Distribution of whole blood vitamin B1 according to C-reactive protein and albumin concentrations (n=553). 
whole blood vitamin B1 
(ng/g Hb) 
CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) whole blood vitamin B1 
according to albumin 
Albumin ≥35 (g/l) 535 (211-2067) 
(n=175) 
619 (201-1508) 
(n=61) 
812 (805-818) 
(n=2) 
547 (201-2067) 
(n=238)  
34-25 (g/l) 611 (175-1781) 
(n=56) 
693 (260-2552) 
(n=77) 
776 (385-3650) 
 (n=18) 
664 (175-3650) 
(n=151)  
<25 (g/l) 574 (233-1248) 
(n=19) 
671 (288-2129) 
(n=71) 
745 (196-3524) 
(n=74) 
701 (196-3524) 
(n=164)  
whole blood vitamin B1 
according to CRP 
543 (175-2067) 
(n=250)  
664 (201-2552) 
(n=209)  
766 (196-3650) 
(n=94)  
 
    Median (range) (number of observation).   
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Table 11-3:  Distribution of red cell B2 according to CRP and albumin concentrations (n=251). 
Red cell B2 (nmol/g Hb CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Red cell B2 according to 
albumin 
Albumin ≥35 (g/l) 2.1 (1.2-5.9) 
(n=121) 
2.2 (1.9-3.1) 
(n=15) 
- 
(n=0) 
2.1 (1.2-5.9) 
(n=136)  
34-25 (g/l) 2.4 (1.2-27.3) 
(n=38) 
2.4 (1.6-5.8) 
(n=38) 
- 
 (n=1) 
2.4 (1.2-27.3) 
(n=77)  
<25 (g/l) 2.5 (2.1-5.0) 
(n=6) 
2.3 (1.3-3.5) 
(n=21) 
2.5 (2.0-5.5) 
(n=11) 
2.3 (1.3-5.5) 
(n=38)  
Red cell B2 according to 
CRP 
2.2 (1.2-27.3) 
(n=165)  
2.3 (1.3-57.8) 
(n=74)  
2.4 (1.6-5.5) 
(n=12)  
 
    Median (range) (number of observation).  
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Table 11-4:  Distribution of red cells B6 according to CRP and albumin concentrations (n=312). 
Red cells B6 (pmol/g Hb) CRP ≤10 (mg/l) 11-80 (mg/l) >80 (mg/l) Red cells B6 according to 
albumin 
Albumin ≥35 (g/l) 478 (138-72374) 
(n=155) 
413 (181-2812) 
(n=18) 
- 
(n=0) 
462 (138-72374) 
(n=173)  
34-25 (g/l) 818 (79-61870) 
(n=47) 
547 (164-9245) 
(n=42) 
669 (320-1017) 
 (n=2) 
644 (79-61870) 
(n=91)  
<25 (g/l) 1037 (206-3036) 
(n=12) 
822 (183-100755) 
(n=24) 
881 (291-23294) 
(n=12) 
840 (183-100755) 
(n=48)  
Red cells B6 according to 
CRP 
534 (79-27374) 
(n=214)  
548 (164-100775) 
(n=85)  
767 (291-23294) 
(n=14)  
 
    Median (range) (number of observation) 
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Figure 11-1a:  The relationship between CRP (log 10) and whole blood vitamin B1 
(ng/g Hb) (rs= 0.290, P<0.001) ) and in the critical illness cohort (rs= 0.051, P=0.581). 
 
Figure 11-1b:  The relationship between albumin and whole blood vitamin B1 
(nmol/l) (rs= - 0.265, P<0.001) and in the critical illness cohort (rs=  -0.567, P<0.001). 
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Figure 11-1c:  The relationship between whole blood vitamin B1 adjusted for albumin 
and CRP (rs= 0.583, P<0.001) and in the critical illness cohort (rs= 0.275, P=0.003). 
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Figure 11-2a:  The relationship between CRP (log 10) and red cell vitamin B2 (nmol/g 
Hb) (rs= 0.189, P=0.003) and in the critical illness cohort (rs, = 0.229, P=0.023). 
 
 
Figure 11-2b:  The relationship between albumin and red cell vitamin B2 (nmol/g Hb) 
(rs= 0.186, P <0.001) and in the critical illness cohort (rs= - 0.139, P=0.173). 
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Figure 11-2c:  The relationship between red cell vitamin B2 adjusted for albumin and 
CRP (rs= 0.543, P <0.001) and in the critical illness cohort (rs= 0.447, P =0.017). 
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Figure 11-3a:  The relationship between CRP (log 10) and red cells vitamin B6 
(pmol/g Hb) (rs= 0.079, P =0.161) and in the critical illness cohort (rs= 0.084, P =0.411). 
 
Figure 11-3b:  The relationship between albumin and red cells vitamin B6 (pmol/g Hb) 
(rs= - 0.217, P <0.001) and in the critical illness cohort (rs=- 0.091, P =0.375). 
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Figure 11-3c:  The relationship between red cell vitamin B6 adjusted to albumin and 
CRP (rs= 0.238, P <0.001) and in the critical illness cohort (rs= 0.248, P =0.014). 
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12. Discussion  
The aim of the thesis was: 
To examine the relationship between the systemic inflammatory response, as evidenced by 
both CRP and albumin, on plasma glucose, plasma and red cell measurements of vitamins 
and trace elements in a nutrition screen cohort and a critical illness cohort. 
12.1. The major findings of the study were: 
In the critical illness cohort, insulin administration only accounted for a small part of the 
daily fluctuation of plasma glucose concentrations.  In the nutrition screen cohort plasma 
concentrations of glucose appeared to be independently associated with both CRP and 
albumin and consistent with the systemic inflammatory response as a major confounding 
factor in determining its status.  However, when this was examined in patients with critical 
illness, within the context of an insulin protocol, the relationship was more complex and 
multifactorial.  Nevertheless, the combination of CRP and albumin concentrations during 
critical illness was independently associated with outcome.  Compared with the complex 
APACHE II score and predicted mortality, the simple combination of CRP and albumin 
effectively predicted actual ICU and hospital mortality. 
In the nutrition screen cohort and the critical illness cohort, the systemic inflammatory 
response was associated with the lower plasma values of a number of vitamins and trace 
elements.  The basis of this association is not clear and may not be causal and so caution 
should be exercised in clinical interpretation.  Therefore, it can be concluded that clinical 
interpretation of such plasma micronutrients only be made when the CRP and albumin 
concentrations are known or where the presence of a systemic inflammatory response can 
be excluded.  The present data suggests that, in the presence of a moderate or severe 
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systemic inflammatory response (as indicated by a CRP concentration >20 mg/L), plasma 
concentrations of lutein, lycopene and β-carotene are not readily interpretable. Similarly, 
plasma concentrations of 25 (OH) D may not be reliably interpreted in the presence of 
abnormal CRP (>10mg/l) and albumin concentrations (<35g/l).  It may be that plasma 
concentrations of 25 (OH) D in the presence of normal CRP and albumin concentrations 
reliably indicate nutritional status of vitamin D and the need for supplementation.  Plasma 
concentrations of α-tocopherol/ cholesterol ratio and ascorbic acid were independently 
associated with both CRP and albumin and consistent with the systemic inflammatory 
response as a major confounding factor in determining their status.  In particular, vitamin C 
concentrations were more profoundly affected by the presence of systemic inflammatory 
response.  These results provide a basis for the better understanding of the impact of the 
systemic inflammatory response on plasma vitamin E and C.  Similarly, plasma 
concentrations of vitamin E and C may not be reliably interpreted in the presence of 
abnormal CRP (>10mg/l) and albumin concentrations (<35g/l).  It may be that plasma 
concentrations of vitamin E and C in the presence of normal CRP and albumin 
concentrations reliably indicate nutritional status of vitamin E and C and the need for 
supplementation. 
Plasma concentrations of zinc were associated with both CRP and albumin.  Moreover, 
that the impact of the systemic inflammatory response (as evidenced by elevation of CRP) 
on plasma zinc concentration may be adjusted by the albumin concentrations. Plasma 
concentrations of selenium were associated with both CRP and albumin.  However, the 
impact of the systemic inflammatory response (as evidenced by elevation in CRP) may not 
be readily adjusted by the albumin concentration. Similar relationships were also observed 
in the cohort of patients with critical illness.  The low plasma zinc and selenium 
concentrations and elevated plasma copper concentrations observed on admission of 
critically ill patients to ICU are in keeping with our knowledge of the systemic 
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inflammatory response and are a consequence of it rather than an indicator of trace element 
status.  Similarly, plasma concentrations of zinc and selenium may not be reliably 
interpreted in the presence of abnormal CRP (>10mg/l) and albumin concentrations 
(<35g/l).  It may be that plasma concentrations of zinc and selenium in the presence of 
normal CRP and albumin concentrations reliably indicate nutritional status of zinc and 
selenium and the need for supplementation. 
Unlike plasma concentrations, red cell concentrations of zinc, selenium, copper, vitamin 
B1, B2 and B6 were not significantly affected by the systemic inflammatory response as a 
major confounding factor in determining their status.  Taken together the results of the 
present thesis also provide a basis for the better understanding of the impact of the 
systemic inflammatory response on plasma and red cell micronutrients.  This work, to my 
knowledge, is the most detailed systematic examination of the relationship between plasma 
glucose, micronutrients and the systemic inflammatory response.  These results have led to 
changes in the methodology and practice of vitamin analysis in the Scottish Trace 
Elements and Micronutrients Reference Laboratory at Glasgow Royal Infirmary. 
12.2. Limitations of the study 
Limitations of the present studies were, principally, that they were observational studies 
and with reference to the critical illness cohort, represented a relatively small sample size. 
The results of the present study, although clear because of their cross-sectional nature, 
cannot prove a causal effect of the systemic inflammatory response on vitamins and trace 
elements concentrations.   There may be an underlying physiologic process that alters both 
the vitamins and trace elements concentrations, and the systemic inflammatory response, 
so that the observed relations could at times be indirect.  In particular, there was no 
information on the presence of chronic disease, co-morbidity, or body composition. 
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Nevertheless, it is likely that the impact of these clinical factors on metabolic vitamins and 
trace elements will involve the systemic inflammatory response, at least in part. 
12.3. Future studies 
Future research is required both to confirm these results in nutrition screen and critical 
illness cohorts and also to carryout longitudinal studies across these cohorts.  It will also be 
important to examine the clinical value of the intracellular micronutrients measurements in 
patient outcome.  The red cell measurements presented in this thesis are an example of 
such an approach. 
If such studies prove to be consistent then it will be important to incorporate these findings 
into future treatments with micronutrients.  Taken together such new investigations will 
improve our understanding of the status of micronutrients in health and treatment in 
disease.  
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14.1.Consent form for participation in the study 
Patient Identification Number for this study: 
19th June 2006 
CONSENT FORM 
The relationship between the systemic inflammatory response, micronutrient status and outcome in 
patients with critical illness 
(Version 2A) 
Name of Researcher: Dr John Kinsella 
I confirm that I have read and understand the information sheet dated 5th June 2006 (version 
2A) for the above study and have had the opportunity to ask questions. 
I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving a reason, without my medical care or legal rights being affected. 
I give my permission for my GP to be informed about my participation in the above study. 
I understand that the blood samples taken from me for routine purposes will be kept and analysed 
for research purposes which include vitamin and trace element concentrations in different blood 
compartments. I understand that these samples will not be returned to me. 
I understand that the sections of any of my medical notes may be looked at by responsible 
individuals from the research team where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
I agree to take part in the above study. 
_____________________    ________________   ________________________ 
Name of patient      Date     Signature 
-----------------------------------     --------------------------   ------------------------------ 
Name of welfare guardian or   Date    Signature 
Next of kin 
Nearest relative: Yes / No   If yes, relationship to patient:__________________ 
Welfare guardian: Yes / No 
_____________________      ________________      _________________________ 
Name of person taking consent   Date    Signature 
(if different from researcher) 
__________________     _____________   _______________________ 
Researcher     Date       Signature 
1 for patient, 1 for researcher, 1 to be kept with hospital notes 
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14.2.Appendix 3 Information leaflet for patients and relatives 
19th June 2006 
PATIENT INFORMATION SHEET 
The relationship between the systemic inflammatory response, micronutrient status and outcome 
inpatients with critical illness 
(Version 2A) 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Ask 
us if there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and You.’ 
This leaflet gives more information about medical research and looks at some questions you may 
want to ask. If you would like to have a copy we will provide one. 
 
Thank you for reading this. 
 
What is the Purpose of the Study? 
We wish to investigate the changes that occur in the concentrations of vitamins and other 
micronutrients in the blood during and after critical illness. This will require the further analysis of 
some of the blood samples that were routinely taken during your illness and a further blood sample 
after you have left intensive care. 
We will also ask you some questions about your state of health and your diet. From this 
information we intend to establish the best method of assessing the vitamin and trace element 
nutritional status in critically ill patients. 
 
Why have I been chosen? 
All patients admitted to Glasgow Royal Infirmary ICU are being considered for admission into this 
study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are 
still free to withdraw at any time and without giving a reason.  This will not affect the standard of 
care you receive. 
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What will happen to me if I take part? 
Your treatment will not be altered by taking part to the study. 
Phase 1 - When in the intensive care unit we would like to run some extra tests on your blood 
samples that have already been taken from you as part of routine. We will not ask you for anything 
else other than your consent to measure the vitamin and trace element concentrations in different 
compartments of your blood. This assessment is not done routinely and it will help us better assess 
the health of other patients admitted in the intensive care unit. 
Phase 2 - If you agree to that we will also ask you to give us one more blood sample at clinic, and 
an interview about your health 3 – 6 months after your discharge from the intensive care unit. At 
this time we would also like you to provide us with a 7 day food diary that you will complete 
before coming to see us. 
 
What do I have to do? 
You don’t have to do anything while in hospital (phase 1). If you agree to take part in phase 2 
(at clinic) you only have to complete a 7 day food diary before visiting the surgical clinic. 
Please try not to change your usual eating habits when completing the diary. You should also 
follow your doctor’s instructions and take your medication as prescribed. 
 
Will any of my travel expenses be covered? 
Travel expenses for routine hospital visits will not be covered. However, if you have to come to the 
hospital just for the purposes of the study your travel expenses will be covered in full. 
 
What are the side effects of taking part? 
There are no side effects of taking part in this study. It is purely an observational study does not 
include drug or nutritional intervention. In addition, if at any point you become concerned in any 
way please contact Dr John Kinsella, Consultant in Critical Care, tel. 0141 211 4625. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks of taking part to this study. 
 
What are the possible benefits of taking part? 
As your treatment will be unchanged, there is no intended clinical benefit from taking part in the 
study. However, the information that we collect may help us to improve the treatment of future 
patients admitted to the intensive care unit. 
 
What happens when the study stops? 
Your treatment and follow up will continue as normal. 
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What if something goes wrong? 
We have seen that the study will be absolutely safe for the patient as being observational in nature. 
If you are harmed by taking part in this study, there are no special compensation arrangements. 
Standard NHS indemnity does, however, apply in any case of adverse event. If you are harmed due 
to someone’s negligence, then you may have grounds for legal action but you may have to pay for 
it. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
 
Will my taking part in this study be kept confidential? 
Yes. All information, which is collected about you during the course of research, will be kept 
strictly confidential. All the information required for the study will be kept strictly within the 
hospital departments. We have also set up a coding system so that your name will be replaced by a 
unique number and all of your information and results will be matched to this unique number and 
not your name. 
If you agree, we will write to your GP and inform them of your participation in the study. 
 
What will happen to the results of the research study? 
The results of the study will be in large part to PhD thesis studies and may be published in 
scientific journals. Moreover, some of the results may also be presented in scientific meetings, e.g. 
conferences. We expect to publish our first results in 2007. If you wish you can obtain a copy of 
the published material from the University Department of Anaesthesia. 
It is important to understand that at no publication or presentation of the results your name and/or 
personal details about your health will be identified. 
 
Who is organizing and funding the research? 
The funding of this research is from collaborative group of clinicians and scientists in the Glasgow 
Royal Infirmary. 
 
Who has reviewed the study? 
The study has been reviewed and approved by the Local Research Ethics Committee of the Royal 
Infirmary of Glasgow and the MREC for Scotland, Committee A. 
 
Contact for Further Information 
If you have any further questions or wish to obtain more information, please do not hesitate to 
contact the chief investigator – 
Dr John Kinsella 
Consultant 
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University Department of Anaesthesia 
Royal Infirmary 
Tel - 0141 211 4625 
